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ABSTRACT OF THE DISSERTATION
The Role of Schwann Cell Mitochondrial Metabolism in Schwann Cell Biology and
Axonal Survival
by
Andreu Viader

Mitochondrial dysfunction has emerged as a common cause of peripheral
neuropathies. While the role of neuronal and axonal mitochondria in peripheral nerve
disease is well appreciated, whether Schwann cell (SC) mitochondrial deficits contribute
to peripheral neuropathies is unclear. Greater insight into the biology and pathology of
SC mitochondrial metabolism could be relevant to the treatment of peripheral
neuropathies, particularly because SCs critically support axonal stability and function as
well as promote peripheral nerve regeneration. The present thesis investigates the
contribution of SC mitochondrial deficits to disease progression in peripheral
neuropathies as well as the gene regulatory network that drives the SC regenerative
response after injury and in disease states.
We describe the generation and characterization of the first mouse model useful in
directly interrogating the contribution of SC mitochondrial dysfunction to peripheral
neuropathy. These mice (Tfam-SCKOs) were produced through the tissue-specific
deletion of the mitochondrial transcription factor A gene (Tfam), which is required for
mtDNA

transcription

and

replication.

Interestingly,

induction

of

SC-specific

mitochondrial dysfunction did not affect SC survival; instead, these deficits resulted in a
severe, progressive peripheral neuropathy characterized by extensive axonal degeneration
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that recapitulated critical features of human neuropathy. Mechanistically, we
demonstrated that SC mitochondrial dysfunction activates a maladaptive integrated stress
response and causes a shift in lipid metabolism away from new lipid biosynthesis towards
increased lipid oxidation. These alterations in lipid metabolism caused the early depletion
of key myelin lipid components as well as a dramatic accumulation of acylcarnitine lipid
intermediates. Importantly, release of acylcarnitines from SCs was toxic to axons and
induced their degeneration. Our results show that normal mitochondrial function in SCs
is essential for maintenance of axonal survival and normal peripheral nerve function,
suggesting that SC mitochondrial dysfunction contributes to human peripheral
neuropathies. Moreover, our work identifies alterations in SC lipid metabolism and the
accumulation of toxic lipid intermediates as novel mechanisms driving some of the
pathology in peripheral neuropathies associated with mitochondrial dysfunction.
Tfam-SCKO mice showed a severe deficiency in their ability to remyelinate
peripheral nerve axons after injury. To gain insight into the highly orchestrated process of
SC-mediated support of axonal regeneration, we also investigated the transcriptional and
post-transcriptional gene regulatory program that drives the SC regenerative response.
We profiled the expression of SC microRNAs (miRNAs) after peripheral nerve lesions as
well as characterized the injury response of SCs with disrupted miRNA processing and
showed that SC miRNAs modulated the injury response largely by targeting positive
regulators of SC dedifferentiation/proliferation. SC miRNAs cooperated with
transcriptional regulators to promote rapid and robust transitions between the distinct
differentiation states necessary to support nerve regeneration. Moreover, we identified
miR-34a and miR-140 as regulators of SC proliferation and myelination. We then used a
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novel computational approach to infer the gene regulatory network involved in this SC
injury response and gain insight on cooperative regulation of this process by transcription
factors and miRNAs.
Together, the results described in the present thesis represent a significant
increase in our understanding of how mitochondrial abnormalities specifically in SCs
contribute to clinical impairment in patients with peripheral neuropathy. Moreover, the
mechanistic characterization of lipid metabolism abnormalities in SCs following
mitochondrial dysfunction elucidates potentially important therapeutic targets. Finally,
our analysis of the transcriptional and post-transcriptional gene regulatory network
involved in the SC regenerative response also provides valuable insight that could be
harnessed to help restore normal nerve function in patients with peripheral neuropathy.
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CHAPTER 1

Introduction: Peripheral Neuropathy and the Role of Schwann Cell Metabolism in
the Biology and Pathology of Peripheral Nerves

1

Peripheral Neuropathies and their clinical impact
Peripheral neuropathy is a general term used to describe any disorder
characterized by peripheral nerve abnormalities. These nerve abnormalities include
electrophysiological deficits such as reduced nerve conduction velocity as well as
structural changes like axonal degeneration or demyelination. Structural and functional
nerve abnormalities in peripheral neuropathies cause the clinical impairment observed in
individuals afflicted with these diseases and can lead to incapacitating pain, sensory loss,
and debilitating muscle weakness (England and Asbury, 2004). With an overall
prevalence of 2400 per 100 000 (2.4%), rising to 8000 per 100 000 (8%) in people older
than 55 years (Hughes, 2002), peripheral neuropathies are a common cause of substantial
morbidity. At the same time these diseases constitute a significant economic and societal
burden. For example, the total annual health care costs in the US for diabetic neuropathy,
the most common form of peripheral nerve disease in developed countries, were
estimated to be between $4.6 and $13.7 billion in 2001 (Gordois et al., 2003). It is
therefore imperative to develop new therapeutic interventions to effectively treat patients
with peripheral neuropathy. Discovery of new therapies could be greatly facilitated by an
increased understanding of the underlying pathophysiological mechanisms of peripheral
nerve disease, which still remain incompletely understood.

Mitochondrial dysfunction as a common element in the diverse etiology of
peripheral neuropathies
The term peripheral neuropathy encompasses a myriad of forms of peripheral
nerve disease with very diverse etiologies. In the developed world, the most common
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cause of peripheral neuropathy is diabetes mellitus (Hughes, 2002). Given the rising
prevalence of diabetes worldwide due to the epidemic in obesity, the incidence of
diabetic peripheral neuropathy is also expected to rise (Fernyhough et al., 2010). In the
developing world, leprosy continues to be a major cause of neuropathy. A range of
metabolic disorders, infectious agents, vasculitis, toxins, and drugs are other common
systemic causes of peripheral neuropathy. Finally, immune abnormalities and genetic
mutations are also responsible for a substantial portion of chronic neuropathies (Hughes,
2002).
Despite this apparent etiological diversity, mitochondrial derangements have
emerged as a common cause of many types of peripheral neuropathy. Ultrastructural
morphological abnormalities of mitochondria, which are commonly associated with
organelle dysfunction, have been reported in the nerves of patients with diabetic
neuropathy as well as in animal models of the disease (Fernyhough et al., 2010;
Kalichman et al., 1998). Dorsal root ganglion neurons in animal models of diabetes also
show decreased mitochondria respiratory chain enzyme activities and overall
mitochondrial respiration (Chowdhury et al., 2010). Similarly, metabolic and
morphological mitochondrial abnormalities are also present in the nerves of patients and
animal models of neuropathy associated with HIV/AIDS as well as with antiretroviral or
chemotherapeutic treatment (Flatters and Bennett, 2006; Lehmann et al., 2011; Lewis and
Dalakas, 1995). Moreover, the recent identification of disease-causing mutations that
affect mitochondrial proteins and function in patients with inherited forms of peripheral
neuropathy (known as Charcot-Marie-Tooth disease, CMT) has further confirmed central
role of mitochondrial derangements in the pathophysiology of peripheral nerve disease
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(Niemann et al., 2006). The need to elucidate the manner in which mitochondrial
dysfunction underlies progression of peripheral nerve disease is thus well appreciated.
To date much effort has been devoted to elucidating the role of neuronal and
axonal mitochondria in peripheral neuropathies (Baloh, 2008). A growing body of
evidence, however, has shown that Schwann cells (SCs), the main glial cell type in the
peripheral nervous system, are essential to supporting axonal survival and peripheral
nerve function (Chen et al., 2003; Meyer zu Horste et al., 2007; Reddy et al., 2003).
These cells are also critical for nerve regeneration to occur after injury and during disease
processes (Geuna et al., 2009). Moreover, glia are increasingly recognized as key
contributors to the pathophysiology of neurodegenerative diseases traditionally thought to
be neuron autonomous (Ilieva et al., 2009). The development of effective therapies for
treatment of peripheral neuropathies will therefore need to address the contribution of SC
mitochondrial dysfunction to disease progression.

SC support of axonal stability and peripheral nerve function
SCs are the main glial cell type in the peripheral nervous system (PNS) and they
cover most of the surface of all axons in peripheral nerves. SCs are best known for their
role in peripheral nerve myelinogenesis, during which individual SCs wrap around single
axons, establish the boundaries for the formation of the nodes of Ranvier, and deposit the
myelin sheath (Sherman and Brophy, 2005). SCs provide in this way the insulation and
clustering of ion channels required for rapid, saltatory transmission of action potentials.
Of the four types of SCs found in the mature nervous system, however, only myelinating
SCs (MSCs) are involved in the formation of the myelin sheath. The majority of SCs in
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the PNS are in intimate contact with neurons but do not form myelin (Corfas et al., 2004).
This suggests that the role of SCs in the PNS extends beyond the assembly and
maintenance of myelin.
A number of studies have now established a critical role for SCs in the
preservation of axonal function and survival. Chen et al.(Chen et al., 2003) showed that
disruption of ErbB receptor-mediated communication between axons and nonmyelinating SCs (NMSCs) causes degeneration of unmyelinated axons and progressive
sensory neuropathy. Similarly, perisynaptic SCs (PSCs), a second type of non myelinforming SCs, are essential for the long-term survival of axon terminals at the
neuromuscular junction (Reddy et al., 2003). MSCs are also vital for the maintenance of
axonal integrity. Axonal degeneration ensues when the interactions between MSCs and
axons are perturbed, as is presumably the case in axonopathies caused by mutations in the
MSC-specific myelin protein zero (P0) (Bienfait et al., 2006; Shy, 2006), as well as in
virtually all demyelinating neuropathies (Shy et al., 2002). In these situations, damage to
axons is not caused by the loss of myelin itself since axonal degeneration and
demyelination can be pharmacologically uncoupled (Meyer zu Horste et al., 2007). Longterm support of axonal integrity is, therefore, a primary function of all SCs separate from
the role of some SCs in the formation and maintenance of myelin.
The mechanisms and cellular machinery underlying SC preservation of axons still
remain largely unknown. It is currently believed that this glial support requires axonal
engulfment and a molecular apparatus that includes some myelin-related components
(Nave and Trapp, 2008). This notion stems from the observation that in the central
nervous system (CNS), where oligodendrocytes (OLs) also preserve axonal integrity
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independent of myelin (Griffiths et al., 1998; Lappe-Siefke et al., 2003), mutations in
some myelin proteins cause axonal loss (Griffiths et al., 1998) while others cause severe
dysmyelination without signs of axonal degeneration (Griffiths et al., 1998; Inoue et al.,
1981; Rosenbluth, 1980). It is not clear, however, whether the same molecular machinery
is at work in the PNS and how it may apply to MSCs and NMSCs.
Trophic support of axons through neurotrophic factors has also been hypothesized
as a potential mechanism behind glia-mediated axonal maintenance. While the role of
glia-derived neurotrophins during development, myelinogenesis, and remyelination has
been described in detail (Rosenberg et al., 2006), there is little experimental evidence of
continuous glial trophic support of mature axons. Further work is necessary before a role
for SC-derived neurotrophins in axonal preservation can be asserted.
Metabolic support of axons by ensheathing cells is also a likely but poorly
understood mechanism of axonal preservation. For example, SCs may support axons
through the transfer of metabolites or by helping axons eliminate certain toxic species, as
is the case between CNS neurons and astrocytes (Benarroch, 2005; Magistretti, 2006).
This type of metabolic support by axon ensheathing glia has not been well analyzed, but
may be particularly relevant in the context of neuropathies associated with mitochondrial
dysfunction. Disruption of the putative SC metabolic support of axons following
abnormalities in SC mitochondrial metabolism could potentially drive some of the
pathology of peripheral neuropathies.
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SC regenerative response after peripheral nerve injury and in disease states
Besides being essential to support axonal survival and normal peripheral nerve
function under physiological conditions, SCs are also critical for nerve regeneration to
occur during pathological processes. In the peripheral nervous system, SCs surrounding
damaged axons undergo an injury response that enables the long distance regeneration of
these axons. SCs have the striking ability to dedifferentiate and revert back to an
immature-like state following axonal loss (Jessen and Mirsky, 2008). After a transient
phase of proliferation, dedifferentiated SCs help support axonal regeneration by clearing
myelin debris, forming tubular structures known as bands of Bungner, and upregulating
the synthesis of a number of neurotrophic factors. As peripheral axons regenerate, SCs
re-differentiate to form mature Remak bundles or new myelin sheaths, helping to restore,
in this way, peripheral nerve function (Geuna et al., 2009). Greater insight into this highly
orchestrated process of SC-mediated support of axonal regeneration could be harnessed
to improve the treatment of peripheral and central neurodegenerative diseases
characterized by axonopathy, including diabetic neuropathy (Coleman, 2005).

Existing evidence of the contribution of SC-specific mitochondrial derangements to
the pathology of peripheral neuropathies
As described above, SCs have a primary role in supporting axonal function and
survival (Chen et al., 2003; Meyer zu Horste et al., 2007; Reddy et al., 2003) and in
enabling peripheral nerve repair in disease processes (Geuna et al., 2009). Given this
critical involvement of SCs in the maintenance of peripheral nerves, mitochondrial
dysfunction specifically in these glia is likely to cause some of the pathophysiological
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changes that lead to clinical impairment in people with peripheral neuropathies. In fact, a
growing body of literature implicates glial dysfunction in a number of neurodegenerative
diseases traditionally thought to be neuron cell autonomous. Expression of diseasecausing mutant proteins specifically in glial cells has been shown to alter disease onset
and progression in transgenic mouse models of amyotrophic lateral sclerosis (Boillee et
al., 2006; Wang et al., 2009; Yamanaka et al., 2008) and Parkinson’s disease (Yazawa et
al., 2005) among others (For review see Ilieva et al., 2009). The contribution of SC
mitochondrial abnormalities to the pathology observed in peripheral nerve diseases,
however, has remained largely unexplored.
Attempts to address how SC mitochondrial deficits may play a role in peripheral
neuropathy have been limited by the fact that the mechanisms that disrupt mitochondrial
function in neuropathic nerves presumably affect all cells and not just SCs. Moreover,
neuropathies associated with mitochondrial dysfunction can display a range of
presentation that make it difficult to establish what cell type is primarily involved. This is
particularly clear in the case of inherited neuropathies caused by mutations in
ubiquitously

expressed

mitochondrial

proteins,

such

as

ganglioside-induced

differentiation associated protein 1 (GDAP1). GDAP1 is a protein that localizes to the
outer mitochondrial membrane and regulates mitochondrial fission (Niemann et al.,
2005). This process is essential to normal mitochondrial function because it regulates the
number, morphology, and localization of these organelles, as well as their ability to
exchange intraorganelle content and to carry out apoptosis (Detmer and Chan, 2007).
GDAP1 mutations that lead to a reduction or loss of mitochondrial fission have now been
identified in CMT patients. These patients can suffer from demyelinating, intermediate or

8

axonal forms of CMT (Niemann et al., 2005). Given that GDAP1 is expressed both in
SCs and neurons, the degree to which SC mitochondrial dysfunction contributes to the
diverse pathology observed in these CMT patients remains to be established.
Evidence from peripheral neuropathy-prone mitochondriopathies, however, first
suggested that mitochondrial dysfunction specifically in SCs may be a major driving
force in the development of both myelin and axonal degeneration. Studies reviewing the
nerve pathology in mitochondrial disorder patients with clinically apparent signs of
peripheral neuropathy found that most mitochondrial abnormalities were localized to SCs
(Bouillot et al., 2002; Schroder, 1993). Enlarged mitochondria with an amorphous matrix,
distorted cristae, or containing paracrystalline material were predominantly found in SCs,
particularly those surrounding unmyelinated axons. Similar observations have been
reported in patients suffering from polyneuropathies associated with diabetes and
HIV/AIDS (Kalichman et al., 1998; Schroder, 1993). SC-mediated nerve regenerative
plasticity is also severely compromised in diabetic neuropathy (Kennedy and Zochodne,
2005), further highlighting the potential importance of SC-specific metabolic
abnormalities in the context of peripheral nerve disease. Therefore, the generation of
novel models of peripheral neuropathy secondary to mitochondrial dysfunction that allow
the examination of pathological processes specifically in SCs could greatly aid the
development of new therapeutic strategies.
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The polyol pathway as an example of SC metabolic abnormalities that drive some of
the pathology in peripheral neuropathies
The notion that understanding how SC mitochondrial dysfunction contributes to
peripheral neuropathies could be therapeutically relevant is supported by earlier work
examining the polyol pathway in diabetic neuropathy. This pathway represents an
example of a metabolic abnormality that primarily affects SCs yet causes some of the
pathology present in diabetic neuropathy. The polyol pathway is an alternative catabolic
pathway that converts glucose to sorbitol. This pathway is normally not very active
because aldose reductase, the first enzyme in the pathway, has a lower affinity for
glucose than the glycolytic enzyme hexokinase. In normal nerves, therefore, most glucose
is converted to glucose-6-phosphate instead of sorbitol. Increased intracellular glucose in
diabetic peripheral nerves, however, saturates hexokinase and increases the flux through
the polyol pathway. A high “flux” rate of glucose through the polyol pathway is thought
to deplete cofactors such as NADPH and NAD+, thus causing peripheral nerve
pathology. Appreciable increases in intracellular sorbitol concentrations may also lead to
some tissue toxicity through an increased osmotic effect (for review see Tomlinson and
Gardiner, 2008).
Interestingly, aldose reductase was found to be mainly expressed in SCs
(Ludvigson and Sorenson, 1980). The pathology present in diabetic nerves secondary to
increased activity of the sorbitol pathway may therefore primarily reflect abnormal
metabolism in SCs. Overexpression of aldose reductase specifically in SCs was in fact
shown to worsen pathophysiolgocial alterations present in a mouse model of diabetes
(Song et al., 2003). Aldose reductase inhibitors have been successfully used to treat
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animal models of diabetic neuropathy and somewhat promising results have been
achieved in human clinical trials (Tomlinson and Gardiner, 2008). Importantly these
results emphasize the potential of targeting metabolic abnormalities that may primarily
affect SCs as a way to treat peripheral neuropathies.

Thesis organization and significance
Mitochondrial dysfunction has emerged as a common cause of peripheral
neuropathies, a heterogeneous group of disorders characterized by peripheral nerve
abnormalities and associated with substantial morbidity (Hughes, 2002). The need to
elucidate the manner in which mitochondrial dysfunction underlies progression of
peripheral nerve disease is thus well appreciated; to date much effort has been devoted to
clarifying the role played by neuronal/axonal mitochondria (Baloh, 2008). The
contribution of SC-specific mitochondrial deficits to the pathophysiology of peripheral
neuropathy, however, has remained largely unexplored. Greater insight into the biology
and pathology of SC mitochondrial metabolism could be relevant to the treatment of
peripheral neuropathies, particularly because SCs critically support axonal stability and
function as well as peripheral nerve regeneration (Chen et al., 2003; Meyer zu Horste et
al., 2007; Reddy et al., 2003). The present thesis addresses the contribution of
mitochondrial deficits specifically in SCs to disease progression in peripheral nerve
disease. We also explore the gene regulatory network that is important for peripheral
nerve regeneration after injury and in disease states.
In the first part of the thesis (Chapter 2) we describe the generation and
characterization of the first mouse model useful in directly interrogating the contribution
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of SC mitochondrial dysfunction to peripheral neuropathy (Viader et al., 2011a). These
mice, Tfam-SCKOs, were produced through the tissue-specific deletion of the
mitochondrial transcription factor A gene (Tfam), which is required for mtDNA
transcription and replication and when excised induces progressive defects in the
mitochondrial electron transport chain (Larsson et al., 1998). Interestingly, induction of
SC-specific mitochondrial dysfunction did not affect SC survival; instead, these deficits
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal
degeneration that recapitulated critical features of human neuropathy. These results
showed that mitochondrial function in SCs is essential for maintenance of axonal survival
and normal peripheral nerve function, suggesting that SC mitochondrial dysfunction
contributes to human peripheral neuropathies.
Having established the relevance of the characterization Tfam-SCKO mice to
understanding and potentially treating peripheral neuropathies, we next focused on
discovering the mechanisms underlying the nerve pathology in these mice. In Chapter 3
(manuscript in preparation), we show that SC mitochondrial dysfunction activates a
maladaptive integrated stress response and causes a shift in lipid metabolism away from
new lipid biosynthesis towards increased lipid oxidation. These alterations in lipid
metabolism caused the early depletion of key myelin lipid components that likely account
for the severe demyelination that characterizes the late pathology in Tfam-SCKO mice.
Moreover, increased lipid oxidation resulted in a dramatic accumulation of acylcarnitine
lipid intermediates, particularly as mitochondrial dysfunction worsened. Importantly, we
found that these lipid intermediates could be released from SCs and were toxic to axons,
inducing them to degenerate. Our results identify alterations in SC lipid metabolism and
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accumulation of toxic lipid intermediates as a novel mechanism driving some of the
pathology of peripheral neuropathies associated with mitochondrial dysfunction.
During our investigation of mice lacking Tfam-specifically in SCs, we
inadvertently deleted Tfam from enteric neurons and glia and generated mice with
disrupted mitochondrial metabolism in the enteric nervous system (Tfam-ENSKOs;
Viader et al., 2011b). This was of interest because mitochondrial dysfunction is a central
mediator of disease progression in diverse neurodegenerative diseases that often present
with prominent gastrointestinal abnormalities. Given the lack of animal models to study
the role of mitochondrial deficits in ENS neurodegeneration and gastrointestinal
dysfunction, we carried out a phenotypic characterization of the Tfam-ENSKO mice.
Interestingly, these mice showed that mitochondrial defects differentially affected
specific subpopulations of enteric neurons and regions of the gastrointestinal tract. This
regional and subtype-specific variability in susceptibility to mitochondrial defects
resulted in an imbalance of inhibitory and excitatory neurons that caused a severe
gastrointestinal pseudo-obstruction phenotype in Tfam-ENSKO mice. Mitochondrial
dysfunction, therefore, is likely to be an important driving force of neurodegeneration in
the ENS and contribute to gastrointestinal symptoms in people with neurodegenerative
disorders.
Tfam-SCKO mice showed a severe deficiency in their ability to remyelinate
peripheral nerve axons after injury. To gain insight into the highly orchestrated process of
SC-mediated support of axonal regeneration, the last part of this thesis investigates the
transcriptional and post-transcriptional gene regulatory program that drives the SC
regenerative response (Chapter 5, Viader et al., 2011c; Chapter 6, Chang et al., 2011).
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Since at the time we started this work it was unclear whether injury-induced changes in
SCs were orchestrated post-transcriptionally by microRNAs (miRNAs), we initially
profiled the expression of SC miRNAs after peripheral nerve lesions and characterized
the injury response of SCs with disrupted miRNA processing. We found that SC miRNAs
modulated the injury response largely by targeting positive regulators of SC
dedifferentiation/proliferation. SC miRNAs cooperated with transcriptional controls to
promote rapid and robust transitions between the distinct differentiation states necessary
to support nerve regeneration. Moreover, we identified miR-34a and miR-140 as
regulators of SC proliferation and myelination. Having identified miRNAs as important
modulators of the SC regenerative response, we used a novel computational approach to
infer the integrated transcription factor (TF) and miRNA regulatory network involved in
this SC process. Further analysis of regulatory network motifs in this SC injury response
network provided insight on cooperative regulation of this process by TFs and miRNAs.
Together, the results described in the present thesis represent a significant
increase in our understanding of how mitochondrial abnormalities specifically in SCs
contribute to the disease progression and clinical impairment in patients afflicted with
peripheral neuropathy. Furthermore, the mechanistic characterization of the lipid
metabolism abnormalities that occur in SCs following mitochondrial dysfunction
provides new potentially important therapeutic targets.

Finally, our analysis of the

transcriptional and posttranscriptional regulatory networks involved in the SC
regenerative response also give new valuable insight that could be harnessed to restore
normal nerve function in patients with peripheral neuropathy.
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CHAPTER 2:

Schwann Cell Mitochondrial Metabolism Supports Long-term Axonal Survival and
Peripheral Nerve Function

Adapted from: Viader A, Golden JP, Baloh RH, Schmidt RE, Hunter DA, Milbrandt J.
(2011). Schwann cell mitochondrial metabolism supports long-term axonal survival and
peripheral nerve function. J Neurosci 31(28): 10128-10140.
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Abstract
Mitochondrial dysfunction is a common cause of peripheral neuropathies. While
the role of neuron and axonal mitochondria in peripheral nerve disease is well
appreciated, whether Schwann cell (SC) mitochondrial deficits contribute to peripheral
neuropathies is unclear. Here we examine how SC mitochondrial dysfunction affects
axonal survival and contributes to the decline of peripheral nerve function by generating
mice with SC-specific mitochondrial deficits. These mice (Tfam-SCKOs) were produced
through the tissue-specific deletion of the mitochondrial transcription factor A gene
(Tfam), which is essential for mitochondrial DNA (mtDNA) transcription and
maintenance. Tfam-SCKOs were viable but, as they aged, they developed a progressive
peripheral neuropathy characterized by nerve conduction abnormalities as well as
extensive muscle denervation. Morphological examination of Tfam-SCKO nerves
revealed early preferential loss of small unmyelinated fibers followed by prominent
demyelination and degeneration of larger-caliber axons. Tfam-SCKOs displayed sensory
and motor deficits consistent with this pathology. Remarkably, the severe mtDNA
depletion and respiratory chain abnormalities in Tfam-SCKO mice did not affect SC
proliferation or survival. Mitochondrial function in SCs is therefore essential for
maintenance of axonal survival and normal peripheral nerve function, suggesting that SC
mitochondrial dysfunction contributes to human peripheral neuropathies.
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Introduction
Peripheral neuropathies are a heterogeneous group of disorders characterized by
peripheral nerve abnormalities. With an incidence of up to 8% in elderly populations,
peripheral neuropathies are a common cause of substantial morbidity and constitute a
significant economic and societal burden (Hughes, 2002). The etiology for these diseases
is varied, ranging from vascular and metabolic irregularities to genetic mutations. Despite
this apparent diversity, mitochondrial derangements have emerged as a common cause of
many types of peripheral neuropathy. A number of mutations that affect mitochondrial
function are now thought to be responsible for several forms of inherited neuropathies
(Niemann et al., 2006). Similarly, diabetic neuropathy, the most prevalent form of
peripheral nerve disease, is also associated with abnormalities in mitochondrial
morphology and metabolism (Fernyhough et al., 2003). With the hope of developing new
therapies, therefore, much effort is being devoted to understanding how mitochondrial
deficiencies influence nerve function.
In recent years, significant progress has been made in elucidating the role of
axonal mitochondria in peripheral neuropathies (Baloh, 2008). Peripheral nerve axons,
however, do not function in isolation. SCs, the main glial cell type in the PNS, are
intimately associated with all peripheral nerve axons and are essential for their long-term
preservation and survival (Chen et al., 2003; Reddy et al., 2003; Meyer zu Horste et al.,
2007). Mitochondrial dysfunction in SCs is thus likely to participate in the disease
progression in peripheral neuropathies. In fact, pathological mitochondria in neuropathic
nerves are often localized to SCs (Schroder, 1993; Kalichman et al., 1998). The
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contribution of SC mitochondrial dysfunction to the pathology observed in peripheral
nerve diseases, however, is poorly understood and remains largely unexplored.
With the goal of understanding whether SC mitochondrial abnormalities affect
axonal survival and contribute to the decline of patients suffering from peripheral nerve
diseases, we generated mice with impaired mitochondrial function exclusively in SCs.
These Tfam-SCKO mice were generated through the tissue-specific deletion of the
mitochondrial transcription factor A gene (Tfam), which is required for mtDNA
transcription and replication (Larsson et al., 1998). Here we show that mitochondrial
function in SCs is essential for maintenance of axonal survival and normal peripheral
nerve function. Importantly, SC mitochondrial dysfunction alone recapitulated a number
of critical features of human neuropathies. Remarkably, the severe mtDNA depletion and
respiratory chain abnormalities in Tfam-SCKO mice did not affect SC survival. SC
mitochondrial dysfunction, therefore, is a likely contributor to the impairment of patients
suffering from peripheral neuropathies.

Results
Schwann cell-specific disruption of the Tfam gene
To study how mitochondrial dysfunction affects SCs and their ability to support
long-term axonal survival, we generated mice with disrupted mitochondria only in SCs
(Tfam-SCKOs). For this purpose we used a previously developed mouse with loxPflanked Tfam alleles (TfamloxP) (Larsson et al., 1998) (Fig. 1a). TFAM is a nuclearlyencoded mitochondrial protein that is essential for mtDNA maintenance, copy number
regulation and transcription (Larsson et al., 1998; Ekstrand et al., 2004). Previous reports
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have shown that the deletion of Tfam in TfamloxP homozygous mice that express crerecombinase in a tissue of interest results in severe tissue-specific mtDNA depletion and
mitochondrial respiratory chain deficiency (Larsson et al., 1998; Wang et al., 1999; Silva
et al., 2000; Sorensen et al., 2001; Wredenberg et al., 2002). This makes the tissuespecific deletion of Tfam an effective way to induce mitochondrial dysfunction in a
selected population of cells.
We mated TfamloxP mice to mice that express cre-recombinase under the control
of the P0 promoter (P0-Cre) (Feltri et al., 1999). P0-Cre mice are well-established to
induce specific recombination of floxed genes in peripheral myelinating and nonmyelinating SCs starting at E13.5-14.5, but not in any other central or peripheral neuron
or glia (Feltri et al., 1999; Feltri et al., 2002). We confirmed this selectivity by crossing
P0-Cre mice with Cre-inducible Rosa26-YFP reporter animals. Indeed, YFP fluorescence
was visible in most sciatic nerve SCs but not in axons or perineurial cells. Similarly, YFP
could also be seen in most dorsal root ganglia SCs (satellite cells) but not in DRG
neurons (Fig. 1b). In agreement with previous reports, therefore, P0-Cre induced selective
recombination in most peripheral SCs.
The observed P0-Cre-mediated excision of Tfam in SCs was highly efficient.
Analysis of Tfam mRNA and protein levels from Tfam-SCKO sciatic nerve extracts
showed an 80% reduction compared to littermate controls (Fig. 1c and d). Considering
that an estimated 15% of endoneurial cells are P0-Cre negative fibroblast and
macrophages (King RH, 2005) and that nerve extracts also contain some perineurial and
endothelial cells, the actual excision rate of Tfam in SCs was probably near complete.
Given the high selectivity and efficiency of the P0-promoter driven expression of cre-
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recombinase, we conclude that the mating of TfamloxP to P0-Cre mice resulted in animals
that lacked Tfam specifically in SCs.

SC mtDNA depletion and respiratory dysfunction in Tfam-SCKOs
To determine the functional effect of deleting Tfam in SCs, we next assessed
mtDNA copy number and transcript level in Tfam-SCKO sciatic nerves. Consistent with
the essential role of Tfam in the maintenance, replication and transcription of mtDNA
(Larsson et al., 1998; Ekstrand et al., 2004), as well as with previous reports describing
tissue-specific Tfam knock-out mice (Larsson et al., 1998; Wang et al., 1999; Silva et al.,
2000; Sorensen et al., 2001; Wredenberg et al., 2002), total mtDNA content was found to
be significantly reduced in Tfam-SCKO nerves compared to control animals (Fig. 2a).
Similarly, transcripts of two different mitochondrially-encoded proteins (mt-ND2 and mtCox1) were also severely depleted in the sciatic nerves of Tfam-SCKO animals (Fig. 2b).
As expected, no differences in the transcript levels of nuclearly-encoded mitochondrial
proteins were observed (Fig. 2b).
The mitochondrial genome encodes 13 subunits that are essential components of
complexes I, III, IV and V of the electron transport chain. The depletion of mtDNA and
mitochondrially-encoded transcripts following Tfam excision has been previously shown
to induce severe respiratory chain deficiency (Larsson et al., 1998; Wang et al., 1999;
Silva et al., 2000; Sorensen et al., 2001; Wredenberg et al., 2002). To examine the
dysfunction of SC mitochondria in Tfam-SCKO mice we first assessed respiratory chain
enzyme activities in the sciatic nerves of 2 month old animals. At this age, Tfam has
already been efficiently excised in sciatic nerve SCs and mtDNA content and transcripts
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have been severely depleted (See Fig. 1c and d and Fig. 2a and b). Mitochondria isolated
from Tfam-SCKO sciatic nerves showed a 60% reduction in COX activity (complex IV),
which contains critical mtDNA-encoded subunits (Fig. 2c). As expected, the activity of
SDH (complex II), which is fully nuclearly encoded, showed no significant change in
mitochondria isolated from Tfam-SCKO sciatic nerves (data not shown).
To further confirm the disruption of SC mitochondria in Tfam-SCKO mice, we
next used high-resolution respirometry to measure mitochondrial respiration under
different substrates in permeabilized 2 month old Tfam-SCKO sciatic nerves. Respiration
induced by substrates delivering electrons to complex I (pyruvate+malate), was
significantly impaired in Tfam-SCKO sciatic nerves compared to littermate controls.
Similarly, respiration induced by the convergent transport of electrons entering at
complexes I and II (using pyruvate+malate+succinate as substrates), which best
corresponds to the mitochondrial substrate supply in vivo (Gnaiger, 2009), was also
significantly reduced in Tfam-SCKO sciatic nerves compared to littermate controls.
These reductions in mitochondrial respiration in Tfam-SCKO nerves are likely explained
by defects in complexes I, III and IV as these complexes contain mtDNA-encoded
subunits. Respiration induced by electrons entering at the level of complex II remained
unchanged in Tfam-SCKO nerves, which is explained by the fact that complex II
contains only nuclearly-encoded subunits (Fig. 2d).
It should be emphasized that while the functional deficits described above were
measured from whole Tfam-SCKO sciatic nerves, they are a reflection of the mtDNAdepletion and mitochondrial dysfunction taking place specifically in SCs. The high
specificity of the P0-cre mediated excision of Tfam ensures this (Fig. 1b). Moreover,
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COX enzymatic staining, which reflects respiratory chain activity in individual cells,
showed reduced staining intensity in the cell bodies of SCs in Tfam-SCKO sciatic nerves
(Fig. 2e). Finally, electron microscopy of Tfam-SCKO nerves revealed abundant
abnormal, enlarged mitochondria, sometimes with distorted cristae, specifically in SC but
not in axons (Fig. 2f). Together, our results confirm that by deleting Tfam specifically in
SCs we were able to generate a mouse with disrupted mitochondrial metabolism only in
peripheral glia.

Tfam-SCKOs develop a progressive degenerative peripheral neuropathy
Despite severe mtDNA and transcript depletion as well as respiratory chain
dysfunction in their SCs, Tfam-SCKO animals were born at the expected Mendellian
ratios and survived to at least 12 months of age (the longest a Tfam-SCKO was allowed
to survive before it was sacrificed). Tfam-SCKO animals developed normally and were
indistinguishable from their control littermates up to 3 months of age. Starting at 3-4
months of age, however, Tfam-SCKOs showed signs of muscle weakness and gait
abnormality. Tfam-SCKOs exhibited abnormal limb clasping, mild tremors, impaired
coordination and developed a characteristic “swimming-gait”.

These deficits

progressively worsened so that by 8 months of age, most Tfam-SCKOs were often unable
to support themselves on their hind legs (Fig. 3a). Such motor abnormalities are
indicative of peripheral nerve disease and have been previously described in other mouse
models of peripheral neuropathy (Le et al., 2005; Ryu et al., 2007; Baloh et al., 2009).
Reduced peripheral nerve conduction velocity is a hallmark and diagnostic marker
of diabetic as well as other mitochondria-related neuropathies (Arezzo and Zotova,
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2002). To further characterize the peripheral nerve deficits in Tfam-SCKOs we
performed nerve conduction studies both on pre-symptomatic and symptomatic mice.
Nerve conduction velocity was significantly reduced in Tfam-SCKO animals as early as
2 months of age and this deficit persisted over time (Fig. 3c). Moreover, Tfam-SCKO
mice displayed marked temporal dispersion at 4 months of age (Fig. 3b and d). Both
these findings are suggestive of a progressive demyelinating phenotype in Tfam-SCKO
mice.
Interestingly, electromyography (EMG) of Tfam-SCKOs showed occasional
fibrillation potentials and fasciculations at 2-3 months of age, which became prominent at
4 months and continued to worsen with increasing age (Fig. 3e and data not shown).
These EMG findings reflect loss of muscle fiber innervation and spontaneous firing of
motor units, and are often seen in human nerve diseases involving motor axon loss. Thus,
our EMG results indicated a progressive axonal degeneration phenotype in Tfam-SCKO
mice. This was confirmed by muscle histology, which revealed abundant denervated
atrophic muscle fibers (Fig. 3f). SC-specific mitochondrial dysfunction caused, therefore,
a progressive peripheral neuropathy characterized by both demyelination as well as
axonal degeneration.

Tfam-SCKOs display early preferential loss of small unmyelinated fibers
To examine in detail the peripheral nerve abnormalities in Tfam-SCKOs we
performed histological and electron microscopy analysis of Tfam-SCKO sciatic nerves at
different ages. Tfam-SCKO nerves initially developed normally and for the first 2-3
weeks of life there were no obvious differences between Ctrl and Tfam-deficient nerves
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(data not shown). As early as 1 month of age, however, Tfam-SCKO nerves started to
display signs of pathology. Interestingly, we found that these early abnormalities
preferentially affected, and were initially limited to, small-caliber unmyelinated fibers (C
fibers) (Fig. 4a-e)
Small caliber fibers are normally associated with non-myelinating SCs, such that
a single SC wraps around multiple axons to form a Remak bundle. The Remak bundle is
delimited by a basement membrane and individual axons are kept separate from one
another inside it by a thin extension of SC cytoplasm (Fig. 4e-1). At 1 month, the
structure of Remak bundles in Tfam-SCKO nerves was clearly disrupted (Fig. 4d and e).
Unmyelinated axons within a Remak bundle were often found touching one another and
interspersed by pathological SC processes known as Bands of Bungner (Fig. 4e-2).
Moreover, degeneration of unmyelinated axons was extensive and evidenced by freefloating, excess basement membrane surrounding empty spaces previously occupied by
axon bundles (Fig. 4e-2, 3). Precise quantification of small fiber loss in the nerves of
Tfam-SCKO mice, however, was not possible because of the difficulty of distinguishing
abnormal unmyelinated axons from SC processes forming Bands of Bungner. Note that,
at this age (1 month old), large-caliber myelinated fibers (A fibers) in Tfam-SCKO
nerves appeared normal (Fig. 4a-c).
The unmyelinated fibers in Tfam-SCKO nerves quickly deteriorated and by 2
months of age most non-myelinating SCs were associated with unstructured,
degenerating Remak bundles. These bundles contained few intact axons and were often
filled with phagocytic vesicles and membranous debris, indicative of axonal degeneration
(Fig. 4e-4). We confirmed the early degeneration of unmyelinated fibers observed in
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Tfam-SCKO sciatic nerves by quantifying C fiber density in the epidermis. Somatic C
fibers are primarily high-threshold nociceptors that terminate in the epidermis (Kennedy
and Wendelschafer-Crabb, 1993). In neuropathies characterized by loss of small
unmyelinated fibers, skin denervation is one of the initial signs of pathology and
correlates with disease severity (Ebenezer et al., 2007). While we did not observe
differences in epidermal fiber density at one month of age, we found a significant
decrease in skin innervation in 2 month old Tfam-SCKO mice (Fig. 4f and g). This was
again in contrast to large myelinated fibers, which at this age were just beginning to show
initial signs of pathology (Fig. 5a). Overall numbers of dorsal root ganglion neurons in
L3, whose axons project to the sciatic nerve, were comparable in 2 month old TfamSCKO and Ctrl mice (average total # of neurons Ctrl= 7048 +/- 186; Tfam-SCKO=
7381+/- 211.3; n=3 mice per genotype). Similarly, TUNEL and cleaved caspase 3
immunostaining of the dorsal root ganglion neurons whose axons project to the sciatic
nerve (levels L3-L5) showed no signs of cell death in either 2 or 4 month old TfamSCKOs (data not shown). The degeneration of small unmyelinated fibers in the nerves of
Tfam-SCKO mice was, therefore, a primary pathological event and was not secondary to
neuronal death.
Together, our results show that Tfam-SCKO mice initially suffered early
preferential loss of small unmyelinated fibers, suggesting that these fibers are most
sensitive to SC mitochondrial dysfunction. The temporal progression of fiber loss in
Tfam-SCKO nerves is particularly interesting because early preferential loss of small
unmyelinated fibers has been reported in polyneuropathies associated with diabetes and
HIV/AIDS (Kennedy et al., 1996; McArthur et al., 2005), diseases in which
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mitochondrial dysfunction is known to occur (Fernyhough et al., 2003; Dalakas et al.,
2001)

Loss of large caliber myelinated fibers in older Tfam-SCKOs
While Tfam-SCKOs suffered an early preferential loss of small unmyelinated
fibers, these mice also developed deficits in large caliber myelinated axons as they aged.
Toluidene blue stained plastic sections of 2 month old Tfam-SCKO sciatic nerves showed
early signs of axonal degeneration (Fig. 5a). This observation was confirmed by electron
microscopic examination, which revealed a few axons undergoing active demyelination
and Wallerian degeneration (data not shown). Note, however, that at this age there was
not a significant decrease in the number of myelinating profiles in Tfam-SCKO nerves
(Fig. 5b).
Severe axonal loss became prominent in Tfam-SCKOs by 4 months (Fig. 5a-c).
At this age, the number of myelinating profiles in Tfam-SCKO nerves was greatly
reduced compared to control littermates (Fig. 5b). Degeneration of myelinated axons
continued to progress as Tfam-SCKO mice aged and by 8 months of age the number of
myelinating profiles in these animals was less than 40% that of control littermates (Fig.
5a, b and c-3). Electron micrographs confirmed the severity of the axonal degeneration in
Tfam-SCKO nerves, revealing large portions of endoneurium completely devoid of axons
(Fig. 5c). Similarly, numerous axons undergoing degeneration were also visible. Detailed
morphometric analysis (Hunter et al., 2007) showed no differences in the size distribution
of myelinated axons in Tfam-SCKO nerves compared to control littermates at different
ages, indicating that myelinated fibers of all calibers were susceptible to degeneration
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(Fig. 5d). As in the case of small unmyelinated fibers, the degeneration of myelinated
fibers was not secondary to neuronal death since no TUNEL or cleaved caspase 3
positive motor neurons were observed in the spinal cords of either 2 or 4 month old
Tfam-SCKOs (data not shown).
At 4 months demyelination was also widespread in Tfam-SCKO nerves. At this
age, large caliber axons without any myelin were a prominent pathological feature (Fig.
5c). Examination of osmicated teased fibers from 4 month old Tfam-SCKO nerves
confirmed the presence of segmental demyelination (Fig. 5e). Consistent with
demyelination, SCs actively digesting myelin debris were present in Tfam-SCKO nerves
at this age (Fig. 5c-4). Occasionally, axons surrounded by abnormally thin myelin were
also observed. Thin myelin was, however, not characteristic, and in fact there was no
difference in the overall g-ratio between Tfam-SCKO and control nerves at different ages
(data not shown). Overall, these results show that extensive axonal degeneration and
demyelination ensue when SC mitochondria are disrupted. Normal SC mitochondrial
function is therefore essential for maintaining the interaction between myelinating SCs
and axons.

Tfam-SCKOs have behavioral deficits consistent with early loss of unmyelinated
fibers followed by extensive degeneration of myelinated axons
To determine the physiological effects and confirm the temporal progression of
the pathology observed in Tfam-SCKO nerves, we carried out a battery of sensorimotor
tests in 2 and 4 month old animals. Behavioral tests that primarily assess the function of
small unmyelinated C fibers were expected to show deficits in both 2 and 4 month old
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Tfam-SCKO mice. On the other hand, behavioral paradigms looking mainly at the
function of large myelinated fibers were predicted to show differences only in 4 month
old Tfam-SCKO mice.
Small unmyelinated C-fibers have a primary role in nociception. To examine the
physiological effect of the early C-fiber loss observed in Tfam-SCKOs we assessed their
sensitivity to a noxious heat stimulus. When a noxious radiant heat stimulus was applied
to the hind paw (Hargreaves test), Tfam-SCKOs displayed a longer withdrawal latency
than their control littermates. As expected, this reduced sensitivity to noxious heat stimuli
was detectable in 2 month old animals and persisted as these mice aged (Fig. 6a).
We also tested innocuous mechanical sensitivity in 2 month old Tfam-SCKOs
using the von Frey test. Innocuous mechanical sensitivity is another form of
somatosensation but, unlike nociception, it is primarily mediated by myelinated fibers.
Interestingly, 2 month old Tfam-SCKO animals showed no deficits in the von Frey test
compared to wild type littermate controls (average withdrawal threshold Ctrl=0.86 g +/0.08g; Tfam-SCKO=1.0g +/- 0.05g; n=4 mice per genotype). The results from these
somatosensory studies supported the pathological observations indicating early
preferential loss of small unmyelinated fibers in Tfam-SCKO mice.
Given that the axons of motor neurons are large myelinated fibers, we next
determined whether the pathology observed in Tfam-SCKO nerves caused any
abnormalities in motor function. As predicted, no motor deficits were detected in 2 month
old Tfam-SCKOs (Fig 6b and c). 4 month old Tfam-SCKO animals, however, spent
significantly less time on an accelerating rotarod (Fig. 6d) as well as on an inverted
screen (Fig. 6b), indicating abnormal coordination and muscle weakness. The results
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from these motor studies are consistent with the observation that large-caliber axons are
not affected in Tfam-SCKO mice until later in the disease. Together, our results confirm
that Tfam-SCKO mice initially suffered early preferential loss of small unmyelinated
fibers followed by extensive loss of large-caliber myelinated axons.

SC mitochondrial dysfunction does not compromise SC survival
To determine whether the axonal loss and demyelination observed in Tfam-SCKO
animals was simply the result of SC death we assessed changes in SC numbers in the
nerves of these animals. Remarkably, we found no differences in the number of SC nuclei
between Tfam-SCKO sciatic nerve and littermate controls up to 8 months of age (Fig. 7a
and b). Moreover, by crossing Tfam-SCKO mice to Cre-inducible Rosa26-YFP reporter
animals we were able to confirm that, at all ages examined, Tfam-deficient SCs present in
Tfam-SCKO nerves (identified by their excision-dependent YFP fluorescence) remained
viable (Fig. 7a and c). These results indicate that the survival of Tfam-deficient SCs was
not compromised despite severe mtDNA depletion and respiratory chain abnormalities.
Consistent with the viability of Tfam-SCKO SCs, we did not detect any
differences in TUNEL staining, a marker of cell death, between Tfam-SCKO sciatic
nerve and controls at different ages (Fig. 7a and d). Similarly, staining with an antibody
that recognizes the proliferation marker phospho-histone 3 showed no changes in
proliferation that could compensate for the potential loss of Tfam-deficient SCs in TfamSCKO nerves (data not shown). The pathology observed in Tfam-SCKOs, therefore, was
not due to the loss of SCs. Together, our findings indicate that normal mitochondrial
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function is not required for SC survival, but is essential for maintenance of axonal
survival and normal peripheral nerve function.

Tfam deficient SCs support axonal regeneration but fail to remyelinate following
injury
Schwann cells play a critical role in promoting axonal regeneration following
peripheral nerve injury. Upon degeneration of peripheral axons, SCs in the distal stump
undergo an orchestrated process that helps support axonal regeneration (Geuna et al.,
2009). To determine whether disrupting mitochondrial function affects the ability SCs to
support axonal regeneration, we studied the response of these cells after peripheral nerve
crush injury in 2 month old Ctrl and Tfam-SCKO mice. At this age, the peripheral nerves
of Tfam-SCKOs show modest pathology that is mainly limited to unmyelinated fibers yet
mitochondrial function has already been severely disrupted (see above).
We first looked at the initial response of SCs to axonal degeneration by assessing
changes in SC proliferation and in their ability to break down existing myelin. Within the
first few days after losing contact with axons SCs de-differentiate and start to proliferate
(Geuna et al., 2009). Immunostaining of nerves harvested 4 days after injury distal to the
site of crush using a phopho-histone 3 antibody showed no impairment in the ability of
Tfam-deficient SCs to proliferate following axonal loss (Fig. 8a and b). Nerve
regeneration also depends on the ability of SCs to break down existing myelin and
remove the resulting debris. This process starts immediately after injury and takes place
over a period of 3-6 weeks (Geuna et al., 2009). We did not observe differences in the
amount of myelin debris present in Ctrl and Tfam-SCKO nerves 3 weeks after injury,
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suggesting that disruption of mitochondrial function in SCs does not interfere with their
ability to break down and remove myelin following axonal degeneration (Fig. 8c).
We next studied the ability of Tfam-deficient SCs to support axonal regeneration
by analyzing toluidene blue stained plastic sections of Tfam-SCKO and Ctrl nerves
collected distal to the site of crush 3 weeks after injury. At this time, we found that
substantial axonal regeneration and SC remyelination had already taken place in Ctrl
nerves (Fig. 8d). In Tfam-SCKO nerves, however, we observed a striking decrease in the
number of myelinated fibers (Fig. 8d). Interestingly, examination of Tfam-SKO nerves
by electron microscopy revealed that this decrease in myelinated profiles was not due to
the inability of Tfam-deficient SCs to support axonal re-growth. In fact, the total number
of fibers (myelinated and unmyelinated) distal to the crush site was equivalent between
Ctrl and Tfam-SCKO nerves 3 weeks after injury (Fig. 8e and f). Moreover, the majority
of regenerated axons in Tfam-SCKO nerves 3 weeks after injury were associated with
SCs in the typical 1 to 1 ratio (Fig. 8g1-4). Tfam-deficient SCs, however, failed to form
mature myelin. Given that the proportion of axons of large enough caliber to induce
myelination (larger than 1 m in diameter) was not different between Ctrl and TfamSCKOs (Fig. 8h), the inability of Tfam-deficient SCs to myelinate is likely a direct
consequence of their disrupted mitochondrial metabolism.
Regenerated Remak bundles were also absent in Tfam-SCKO nerves compared to
Ctrl littermates 3 weeks after crush injury. Instead, we observed pathological bundles of
unorganized unmyelinated axons interspersed by Bands of Bungner (Fig. 8g-5,6), similar
to those present in 2 month old Tfam-SCKO mice prior to injury. We conclude that
disrupting SC mitochondrial function does not affect the ability of these glia to de-
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differentiate, proliferate or support axonal regeneration following injury. Normal SC
mitochondrial metabolism, however, is essential for SCs to form mature myelin and
Remak bundles, suggesting that the formation and maintenance of these mature structures
poses a high metabolic challenge.

Discussion
In the present study we describe the generation and characterization of mice with
disrupted mitochondrial function only in SCs. We found that the induction of SC-specific
mitochondrial dysfunction did not affect the survival of these cells but resulted in a
severe,

progressive

peripheral

neuropathy

characterized

by

extensive

axonal

degeneration. SC mitochondrial dysfunction, therefore, disrupts the axo-glial interactions
required for the long-term support of axons and is a likely contributor to the clinical
impairment of patients suffering from peripheral neuropathies.
Mitochondrial dysfunction is a common cause of peripheral neuropathies. An
extensive body of literature has now addressed how neuronal/axonal mitochondria may
contribute to the pathology observed in these diseases (Niemann et al., 2006; Baloh,
2008). The results described above show for the first time that disrupted mitochondrial
function specifically in SCs can itself also cause axonal degeneration and peripheral
nerve disease. These findings are consistent with observations in patients suffering from
polyneuropathies associated with diabetes, HIV/AIDS, and mitochondrial disorders, in
which most nerve mitochondrial abnormalities are localized to SCs (Schroder, 1993;
Kalichman et al., 1998).
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Moreover, the Tfam-SCKO mice generated in our study recapitulated a number of
critical pathological features of human peripheral neuropathies. Disrupting mitochondrial
metabolism specifically in SCs was sufficient to induce both axonal degeneration as well
as demyelination. Tfam-SCKOs also displayed distal weakness and sensory deficits, two
common problems in human patients. Finally, Tfam-SCKOs suffered preferential early
loss of unmyelinated C fibers followed by the degeneration of large-caliber myelinated
axons. This was of particular interest because preferential loss of small-caliber
unmyelinated fibers is characteristic of peripheral and optic neuropathies associated with
systemic diseases such as diabetes or with exposure to environmental toxins (Kennedy et
al., 1996; McArthur et al., 2005; Sadun, 2002). Together, our results indicate that SC
mitochondria are underappreciated contributors to the abnormalities observed in
peripheral neuropathies. Furthermore, key pathological features commonly encountered
in human peripheral nerve disease can potentially be explained by SC-specific
mitochondrial dysfunction.
The findings described in the present paper are consistent with a growing body of
literature that implicates glial dysfunction in a number of neurodegenerative diseases
traditionally thought to be cell autonomous. This is best exemplified by amyotrophic
lateral sclerosis (ALS), a disease characterized by premature death of motor neurons
which is sometimes linked to dominant mutations in the antioxidant protein superoxide
dismutase 1 (SOD1) (Rosen et al., 1993). While neuronal expression of mutant SOD1 in
transgenic mouse models of ALS was found to be important for the initial timing of
disease onset (Boillee et al., 2006; Yamanaka et al., 2008; Wang et al., 2009), expression
in microglia cells (Boillee et al., 2006; Wang et al., 2009) and astrocytes (Yamanaka et
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al., 2008) was found to significantly contribute to disease progression. Similarly, in a
mouse model of Parkinson’s disease, oligodendrocyte-specific overexpression of the
disease-related protein -synuclein resulted in neurodegeneration (Yazawa et al., 2005).
A central role for glia in diseases such as Huntington’s, spinocerebellar ataxia or
Alzheimer’s has also been reported (For review see Ilieva et al., 2009). The development
of effective therapies for peripheral neuropathies and neurodegenerative disorders,
therefore, will need to address the contribution of SCs and other glia to disease
progression.
An unexpected finding of our work was that severe mtDNA depletion and
respiratory chain abnormalities in the SCs of Tfam-SCKO mice did not affect their
survival. This observation suggests that SCs have an adaptable energy metabolism and
that their survival and ATP production are not fully dependent on mitochondrial function.
Previous studies looking at the effect of Tfam deletion in a number of tissues have indeed
reported cell-specific metabolic changes that take place following the Tfam deletioninduced disruption of the electron transport chain. For example, following the musclespecific deletion of Tfam, myocytes increased their mitochondrial mass to compensate for
any deficiencies in their respiratory chain (Wredenberg et al., 2002). Cardiomyocytes, on
the other hand, were reported to switch to a primarily glycolytic metabolism in response
to the heart-specific excision of Tfam (Hansson et al., 2004). Some of these adaptations
likely account for the limited or largely delayed cell death observed in several tissuespecific Tfam KOs (Larsson et al., 1998; Wang et al., 1999; Silva et al., 2000; Sorensen
et al., 2001; Wredenberg et al., 2002). Specific metabolic adaptations following Tfam

41

depletion-induced mitochondrial dysfunction may also explain why SC viability was not
affected in Tfam-SCKO mice.
SCs have, in fact, been hypothesized to be largely glycolytic and rely on the nonoxidative catabolism of glucose to meet their energy needs (Pellerin and Magistretti,
2003). This idea is supported by the observation that in explant systems SCs take up a
disproportionately large amount of glucose (Vega et al., 2003). The fact that disruption of
mitochondrial energy metabolism in Tfam-SCKO mice did not affect SC survival
provides indirect support for this hypothesis. Our current knowledge of the basic energy
metabolism and requirements of SCs, however, is still very rudimentary. Future work
aimed at understanding the metabolic changes that take place in SCs following Tfam
deletion-induced respiratory chain deficiency should provide valuable insight into both
the biology and pathology of SCs.
Following peripheral nerve injury, SCs undergo a process of de-differentiation,
proliferation, and formation of tubular structures known as bands of Bungner, which
together with their production of neurotrophic factors, helps support axonal regeneration
(Geuna et al., 2009). Interestingly, we found that Tfam depletion-induced mitochondrial
dysfunction did not interfere with the ability of SCs to perform these duties and support
axonal re-growth. However, Tfam-deficient SCs failed to re-differentiate and form
mature Remak bundles and myelin sheaths after having promoted axonal regeneration.
The high metabolic challenge posed by the reconstruction of these mature structures,
therefore, appears to require an undisturbed SC mitochondrial anaplerotic metabolism.
Elucidation of deficiencies in the intermediate metabolism of Tfam-SCKOs could thus
provide new targets whose manipulation may promote the remyelination and the
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restoration of normal nerve function in patients suffering from mitochondrial-related
peripheral neuropathies.
SCs have a primary role in supporting axonal function and survival (Chen et al.,
2003; Reddy et al., 2003; Meyer zu Horste et al., 2007), yet the mechanisms and cellular
machinery underlying SC preservation of axons still remain largely unknown. Others
have hypothesized that glial support requires axonal ensheathment as well as some
myelin-related proteins. Trophic support of axons through neurotrophic factors has also
been postulated as a potential mechanism behind glia-mediated axonal maintenance.
Metabolic support of axons by ensheathing cells is also a likely but poorly understood
mechanism of axonal preservation (Nave and Trapp, 2008). For example, SCs may
support axons through the transfer of metabolites or by helping axons eliminate certain
toxic species, as is the case between CNS neurons and astrocytes (Benarroch, 2005). Our
results show that SC mitochondria are essential for the SC-mediated support of axonal
function and survival. Given the central role of mitochondria in cellular energy and
anaplerotic metabolism, we speculate that the axonal degeneration in Tfam-SCKOs
reflects a disruption of SC-mediated metabolic support of axons. The preferential loss of
small unmyelinated fibers early in the Tfam-SCKO disease process would then reflect a
greater dependence of these fibers on SC metabolic support. Consistent with this
hypothesis, unmyelinated axons have been found to be more energetically demanding
than myelinated axons and are estimated to consume 2.5-10 fold more energy per action
potential generated (Wang et al., 2008).
In summary, Tfam-SCKOs are, to our knowledge, the first SC-specific metabolic
mutant that recapitulates some of the pathology of human peripheral neuropathies. These
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mice demonstrate that SC-specific mitochondrial dysfunction can be sufficient to cause
both demyelination and axonal degeneration. Our study also provides evidence that SC
mitochondria help maintain the axo-glial interactions required for the long-term support
of axons. A greater understanding of SC mitochondria and how to prevent their
dysfunction is, therefore, relevant to the treatment of patients suffering from peripheral
neuropathies.

Materials and Methods
Matings of transgenic animals: All animal experiments were carried out in compliance
with institutional animal protocols. TfamloxP/loxP mice in a pure C57Bl6 background
(Larsson et al., 1998) were crossed to P0-Cre mice also in a pure C57Bl6 background
(Feltri et al., 1999). Compound heterozytoges (P0-Cre

+/-

, Tfam+/loxP) were then

backcrossed to homozygous TfamloxP/loxP to generate the Tfam-SCKO mice (P0-Cre
TfamloxP/loxP) and their Ctrl littermates (P0-Cre

+/-

,

-/-

, TfamloxP/loxP). TfamloxP/loxP mice were

also crossed to homozygosity to Rosa26-YFP reporter mice. TfamloxP/loxP/Rosa26-YFP+/+
were then crossed to P0-Cre mice using an analogous breeding scheme. TfamloxP/loxP
genotyping was carried out as previously described (Larsson et al., 1998).

Immunohistochemistry and cell quantification: The following primary and secondary
antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), chicken anti-GFP (1:1000,
Aves), rabbit anti-βIII tubulin (1:1000, Covance), rabbit anti-phospho histone 3 (1:200,
Millipore), rabbit anti-Kv1.1 (1:100, Abcam), rabbit anti-Nav1.6 (1:100, Millipore),
mouse anti-Caspr (1:1000, gift from Dr. Elior Peles, Weizmann Institute of Science,
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Rehovot, Israel), anti-rabbit Cy3 (1:500, Jackson ImmunoResearch Laboratories),
streptavidin conjugated Cy3 (1:500, Jackson ImmunoResearch Laboratories), anti-rabbit
Alexa 488 (1:500, Jackson ImmunoResearch Laboratories), and anti-chicken Alexa 488
(1:500, Jackson ImmunoResearch Laboratories).
For immunohistochemical analysis of sciatic nerves, nerves were dissected,
immersion fixed in 4% paraformaldehyde for 2 h, rinsed with PBS, and cryoprotected in
30% sucrose. Sciatic nerves were then embedded in Tissue-Tek OCT Compound (Sakura
Finetek) and sectioned at 6 m. For analysis of DRGs, mice were transcardially perfused
with 4% paraformaldehyde. The entire spinal cord was then dissected, post-fixed in PFA
overnight, rinsed in PBS and cryoprotected in 30% sucrose. After cryoprotection DRGs
were dissected, embedded in Tissue-Tek OCT Compound, and sectioned at 6 m. For
analysis of foot pads, foot pad skin was removed from the plantar surface of the hindpaw,
immersion fixed in Zamboni's fixative for 2 h, rinsed with PBS, and cryoprotected in 30%
sucrose. Skin was sectioned at 30 µm in a plane perpendicular to the skin surface. For
analysis of teased nerve fibers, mouse sciatic nerves were dissected and incubated in 4%
paraformaldehyde in PBS for 30 min at room temperature. The nerves were washed three
times in PBS for 5 min and de-sheathed, and bundles of nerve were dissected with fine
needles in PBS on Fisherbrand Superfrost/Plus microscope slides. Slides were air dried
for at least 2hrs at room temperature and stored at -20°C until staining.
All frozen sections were immunostained by post-fixing in ice-cold acetone at 20°C for 10 min and blocking in 10% horse serum (DRG and foot pads) or 5% fish skin
gelatin (sciatic nerve and teased fibers) in PBS-0.2% Triton for 1 h at room temperature.
Sections were then incubated with primary antibody diluted in blocking buffer overnight
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at 4°C. Secondary antibody incubation was performed at room temperature for 1 h also in
blocking buffer. TUNEL staining was performed as previously described (Grinspan et al.,
1996). After all stainings, sections were mounted with Vectashield Mounting Medium
with DAPI (Vector Laboratories) for microscopic visualization. Images were captured
using an upright microscope equipped for epifluorescence microscopy (Nikon 80i;
CoolSnapES camera) and were processed using MetaMorph, Image-J and Gimp software
using global adjustments in brightness and contrast.
All cell number quantifications were carried out by counting the cells of interest
in 4 randomly selected regions in longitudinal nerve sections from each animal assessed
(at least 3 mice per genotype at each age) at a 20x magnification. Epidermal innervation
density was quantified by tracing the dermal–epidermal border and determining the
number of fibers that crossed this borders as previously described (Golden et al., 2010).

Western Blotting: Sciatic nerves were isolated, desheathed in PBS, and immediately
frozen in liquid nitrogen. Lysates were prepared by homogenizing the tissue by
sonication in a buffer containing 150 mM sodium chloride, 50 mM Hepes, 1% NP-40,
1mM EDTA, 1mM sodium fluoride, 1mM sodium orthovanodate, and complete protease
inhibitor cocktail (Roche Applied Science). The lysates were clarified by centrifugation
at 14,000 rpm for 10 min and quantified using the MicroBCAProtein Assay kit (Pierce).
For Western blotting, the proteins were separated by SDS-PAGE and transferred to a
PVDF membrane (Millipore). Membranes were blocked in 5% milk in 0.5% TBS-Tween
and incubated overnight with the appropriate primary antibody. Following incubation
with secondary antibodies conjugated to HRP (GE Healthcare), membranes were
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developed with SuperSignal West Dura substrate (Pierce). The primary antibodies used
were rabbit anti-Tfam (1:4000, Dr. Nils-Goran Larsson), mouse anti-Porin 31HL (ab2)
(1:200, Calbiochem) and mouse anti-tubulin (1:1000, Sigma). The secondary antibodies
used were anti-mouse and anti-rabbit HRP (1:5000; Jackson ImmunoResearch
Laboratories).

RNA and DNA preparation and quantitative real-time PCR: Sciatic nerves were
harvested from Tfam-SCKO mice at different ages and immediately frozen in liquid
nitrogen. For RNA isolation, tissue was homogenized in Trizol reagent (Invitrogen) and
total RNA prepared according to the manufacturer’s protocol. For DNA isolation, tissue
was digested and DNA isolated using DNeasy Blood and Tissue Kit (Qiagen) according
to the manufacturer’s protocol. DNA and RNA concentration were quantified using an
ND-1000 spectrophotometer (Nanodrop Technologies).
For RNA qRT-PCR cDNA was reverse transcribed from total RNA using MMLV reverse transcriptase (Invitrogen). qRT-PCR was performed using a SYBR greenbased detection system on a 7700 Sequence Detector instrument (Applied Biosystems) as
described

previously

(Nagarajan

et

al.,

2001).

Glyceraldehyde-3-phosphate

dehydrogenase expression was used to normalize samples and obtain relative expression
values that were used to calculate fold changes. mtDNA content was also quantified by
qRT-PCR using a SYBR green-based detection system on a 7700 Sequence Detector
instrument (Applied Biosystems) in a similar way as described previously (Nagarajan et
al., 2001). Instead of cDNA, however, 15ng of total DNA were used per reaction. Primers
that recognized a region unique to the mitochondrial genome were used to determine the
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mtDNA content relative to a serial dilutions standard curve. mtDNA content values were
normalized to nuclear DNA content as determined by a set of primers directed to the
genomic locus of Smrt1. DNA and RNA qRT-PCR primer sequences were as follows
(5’-3’):

Tfam:

F,

ATGTCTCCGGATCGTTTCAC;

CAGGAGGCAAAGGATGATTC;
GAPDH: F,

TGCCCCCATGTTTGTGATG;

R,
R,

TGTGGTCATGAGCCCTTCC; mt-ND2: F, CGCCCCATTCCACTTCTGATTACC; R,
TTAAGTCCTCCTCATGCCCCTATG.

mt-Cox1:

F,

GAACCCTCTATCTACTATTCGG; R, CAAGTCAGTTTCCAAAGCCT. SDHB: F,
TGTAGAGAAGGCATCTGTGG ; R, CGTAGAAGTTACTCAAATCAGGG. mtDNA:
F, AAGTCGTAACAAGGTAAGCA; R, ATATTTGTGTAGGGCTAGGG. Nuc.DNA:
F,

GGGTATATTTTTGATACCTTCAATGAGTTA;

R,

TCTGAAACAGTAGGTAGAGACCAAAGC

Mitochondrial

isolation,

respiratory

enzyme

activity

measurements,

and

respirometry: For mitochondrial isolation, 4 sciatic nerves were dissected, desheathed,
mechanically dissociated, digested with collagenase for 20 min and pooled together in 2
ml of homogenization buffer (HM) containing 0.22 M mannitol, 70 mM sucrose, 10 mM
Tris-HCl, 0.5 mM EDTA, 1mM EGTA and 0.5% delipidated BSA. Nerves were
homogenized for about 2 minutes (12 strokes) using a Teflon-glass homogenizer turning
at 200 rpm. The homogenate was then centrifuged at 800xg for 10 min. The clarified
supernatant was centrifuged at 8,000xg for 10 min and the pellet was resuspended in 1ml
of HM buffer without BSA and spun once more at 7,500xg. The resulting pellet was
resuspended in 250 l of HM buffer without BSA. The protein concentration of the

48

resuspended mitochondrial fractions was determined using a MicroBCAProtein Assay kit
(Pierce). Five micrograms of protein from these mitochondrial preps were used to
measure complex II and complex IV activity spectrophotometrically as previously
described (Birch-Machin and Turnbull, 2001).
For high resolution respirometry 2 sciatic nerves were dissected, briefly digested
with collagenase for 10 min, then desheathed and fluffed using a pair of fine forceps. At
this point, nerve respiration was measured in a 2-ml chamber using and OROBOROS
Oxygraph 2k (Oroboros) as previously described (Mancuso et al., 2010).

Surgical procedure: Mice were anesthetized by intraperitoneal injection of 2-2-2
tribromoethanol at a dose of 500 mg/kg. The sciatic nerve was exposed at the hip and a
reproducible crush injury was created by using #5 jeweler’s forceps for 30 sec. The site
of injury was marked with a single 10-0 nylon epineural suture. Nerve lesions were
produced on the right side and the contralateral nerve was left intact and served as the
uninjured control. At the appropriate time nerves were harvested and processed for
histology.

Nerve light and electron microscopy and morphometry: Sciatic nerves from Ctrl and
Tfam-SCKO mice at different ages were dissected and placed in 3% glutaraldehyde
overnight. After washing with phosphate buffer, nerves were postfixed in 1% osmium
tetraoxide in phosphate buffer overnight at 4°C. Specimens were then dehydrated in
graded alcohols and embedded in 100% epoxy (Araldite 502). One-micrometer-thick
plastic embedded sections were prepared and stained with toluidene blue for light
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microscopy. For electron microscopy, thin sections were prepared, stained with uranyl
acetate and lead citrate, and photographed with a JEOL (Akishima) 1200 electron
microscope. All nerves underwent qualitative assessment of neural architecture followed
by detailed histomorphometric analysis carried out as previously described (Hunter et al.,
2007).

Nerve

electrophysiology

and

electromyography:

Electrophysiology

and

electromyography were performed on mice at 2, 4 and 8 months of age using a Viking
Quest electromyography machine (Nicolet) as previously described (Baloh et al., 2009).
Briefly mice were anesthetized with avertin, and placed on a heating pad. For nerve
electrophysiology subcutaneous platinum subdermal EEG electrodes 0.4 mm diameter,
12 mm length (Viasys) were used. Stimulating electrodes were placed just above the left
ankle and the left sciatic notch for nerve stimulation. Recording electrodes were placed in
the footpad. Evoked CMAPs were obtained using supramaximal stimulation, and distance
between the two sites of stimulating electrodes was used to calculate conduction velocity.
For EMG recordings a 27-gauge, Teflon-coated, monopolar needle electrode with a 70 ×
500 μm recording surface (PRO-37SAF; Electrode Store) was used. A 29-gauge
reference needle electrode (GRD-SAF; Electrode Store) was inserted subcutaneous in
close approximation to the recording electrode. A subdermal ground electrode was placed
on the back. The recording electrode was inserted into the tibialis anterior (TA) or
gastrocnemius/soleus muscles, and spontaneous electrical activity was recorded for 90 s.
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Muscle histology: Gastrocnemius muscles were dissected fresh, immediately frozen in
isopentane cooled in liquid nitrogen. Cryostat sections of gastrocnemius muscle were cut
at 10 m onto slides and stained with hematoxylin and eosin.

Nerve Cytochrome oxidase staining: Sciatic nerves were dissected fresh, placed in
Tissue-Tek OCT Compound, and immediately frozen in isopentane cooled in liquid
nitrogen. Tissue was then sectioned at 6 m. Sections were placed in an incubating
solution containing sucrose (100mg/ml), 3,3'-diaminobenzidine tetrahydrochloride 2
(DAB, 0.6 mg/ml), sodium phosphate buffer (final concentration 0.05 M), catalase 3 (2.6
g/ml), and cytochrome c (1.6 mg/ml) for 60 minutes at room temperature. After
incubation, sections were washed 3 times with deionized water, dehydrated in a series of
ascending alcohols and cleared with xylene, and mounted using permount.

Behavioral testing: Behavior testing was performed using male and female Tfam-SCKO
mice and littermate controls at 2 and 4 months of age. The experimenter was blind to the
genotypes of the mice during data acquisition. Noxious heat sensitivity (Hargreaves test)
was determined as previously described (Golden et al., 2010). Briefly, the thermal
threshold was determined by measuring the withdrawal latency to a radiant heat source
applied to the plantar surface of the hindpaw in 5 separate trials for each hindpaw with a
15 min interval between trials. The withdrawal threshold was determined by averaging
the withdrawal latency obtained in each of the trials. Mechanical sensitivity was
determined using the von Frey test. Beginning with the smallest filament and continuing
from smallest to largest, calibrated von Frey filaments were pressed to the plantar surface
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of the hindpaw until the filament just bent. The withdrawal threshold is defined as the
force that produces a withdrawal response in 3 of 5 consecutive applications within one
trial. The threshold was determined in 3 trials per hindpaw with a 15 min interval
between trials. An accelerating rotarod was used to evaluate motor coordination and
balance. Five consecutive acceleration trials were performed with a 5 min interval
between trials as described previously (Montana et al., 2009). Muscle strength was
measured using an inverted screen test as previously described (Golden et al., 2010).

Osmicated teased sciatic nerve fibers: Sciatic nerves were dissected and immersion
fixed in 3% glutaraldehyde overnight. After washing with 0.1M phosphate buffer nerves
were incubated in 1% osmium tetraoxide plus 1.5% potassium ferricyanide in 0.5 M
phosphate buffer for 1 h. Nerves were washed in PBS followed by incubation in 33, 66,
and 100% glycerol/PBS for 6 h each. Nerves were then treated with 0.6% sudan black
dissolved in 70% ethanol at 25 °C for 30 minutes, rinsed with 70% ethanol and with
water and then placed back in 100% glycerol. Nerves were teased in 100% glycerol and
coverslipped for imaging.

Statistical analysis: All values are expressed as mean ± SEM. If not stated otherwise, p
values were determined by unpaired, two-tailed Student's t test. All statistical analyses
were performed using Microsoft Excel 2007.
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Figures
Figure 1: P0-Cre deletes Tfam from SCs specifically and efficiently in Tfam-SCKO
mice. a) Diagram of the targeted Tfam locus in TfamloxP mice. When TfamloxP mice are
crossed with mice that express Cre recombinase under the control of the P 0 promoter,
exons 6 and 7 of Tfam are excised to produce Tfam– mice. b) YFP fluorescence in SCs
(arrowheads) of longitudinal sciatic nerve sections (ScN), as well as satellite SCs
(arrowheads) in DRGs (DRG) of Rosa26-YFP/P0-Cre mice. P0-Cre induces
recombination specifically in SCs and excision-dependent YFP fluorescence is localized
to regions of SC cytoplasm but not to axons (Tuj1 and stars; note non-overlapping Tuj1
and YFP staining) or DRG neuron cell bodies (stars). Scale Bars: top and bottom panels
100 m, middle magnified panel 50 m. c) qRT-PCR results showing efficient depletion
of Tfam mRNA in Tfam-SCKO sciatic nerves. Tfam mRNA levels in the sciatic nerve of
1 month old Tfam-SCKOs were decreased by 60% (p=0.001, two-tailed Student’s t-test)
compared to Ctrl littermates. By 2 months of age Tfam mRNA levels were reduced by
85% (p=0.002, two-tailed Student’s t-test) compared to Ctrl littermates. Reported values
are normalized to GAPDH; error bars, SEM; n=2 pools of 3 mice run in 3 independent
experiments. d) Western blot showing efficient depletion of Tfam protein in the sciatic
nerves of Tfam-SCKO mice compared to Ctrl littermates by 2 months of age.
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Figure 2: SC-specific excision of Tfam induces mtDNA and transcript depletion and
respiratory dysfunction in Tfam-SCKOs. a) qRT-PCR results showing depletion of
mtDNA content in the sciatic nerves of Tfam-SCKO mice compared to littermate Ctrls.
mtDNA content was significantly reduced by 50% (p=0.01, two-tailed Student’s t-test) in
2 month old Tfam-SCKO sciatic nerves compared to Ctrl nerves. Reported values are
normalized to nuclear DNA content; error bars, SEM; n=3 mice per genotype run in 2
independent experiments. b) qRT-PCR results showing depletion of mitochondriallyencoded electron transport chain subunit transcripts (mt-ND2 and mt-Cox1) in TfamSCKO sciatic nerves. mRNA levels of these subunits were decreased 85% (p=0.02, twotailed Student’s t-test) in 2 month old Tfam-SCKO sciatic nerves compared to Ctrl
littermates. In contrast, transcripts of nuclearly-encoded electron transport chain subunits
(nuclear SDHB) are not depleted in Tfam-SCKO sciatic nerves. Reported values are
normalized to GAPDH; error bars, SEM; n=2 pools of 3 mice run in 3 independent
experiments. c) Respiratory chain enzyme activity measured from mitochondria isolated
from the sciatic nerves of 2 month old Tfam-SCKO nerves and Ctrl littermates. COX
activity (complex IV), which contains critical mtDNA-encoded subunits, is reduced 65%
(p<0.01, two-tailed Student’s t-test) in Tfam-SCKO mice. Error bars, SEM; n=3 pools of
2 mice per genotype. d) Mitochondrial respiration in 2 month old Tfam-SCKO and
littermate Ctrl permeabilized sciatic nerves measured using high resolution respirometry.
Respiration induced by substrates delivering electrons to complex I (pyruvate+malate) is
reduced by 35% (p=0.04, two-tailed Student’s t-test) in Tfam-SCKO sciatic nerves
compared to littermate controls. Respiration induced by the convergent transport of
electrons entering at complexes I and II (using pyruvate+malate+succinate as substrates)
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is decreased by 25% (p=0.04, two-tailed Student’s t-test) in Tfam-SCKO sciatic nerves
compared to littermate Ctrls. Respiration induced by substrates delivering electrons to
complex II alone (succinate), which is fully nuclearly-encoded, was not significantly
changed in Tfam-SCKO nerves compared to littermate Ctrls. Error bars, SEM; n=5 mice
per genotype. e) COX enzymatic staining of 4 month old Ctrl and Tfam-SCKO sciatic
nerves. The intense COX staining that localizes to SCs in Ctrl nerves (arrowheads) is
largely lost in Tfam-SCKO nerves, indicating mitochondrial dysfunction specifically in
this cell type. f) Electron micrographs of Tfam-SCKO sciatic nerves show abundant
abnormal enlarged mitochondria (arrowheads), often with distorted cristae. Aberrant
mitochondria are mainly found in SCs, while axonal mitochondria show no
morphological abnormalities (arrows). Pathological mitochondria are visible as early as 1
month in Tfam-SCKO nerves (top 3 panels) and become more abundant as these mice
age (bottom panels from 4 month old mice). Scale bars: 500 nm
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Figure 3: Tfam-SCKOs develop a progressive degenerative peripheral neuropathy.
a) Photograph of end-stage Tfam-SCKO mouse (≈8 months old). At this stage TfamSCKOs display a characteristic “swimming-gait” and are unable to support themselves on
their hind legs. b) Typical nerve conduction trace from a 4 month old Tfam-SCKO mouse
showing marked temporal

dispersion.

Scale bars 1ms

and 1 mV.

c, d)

Electrophysiological studies of Tfam-SCKO mice show that, as early as 2 months of age,
these mice have significantly reduced nerve conduction velocity (c, p<0.001, two-tailed
Student’s t-test) compared to littermate Ctrls. This deficit persists in 4 month old animals
(c, p<0.001, two-tailed Student’s t-test), which also have severe temporal dispersion as
shown by an increased response duration (d, p <0.001, two-tailed Student’s t-test). These
findings indicate segmental demyelination. Error bars, SEM. N=4 mice per genotype at
each age. e) Typical electromyography traces from a 4 month old Tfam-SCKO mouse
showing fibrillation (arrowheads) and fasciculations (arrows), common findings in
diseases involving motor axon loss, indicative of muscle fiber denervation and motor unit
degeneration/regeneration. These findings were never present in Ctrl littermates. Scale
bars 50 ms, 500 V f) Hematoxylin and eosin stain of the gastrocnemius muscle from a
Ctrl and a Tfam-SCKO mouse showing scattered and grouped muscle fiber atrophy
(arrowheads). This is characteristic of motor axon degeneration. Scale bar 50 m.

66

67

Figure 4: Tfam-SCKOs display early preferential loss of small unmyelinated fibers.
a-c) Toluidene blue stained plastic sections of 1 month old Tfam-SCKO sciatic nerve and
littermate Ctrls (a) show that at this age there are no differences in the number of
myelinated fibers (b) or the extent of myelination (g-ratio, axon area/fiber area) (c). Scale
bar 25 m. Error bars, SEM. n=4 mice per genotype. d) Electron micrographs of 1 month
old Ctrl and Tfam-SCKO sciatic nerves show that while large myelinated fibers are
mostly normal in Tfam-SCKO mice at this age (arrows), the structure of Remak bundles
(arrowheads) is largely abnormal. Scale bar 2 m. e 1-4) Compared to Ctrl littermates
(1), unmyelinated axons in Tfam-SCKO Remak bundles are found touching one another
(2, 4, stars) and interspersed by pathological SC processes known as Bands of Bungner
(2, arrowheads). Free-floating excess basement membrane (2, 3, arrows) enclosing SC
cytoplasm (3, star) with few or no axons left, indicative of extensive degeneration of
unmyelinated axons, is also visible. By 2 months of age most non-myelinating SCs are
associated with unstructured, degenerating Remak bundles, containing abnormal axons
(4, star) and filled with phagocytic vesicles and membranous debris (4, arrowhead). Scale
bar 500 nm. f) Representative photographs of epidermal fiber innervation (arrowheads) in
the foot pads of 2 month old Tfam-SCKO and littermate Ctrl mice. Scale bar, 10 m g)
Quantification of fiber density in the epidermis shows a 30% decrease in Tfam-SCKO by
2 months of age (p=0.02, two-tailed Student’s t-test), indicating early degeneration of
small unmyelinated C-fibers. Results reported are normalized to per unit area. Error bars,
SEM; n=3 mice per genotype at each age.
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Figure 5: Degeneration of large caliber myelinated fibers in older Tfam-SCKOs. a,
b) Toluidene blue stained plastic sections of Tfam-SCKO sciatic nerves and littermate
Ctrls at different ages (a) and quantification of total number of myelinated profiles per
nerve (b). At 2 months, some initial signs of axonal degeneration are apparent
(arrowhead) in Tfam-SCKO nerves, but at this age there are no differences in the number
of myelinated fibers (b). By 4 months there is prominent axonal degeneration, as shown
by a significant decrease (p>0.001, two-tailed Student’s t-test) in the total number of
myelinated profiles in Tfam-SCKO nerves. Axonal degeneration worsens by 8 months of
age (p>0.001, two-tailed Student’s t-test). Scale bar 25 m. Error bars, SEM. n=4 mice
per genotype at each age. c 1-4) Electron micrographs of Tfam-SCKO nerves at different
ages confirm that large myelinated fiber degeneration becomes prominent by 4 months of
age (2) and worsens by 8 months (3), as shown by large portions of endoneurium
completely devoid of axons (stars). By 4 months of age actively demyelinating and
degenerating axons filled with membranous debris (arrowheads) are also common in
Tfam-SCKO nerves (4).By this age segmental demyelination as shown by large caliber
axons without myelin is also prominent (2-4, arrows). This type of pathology is not
visible in Ctrl nerves (1). Scale bar, 2 m. d) Fiber size distribution analysis in TfamSCKO and Ctrl littermate nerves at different ages. No differences in fiber size
distribution are evident despite severe axonal degeneration, indicating that myelinated
fibers of all calibers are susceptible to degeneration. Error bars, SEM. n=4 mice per group
at each age e) Osmicated teased fibers from 4 month old Tfam-SCKO nerves confirm the
presence of segmental demyelination. Scale bar 25 m.
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Figure 6: Tfam-SCKOs have behavioral deficits consistent with early loss of
unmyelinated fibers followed by extensive degeneration of myelinated axons a) 2
month old Tfam-SCKOs are less sensitive to an applied noxious heat stimulus than Ctrl
littermates (p<0.01, two-tailed Student’s t-test), as shown by an increased withdrawal
latency, which indicates loss of unmyelinated C-fiber nociceptors. This deficiency
persists in 4 month old Tfam-SCKO mice (p<0.01, two-tailed Student’s t-test). b-d) At 2
months of age, consistent with the early preservation of large myelinated motor axons,
Tfam-SCKOs do not display significant motor deficits as shown by the inverted screen
test (b) or accelerating rotarod (c). 4 month old Tfam-SCKOSs, however, spend
significantly less time on an inverted screen (p<0.01, two-tailed Student’s t-test) (b) and
accelerating rotarod (p<0.01, two-tailed Student’s t-test) (d), motor deficits that indicate
the loss of large myelinated fibers by this age. Error bars, SEM. N=4 mice per genotype
at each age.
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Figure 7: SC mitochondrial dysfunction does not compromise SC survival. a, b)
Nuclear staining (a Dapi) and quantification (b) shows that there is no difference in the
number of SC nuclei between Tfam-SCKO and Ctrl sciatic nerves at different ages. a, c)
Quantification of Rosa-YFP immunofluorescence (a YFP/DAPI, c) in Tfam-SCKO/RosaYFP nerves at different ages shows that the majority of SCs are Tfam-deficient at all
ages. a, d) Quantification of TUNEL immunohistochemistry (a Tunel/DAPI, d) of TfamSCKO and Ctrl littermate shows no differences in the number of TUNEL positive cells at
different ages, indicating that SCs are able to survive despite the disruption in their
mitochondria. Scale bar 100 m. Error bars, SEM. n=3 mice per genotype at each age.
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Figure 8: Tfam-deficient SCs support axonal regeneration but fail to remyelinate
following injury. a, b) Phospho-histone 3 (PH3) immunostaining (a) and quantification
(b) shows that there is no difference in the number of proliferating SCs (arrowheads)
between Tfam-SCKO and Ctrl sciatic nerves 4 days after crush injury. Scale bar 100 m.
Error bars, SEM. n=at least 3 mice per genotype. c) Quantification of the amount of
myelin debris present in Ctrl and Tfam-SCKO nerves 3 weeks after crush injury shows
no impairment in the ability of Tfam-deficient SCs to break down existing myelin. Error
bars, SEM. n=3 mice per genotype. d) Quantification of the number of myelinated
profiles in Ctrl and Tfam-SCKO nerves 3 weeks after crush distal to the site of injury
shows a significant decrease (p<0.001, two-tailed Student’s t-test) in the number of
myelinated profiles formed by Tfam-deficient SCs following injury. Error bars, SEM.
n=3 mice per genotype. e) Electron micrographs of Ctrl and Tfam-SCKO nerves 3 weeks
after crush depicting the inability of Tfam-deficient SCs to form mature myelin even
though they are capable of supporting axonal regeneration. Scale bar, 2 m. f)
Quantification of the total number of fibers (myelinated and unmyelinated) distal to the
site of injury 3 weeks after crush shows no differences between Tfam-SCKO and Ctrl
nerves, confirming that Tfam-deficient SCs are able to support axonal regeneration. Error
bars, SEM. n=3 mice per genotype g) Electron micrographs of Ctrl (1) and Tfam-SCKO
(2-4) large caliber fibers distal to the site of injury 3 weeks after crush showing that while
Tfam-deficient SCs are capable of ensheathing axons and forming 1 to 1 associations
with them (arrowheads, axons; arrows, SCs) they are not able to form mature myelin.
Regenerating Remak bundles are present in Ctrl nerves (5) but are absent in Tfam-SCKO
nerves (6; arrowheads, axons; arrows, SCs). h) Proportion of axons larger than 1 m is
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similar between Tfam-SCKO and Ctrl nerves following injury and cannot explain the
absence of myelin in Tfam-SCKO nerves.
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Supplementary Figure 1: Tfam-SCKOs initially develop and myelinate normally. ac) Toluidene blue stained plastic sections of 2 week old Tfam-SCKO sciatic nerve and
littermate Ctrls (a) show that at this age there are no differences in the number of
myelinated fibers (b) or extent of myelination (c) (g-ratio, axon area/fiber area). Scale bar
25 m. Error Bars, SEM. n= 3 mice per genotype d,e) Electron micrographs from 2 week
old Tfam-SCKO sciatic nerve and littermate Ctrls confirm that myelin (d) as well as
nodes of Ranvier initially develop normally. N, node; Mv, microvilli; Pn, paranode;
arrowheads, paranodal loops. Scale bar 2 m (d) and 500 nm (magnified panels)(e). f)
Immunostaining of teased nerve fibers from 3 week old Tfam-SCKO and Ctrl mice with
antibodies against nodal (Nav1.6), paranodal (Caspr) and juxtaparanodal (Kv1.1) markers
confirm that nodal architecture initially develops normally in these mice. Scale bar 50
m.
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CHAPTER 3:

Mitochondrial Dysfunction-induced Abnormalities in Schwann Cell Lipid
Metabolism Lead to Axonal Degeneration and Peripheral Neuropathy

Adapted from: Viader A, Sasaki Y, Yang K, Gross RW, Milbrandt J. (2011).
Mitochondrial dysfunction-induced abnormalities in Schwann cell lipid metabolism lead
to axonal degeneration and peripheral neuropathy. Submitted.
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Abstract
Mitochondrial dysfunction is a common cause of peripheral neuropathy. Much
effort has been devoted to examining the role played by neuronal/axonal mitochondria,
but how mitochondrial deficits in peripheral nerve glia (Schwann cells, SCs) contribute to
peripheral nerve diseases remains unclear. Here, we investigate a mouse model of
peripheral neuropathy secondary to SC mitochondrial dysfunction (Tfam-SCKOs). We
show that disruption of SC mitochondria activates a maladaptive integrated stress
response and causes a shift in lipid metabolism away from fatty acid synthesis toward
oxidation. These alterations in SC lipid metabolism result in depletion of important
myelin lipid components as well as in extensive accumulation of acylcarnitines, an
intermediate of fatty acid -oxidation. Importantly, we show that acylcarnitines are
released from SCs and induce axonal degeneration. Altered SC lipid metabolism
accompanied by toxic accumulation of lipid intermediates is thus an underlying
pathological mechanism in mitochondria-related peripheral neuropathies.
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Introduction
Mitochondrial metabolic irregularities are a common culprit in diverse
neurodegenerative diseases and are key pathological contributors to peripheral
neuropathy. Mitochondrial dysfunction is thought to be largely responsible for the
peripheral nerve deficits that afflict up to 50% of all people with diabetes and can lead to
incapacitating pain, sensory loss, and debilitating muscle weakness 1. Similarly, a number
of mutations in mitochondrial proteins have now been identified as the cause of several
forms of inherited neuropathies known as Charcot Marie Tooth (CMT) 2. The need to
elucidate the manner in which mitochondrial dysfunction underlies progression of
peripheral nerve disease is thus well appreciated; to date much effort has been devoted to
clarifying the role played by neuronal/axonal mitochondria 3.
Glial cells, the main non-neuronal cell component of the nervous system, are
involved in virtually every aspect of nervous system function 4. Moreover, glia are
increasingly recognized to influence neurodegenerative diseases traditionally thought to
be neuron autonomous (e.g. amyotrophic lateral sclerosis) 5. Schwann cells (SCs), the
glial cells in the peripheral nervous system (PNS), intimately associate with all peripheral
nerve axons to support their long-term preservation and function

6-8

. Moreover, SCs are

also essential for peripheral nerve repair after axonal damage 9. Interestingly, SCs from
nerves of patients with neuropathy often present with abnormal mitochondria

10, 11

. Given

this critical involvement of SCs in the maintenance of peripheral nerves and the role of
mitochondria in cell energy and anaplerotic metabolism, mitochondrial dysfunction in
these glia is likely to contribute to disease progression of peripheral neuropathies.
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With the goal of understanding whether SC mitochondrial abnormalities affect
axonal survival and peripheral nerve function we recently generated mice (Tfam-SCKOs)
with disrupted mitochondrial metabolism exclusively in SCs 12. Using this novel model of
peripheral neuropathy, the present work demonstrates that SC mitochondrial dysfunction
activates a maladaptive integrated stress response and causes a shift in lipid metabolism
away from new lipid synthesis towards increased fatty acid oxidation. This metabolic
alteration results in early depletion of myelin lipid components as well as a large
accumulation of acylcarnitine lipid intermediates. Importantly, we show that
acylcarnitines are released from SCs and induce axonal degeneration. Altered SC lipid
metabolism accompanied by the toxic accumulation of lipid intermediates is thus an
underlying mechanism of axonal degeneration and demyelination in peripheral
neuropathies and constitutes a potentially important therapeutic target.

Results
Energy depletion does not drive nerve pathology in Tfam-SCKO mice
To directly interrogate the contribution of SC mitochondrial dysfunction to
peripheral neuropathy, we recently generated mice (Tfam-SCKOs) with impaired
mitochondrial function exclusively in SCs

12

. These mice were produced through the

tissue-specific deletion of the mitochondrial transcription factor A gene (Tfam), which is
required for mtDNA transcription and replication and when excised induces progressive
defects in the mitochondrial electron transport chain 13. Interestingly, induction of SCspecific mitochondrial dysfunction did not affect SC survival; instead, these deficits
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal
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degeneration that recapitulated critical features of human neuropathy. Tfam-SCKO
nerves displayed early morphological abnormalities and preferential loss of small
unmyelinated C fibers (starting at 1-2 months of age, Fig. 1a) followed by the
degeneration of large-caliber myelinated axons (starting at 3-4 months of age, Fig 1b and
c)

12

. Extensive demyelination was apparent at late stages of the disease (Fig 1b).

Consistent with this nerve pathology, Tfam-SCKO mice developed progressive distal
weakness and sensory deficits

12

, common symptoms in patients with peripheral

neuropathy.
Having established the utility of the Tfam-SCKO mouse model in understanding
and potentially treating peripheral neuropathies, we explored causal mechanisms of the
nerve pathology in these mice. We focused on identifying processes that drive disease
progression in 2 month old Tfam-SCKOs, an age when SC mitochondrial function is
already disrupted yet Tfam-SCKO nerves display only limited, early pathological
changes (Fig 1c) 12. All experiments described below were carried out on mice this age.
We first determined the energy status of Ctrl and Tfam-deficient SCs, because clinical
deficits in diseases associated with mitochondrial dysfunction are often assumed to be
directly related to depletion of cellular energy levels. Surprisingly, HPLC measurement
of nerve adenylate pools and determination of the Adenylate Energy Charge (EC), an
index used to measure cellular energy status (see methods) 14, revealed only a very slight
energy reduction (≈8%) in Tfam-SCKO nerves (EC Ctrl=0.812 +/- 0.009; EC TfamSCKO=0.747 +/-0.008; p<0.001; Fig. 1d). Increased mitochondrial content and
glycolysis in Tfam-deficient SCs (Supplementary Fig.1), two metabolic adaptations that
often follow mitochondrial deficits

15, 16

, likely account for this relative preservation of

85

energy levels in Tfam-SCKO nerves. When we assessed the activation status
(phosphorylation at Thr172) of the cellular energy sensor AMP-activated protein kinase
(AMPK) 17, we observed no differences between Ctrl and Tfam-SCKO nerves (Fig. 1e
and f). This indicates that Tfam-deficient SCs do not experience a significant energy
depletion to an extent that is likely responsible for the pathology observed in the nerves
of these mice.

Mitochondrial dysfunction activates a maladaptive stress response and shifts the
balance of lipid metabolism in SCs
In an attempt to identify other potential disease-causing processes, we carried out
gene expression profiling of 2 month old Ctrl and Tfam-SCKO nerves. This analysis
uncovered the upregulation of a number of genes activated by the integrated stress
response (ISR), including Chop10, Asns, and Trib3, in SCs with disrupted mitochondrial
metabolism (data not shown). The ISR is an evolutionarily conserved, “stress”-activated,
gene expression program controlled by the phosphorylation of translation initiation factor
2 (eIF2) 18. Importantly, previous studies examining neuropathy models induced by
mutations in structural myelin proteins have shown that activation of the ISR by
endoplasmic reticulum (ER) accumulation of the mutant proteins is particularly
maladaptive to SCs 19. Thus, we first used qRT-PCR to confirm the activation of ISR in
Tfam-SCKOs nerves and verified the upregulation of ISR target genes (Fig 2a).
Moreover, Western blot analysis showed hyper-phosphorylation of eIF2in Tfam-SCKO
nerves compared to Ctrl (Fig. 2b), further establishing the activation of ISR following SC
mitochondrial dysfunction.
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To ensure that ISR activation in Tfam-SCKO nerves was a primary effect of
mitochondrial defects in Tfam-deficient SCs, we treated SCs in vitro with mitochondrial
inhibitors (e.g. FCCP, antimycin, oligomycin) and examined the effect on the activity of
the pathway. Application of mitochondrial inhibitors on SCs in vitro also increased
phosphorylation of eIF2 (Fig. 2c) and induced ISR target genes (Fig. 2d). These results
suggest that the activation of the ISR in Tfam-SCKO nerves was a consequence of SC
mitochondrial deficits. Note, however, that unlike previous reports on other mouse
models of neuropathy 19, activation of the ISR in Tfam-SCKOs was not associated with
ER stress or an unfolded protein response (UPR). Levels of activated PERK (as
determined by its phosphorylation), the main ER-stress sensor known to induce ISR 18,
were not elevated in Tfam-SCKO nerves (Fig. 2e). Similarly, IRE-1, a second ER stress
sensor normally activated by the UPR 18, was not engaged either in Tfam-SCKO nerves
or in cultured SCs treated with mitochondrial inhibitors (as determined by splicing of the
IRE-1 target Xbp-1; Fig. 2f). Therefore, SC mitochondrial electron transport chain
deficits activate ISR through a process that is distinct from ER-stress. Maladaptive
activation of the ISR in SCs by a variety of stressors may thus be a central pathological
mechanism common to different forms of peripheral neuropathy.
The downstream cellular processes initiated by the ISR that are maladaptive to
SCs are unclear. Recent reports have linked activation of this pathway to a decrease in
expression of lipid biosynthesis genes

20

as well as alterations in intermediate lipid

metabolism 21. Moreover, increased expression of the ISR target gene Trib3, which we
found to be highly upregulated in Tfam-SCKO nerves, shifts the balance of fatty acid
metabolism away from lipogenesis and toward oxidation in muscle and fat cells 22. Given
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the central role of lipids in the normal biology of SCs (e.g. myelin formation) (Chrast et
al., 2010) and the importance of mitochondria to lipid metabolic reactions (e.g. as a
source of intermediates), we hypothesized that nerve deficits in neuropathies modeled by
Tfam-SCKO mice might be largely caused by alterations in SC lipid metabolism
secondary to mitochondrial derangements. Consistent with this idea we found that
differentially expressed genes in Tfam-SCKO vs. Ctrl nerves were enriched for targets
involved in lipid metabolism. Lipid-related metabolic pathways were in fact overrepresented among differentially expressed genes in Tfam-SCKO nerves (Fig. 3a). qRTPCR confirmed that a number of genes critically involved in lipid synthesis were
downregulated in Tfam-deficient SCs following mitochondrial dysfunction, including
fatty acid synthetase (FASN) and HMG-CoA reductase (HMGCR) (Fig. 3b). Moreover,
we found that Acetyl-coA carboxylase (ACC) phosphorylation, which inhibits the
activity of this enzyme (Fig. 3c), was increased 3-fold in Tfam-SCKO nerves compared
to Ctrls (Fig. 3d and e). ACC supplies malonyl-coA required for lipid biosynthesis and as
such critically regulates the balance between lipid synthesis vs. oxidation (Fig. 3c)

23

.

Increased phosphorylation of ACC in Tfam-SCKO nerves and decreased expression of
lipid synthetic genes is consistent with a shift in lipid metabolism away from new lipid
synthesis and towards increased lipid oxidation. Together, these results show that
mitochondrial dysfunction in SCs activates a maladaptive stress response and remodels
SC lipid metabolism.

SC mitochondrial dysfunction causes depletion of myelin lipids and accumulation of
fatty acid oxidation intermediates
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The signs of altered lipid metabolism in SCs with disrupted mitochondria
prompted us to examine in more detail the implications of these changes for the
pathology observed in Tfam-SCKO nerves. To this end, we analyzed the lipid
composition of 2 month old Ctrl and Tfam-SCKO nerves using multidimensional mass
spectrometry-based shotgun lipidomics. This method provides a comprehensive
description of alterations in cellular lipids by identifying and quantifying individual lipid
molecular species in a high-throughput fashion from a database of over 36,000 potential
lipid molecular species 24. Among all the different lipid classes examined, cerebrosides
and sulfatides were the only lipid classes showing a depletion in 2 month old TfamSCKO nerves compared to Ctrls, with a 30% and a 40% reduction respectively (Fig. 4a
and b, Supplementary Fig. 2a). In peripheral nerves, cerebrosides and sulfatides are
almost exclusively produced by SCs and are particularly enriched in myelin; together
they represent almost 30% of all lipid content in peripheral myelin 25. The depletion of
these two important myelin glycosphingolipids from Tfam-SCKO nerves is in agreement
with our observations suggesting that mitochondrial dysfunction in SCs results in a
metabolic shift away from lipid biosynthesis. Moreover, sulfatide and cerebroside
depletion disrupts saltatory conduction of action potentials by increasing myelin fluidity
and interfering with the maintenance of SC-axon contacts

26-28

. The reduction of myelin

lipid components induced by mitochondrial dysfunction may underlie the prominent
demyelinating phenotype apparent in late stages of the disease in Tfam-SCKO mice (Fig.
1b and d)

12

. This is supported by the observation that depletion of sulfatides and

cerebrosides preceded the extensive demyelination or reduction in expression of myelin
proteins in Tfam-SCKO nerves (Fig.1b and c, Fig. 4c) 12.

89

The most prominent alteration in lipid composition in 2 month old Tfam-SCKO
nerves was a 25-fold increase in acylcarnitine species (Fig. 5a). This dramatic increase
affected most long-chain acylcarnitines with some species being hundreds of times higher
in Tfam-SCKO nerves compared to Ctrls (Fig. 5b, Supplementary Fig. 2b).
Acylcarnitines are intermediates in the transport of fatty acyl groups across the
mitochondrial membrane required for them to undergo mitochondria fatty acid oxidation, an important source of cellular energy and anabolic metabolites 29. Fatty acids
longer than 10 carbon atoms are converted to acylcarnitines to be shuttled into the
mitochondrial matrix, the site of -oxidation, where they are oxidized through repeated
cycles of four enzymatic reactions that catalyze this process (Fig. 5c)

29

. Increased

acylcarnitine levels in Tfam-SCKO nerves, therefore, support our previous observations
suggesting a shift away from lipid synthesis toward oxidation following SC
mitochondrial deficits (Fig. 3). The severity of the acylcarnitine accumulation in Tfamdeficient SCs, however, likely indicates that the increased shunting of lipids toward oxidation was accompanied by a decrease in the ability of SCs to oxidize them. The large
presence of hydroxy-acylcarnitines (Fig. 5d) and reduced NAD+/NADH ratio in TfamSCKO nerves (Fig. 5e), likely related to the inability of Tfam-deficient SCs to re-oxidize
NADH as mitochondrial dysfunction worsened, suggests the inhibition of the rate
determining step in -oxidation of fatty acids that is catalyzed by 3-hydroxyacyl CoA
dehydrogenase. This step normally converts -hydroxy-acyl-CoA to keto-acyl-CoA (Fig.
5c); inhibition of this NAD+-dependent step of -oxidation (by a decreased NAD+/NADH
ratio) leads to accumulation of the transient intermediate 3-hydroxy acyl CoA, which can
then be converted to hydroxy-acylcarnitines (Fig. 5c) 30, 31.
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The accumulation of acylcarnitine -oxidation intermediates can be toxic and has
been observed to exacerbate pathological states

32

. We hypothesized therefore that

accumulation of acylcarnitines in Tfam-SCKO nerves may contribute to the neuropathy
present in these mice. In fact, genetic diseases that inhibit fatty acid -oxidation and lead
to a significant accumulation of acylcarnitines often present with severe forms of
peripheral neuropathy

33, 34

. Together, these results suggest that depletion of myelin lipid

components and accumulation of toxic lipid intermediates in SCs with dysfunctional
mitochondria are underlying pathological mechanisms in peripheral neuropathies.

Acylcarnitines can be released from SCs and cause axonal toxicity
Given the dramatic increase in acylcarnitine concentration in Tfam-SCKO nerves
we examined the possibility that acylcarnitines cause the axonal degeneration observed in
Tfam-SCKO mice. This amphiphilic metabolite adversely alters the properties of
membranes and ion channels with devastating effects. In the heart, for example,
acylcarnitine-mediated disruption of ion homeostasis can predispose the myocardium to
lethal ventricular tachyarrhythmias and sudden death during ischemic episodes
Given the ability of acylcarnitines to cross the plasma membrane

29

35-37

.

and the intimate

association between SCs and axons in peripheral nerves, we hypothesized that release of
acylcarnitines from SCs onto the surrounding axons could alter axonal membrane
properties and ion homeostasis and contribute to the severe axon degeneration phenotype
in Tfam-SCKO nerves as well as in neuropathies that present with prominent axonal loss.
To test this hypothesis we first examined whether long-chain acylcarnitines are
released from SCs onto surrounding axons. Two-month old Ctrl and Tfam-SCKO nerves

91

were cultured as explants for 2.5 days. At the end of this time, we measured the amount
of long-chain acylcarnitines released from the nerves into the culture media. While Ctrl
nerves released very low levels of long-chain acylcarnitines into the surrounding media,
Tfam-SCKO nerves secreted 35-fold more long-chain acylcarnitines (primarily C16 and
C18; Fig. 6a). Remarkably, the buildup of long-chain acylcarnitines from a single TfamSCKO nerve in 100 l of media reached up to ≈ 2 M within 2.5 days. Tfam-deficient
SCs therefore not only accumulate acylcarnitines following mitochondrial dysfunction,
but also release them in significant quantities onto surrounding axons.
We next assessed the ability of acylcarnitines to disrupt axonal membrane
properties and ion homeostasis. We specifically focused on the effect of acylcarnitines on
axonal calcium levels (Ca2+), since long-chain acylcarnitines have been previously shown
to alter Ca2+ homeostasis in cardiac and skeletal muscle

. Ca2+ is also important for

37

axonal integrity and function; intra-axonal Ca2+ elevation often leads to severe axon
degeneration

38

, and its homeostasis is disrupted in peripheral neuropathies

39

. Acute

application of palmitoyl-carnitine, one of the most highly increased acylcarnitine species
in Tfam-SCKO nerves, caused a significant elevation of intracellular Ca2+ in cultured
dorsal root ganglion (DRG) neurons loaded with the calcium dye Fluo-4 (Fig. 6b and c).
This rise in intracellular Ca2+ took place within minutes after exposure to acylcarnitine,
was dose-dependent, and was specific to acylcarnitines; application of the corresponding
free fatty acid at the same concentrations exerted no comparable effect (Fig. 6b and c).
The acute influx of Ca2+ after addition of palmitoyl-carnitine also caused significant
axonal blebbing (Fig. 6b and d), which when severe enough results in axonal
degeneration.
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Finally, we explored the long-term effect of chronic exposure to moderate levels
of acylcarnitines on axonal stability as this more likely recapitulates the situation in vivo.
For these experiments we applied 25 M palmitoyl-carnitine onto DRG neurons daily for
up to nine days; this concentration caused no immediate axonal degeneration when
applied acutely and was close to the range of long-chain acylcarnitines released from a
single Tfam-SCKO nerve cultured as an explant (Fig. 6a). Interestingly, axons were able
to withstand exposure to 25 M palmitoyl-carnitine for up to four days. After four days,
however, prominent axonal blebbing started to develop and axonal degeneration followed
soon thereafter and progressively worsened (Fig. 6e and f). Note, that 12.5 M palmitoylcarnitine applied chronically resulted in axons of unhealthy appearance that displayed
morphological abnormalities, but no statistically significant increase in the degeneration
index of these axons was observed within the time frame of our experiments (data not
shown). Together, these results demonstrate that the long-chain acylcarnitines that
accumulate in SCs following mitochondrial dysfunction can be released out of these glia
onto the surrounding axons. Moreover, exposure of axons to long-chain acylcarnitines
can disrupt axonal membrane properties and ion homeostasis, compromising axonal
stability over time.

Discussion
In the present study we have found that a lipid metabolic shift away from
synthesis towards oxidation is induced in SC following mitochondrial dysfunction. This
metabolic shift is induced, at least in part, by the activation of a conserved stress response
(the ISR), which is maladaptive in SCs. We demonstrate that this shift in lipid
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metabolism results in the depletion of important lipid myelin components, which
preceded overt demyelination and is therefore a likely driver of this process in
mitochondria-related neuropathies. Finally, we propose a novel mechanism by which
lipid abnormalities in SCs can exacerbate axonal loss in peripheral neuropathies through
the release of toxic long-chain acylcarnitines (Fig. 7). Disruption of SC lipid metabolism
homeostasis secondary to mitochondrial dysfunction is thus a critical underlying
pathological mechanism in peripheral neuropathies.
Mitochondrial dysfunction is a common cause of peripheral neuropathies. We
recently generated the first mouse model (Tfam-SCKOs) useful in directly interrogating
the contribution of SC mitochondrial derangements to peripheral neuropathy, by
disrupting mitochondria specifically in these glia

12

. Interestingly, SC mitochondrial

deficits in Tfam-SCKO mice did not affect the survival of these glia but instead resulted
in a severe, progressive peripheral neuropathy characterized by extensive axonal
degeneration that recapitulated critical features of human neuropathy

12

. These results

showed that normal mitochondrial function in SCs is essential for maintenance of the
axo-glial interactions required for the long-term support of axons and normal peripheral
nerve function. Importantly this work indicated that SC mitochondrial dysfunction may
contribute to human peripheral neuropathies and that Tfam-SCKO mice, a new model of
neuropathy secondary to SC mitochondrial dysfunction, could be useful in identifying
causal pathophysiological mechanisms.
The examination of Tfam-SCKO mice described above uncovered the activation
of the ISR in Tfam-deficient SCs secondary to mitochondrial dysfunction. The ISR is an
evolutionarily conserved, “stress”-activated, gene expression program centered on
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phosphorylation of eIF2. Activation of this program is meant to promote a cellular
stress-resistant state by global attenuation of protein synthesis, which reduces the ER load
and diverts amino acids from energetically costly protein synthesis to other metabolic
pathways 18. Activation of this program in SCs, however, has previously been shown to
be particularly maladaptive. In a study examining a model of CMT caused by mutations
to myelin protein zero (P0), the authors found that accumulation of mutant P0 in the ER
activated the ISR as part of an UPR

19

. Importantly, by blocking the induction of this

pathway through the deletion of a key downstream mediator (Chop), the behavioral and
pathological presentations of this disease model could be prevented 19. These and other
studies have led to the notion that UPR-mediated activation of the ISR in SCs contributes
to the pathology in myelin-related neuropathies 40. Activation of the ISR in Tfam-SCKO
mice, however, was not associated with ER stress or an UPR. The maladaptive induction
of the ISR in SCs may therefore be a central pathological mechanism common to
different forms of peripheral neuropathy, including those associated with mutations to
structural

myelin

proteins

as

well

as

metabolic

abnormalities.

Intriguingly,

chemotherapeutic agents that cause neuropathy also activate the ISR in cultured cells 41,
which highlights the fact that this maladaptive pathway in SCs could be operant in
diverse forms of neuropathy.
The downstream cellular processes initiated by the ISR that are maladaptive to
SCs are unclear. Activation of this pathway, however, has been linked to alterations in
lipid metabolism that are characterized, overall, by a shift away from lipid synthesis and
towards lipid oxidation

20-22

. The results described above are consistent with a decreased

shunting of fatty acids towards new lipid synthesis and a concomitant increase in fatty
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acid oxidation in the nerves of Tfam-SCKO mice. Lipids play a crucial role in the normal
biology of SCs; they are required for myelin assembly and maintenance, regulate the
differentiation status of these glia, and may also be important for SC-mediated metabolic
support of axons 42. The observed early shift in the lipid metabolism of Tfam-deficient
SCs secondary to mitochondrial dysfunction is thus a likely cause of the phenotype in
Tfam-SCKO mice. Given that abnormalities in peripheral nerve lipid composition are
present in mitochondrial disorders

42, 43

, our results suggests that alterations in SC lipid

metabolism may be central pathological mechanisms of mitochondrial-related
neuropathies.
The shift in lipid metabolism of Tfam-deficient SCs resulted in depletion
(sulfatides and cerebrosides) as well as in accumulation (acylcarnitines) of specific lipid
molecular species. Both of these lipid alterations in Tfam-SCKO nerves are likely to
participate in the subsequent neuropathy phenotype of these mice. The depletion of
cerebrosides and sulfatides from Tfam-deficient SCs, which together represent almost
30% of all myelin lipid content 25, likely underlie the prominent demyelinating phenotype
apparent in late stages of disease in Tfam-SCKO mice 12. Moreover, given the central role
of sulfatides and cerebrosides in maintaining axon-glial contact

27, 28

, depletion of these

glycosphingolipids could also drive some of the axon loss in Tfam-SCKO nerves by
disrupting the ability of SCs to properly associate with and support axons. This axonal
degeneration is likely exacerbated by the accumulation of acylcarnitines in Tfam-SCKO
nerves following mitochondrial dysfunction. Accordingly, long-chain acylcarnitines
accumulating in SCs could be released onto surrounding axons where they could disrupt
axon membrane properties and induce axon degeneration. These results are consistent
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with presentations of peripheral neuropathy in patients with genetic defects in fatty acid
-oxidation that lead to a buildup of acylcarnitines 33, 34.
In summary, Tfam-SCKO mice, a novel model of neuropathy secondary to
mitochondrial dysfunction, have enabled us to examine for the first time the mechanisms
by which deficits in mitochondrial metabolism in SCs specifically contribute to
peripheral nerve diseases. Our work demonstrates that mitochondrial deficits activate a
maldaptive stress response in SCs and cause a shift in the lipid metabolism of these glia.
We provide evidence that the resulting early depletion of important lipid myelin
components as well as the accumulation and release of toxic lipid intermediates from SCs
drive the pathology observed in Tfam-SCKO mice. New therapeutic strategies that
prevent the depletion of lipids that support axo-glial interactions as well as the
accumulation of fatty acid intermediates with marked axonal toxicity may be useful in
treating patients with diabetic neuropathy and other mitochondria-related peripheral
nerve disorders.
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Methods
Matings of transgenic animals: All animal experiments were carried out in compliance
with institutional animal protocols. Tfam-SCKO mice (P0-Cre

+/-

, TfamloxP/loxP) and Ctrl

littermates (P0-Cre -/-, TfamloxP/loxP) were generated by crossing TfamloxP/loxP mice 13 to P0Cre mice 44. Mating and genotyping were carried out as previously described 12.

Nerve histology and morphometry: Sciatic nerves from Ctrl and Tfam-SCKO mice at
different ages were dissected and placed in 3% glutaraldehyde overnight. After washing
with phosphate buffer, nerves were postfixed in 1% osmium tetraoxide in phosphate
buffer overnight at 4°C. Specimens were then dehydrated in graded alcohols and
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embedded in 100% epoxy (Araldite 502). One-micrometer-thick plastic embedded
sections were prepared and stained with toluidene blue for light microscopy. For electron
microscopy, thin sections were prepared, stained with uranyl acetate and lead citrate, and
photographed with a JEOL (Akishima) 1200 electron microscope. All nerves underwent
qualitative assessment of neural architecture followed by detailed histomorphometric
analysis carried out as previously described 45.

Metabolite measurements: For ATP, ADP, AMP, and lactate measurements sciatic
nerves were excised from Ctrl and Tfam-SCKO mice, weighted, and metabolites
extracted with 1M perchloric acid (10 to 1 volume : weight). Extracts were centrifuged
and neutralized with 3 M potassium carbonate. For ATP, ADP and AMP determination,
neutralized extracts were diluted 1:10 with potassium phosphate buffer and assayed by
HPLC (Shimazu) using an LC-18T HPLC column (Supelco) at flow rate of 1 ml/min and
the absorbance at 254 nm was recorded. Each elution peak was compared with standards
for identification and quantification and levels were normalized to tissue weight. EC was
defined as follows: EC=[ATP]+1/2[ADP])/([ATP]+[ADP]+[AMP]. Lactate levels were
determined spectrophotometrically as previously described

46

. NAD+, NADH+ and the

NAD+/NADH ratio was determined using a CycLex NAD+/NADH colorimetric assay
kit (MBL International) according to the manufacturer’s protocol.

Western Blotting: Sciatic nerves were isolated, desheathed in PBS, and immediately
frozen in liquid nitrogen. Lysates were prepared by homogenizing the tissue by
sonication in a buffer containing 150 mM sodium chloride, 50 mM Hepes, 1% NP-40, 1
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mM EDTA, 1 mM sodium fluoride, 1mM sodium orthovanodate, and complete protease
inhibitor cocktail (Roche Applied Science). The lysates were clarified by centrifugation
at 14,000 rpm for 10 min and quantified using the MicroBCA Protein Assay kit (Pierce).
For Western blotting, the proteins were separated by SDS-PAGE and transferred to a
PVDF membrane (Millipore). Membranes were blocked in 5% milk in 0.5% TBS-Tween
and incubated overnight with the appropriate primary antibody. Following incubation
with secondary antibodies conjugated to HRP (GE Healthcare), membranes were
developed with SuperSignal West Dura substrate (Pierce). The primary antibodies for pAMPK AMPK p-ACC, ACC, and p-Perk were all raised in rabbit, used 1:1000 and
purchased from Cell Signaling. We also used mouse anti-Porin (31HL, 1:1000,
Calbiochem), mouse anti-actin (1:1000, Sigma), mouse anti-myelin basic protein (SMI
94, 1:1000, Covance), and rabbit anti-myelin protein zero (1:1000, Sigma). The
secondary antibodies used were anti-mouse and anti-rabbit HRP (1:5000; Jackson
ImmunoResearch Laboratories). Optical density of the signals was determined using
Image-J.

RNA preparation and quantitative real-time PCR: Total RNA was isolated after
homogenization (for sciatic nerves) or lysis (for cultured SCs) in Qiazol lysis reagent
(Qiagen) using a miRNeasy Minikit (Qiagen) according to the manufacturer’s protocol.
RNA concentration was quantified using an ND-1000 spectrophotometer (Nanodrop
Technologies). mRNA was reverse transcribed from 100 ng of total RNA using qScript
cDNA SuperMix (Quanta Biosciences). mRNA qRT-PCR was performed using a SYBR
green-based detection system on a 7900 HT Sequence Detector instrument (Applied
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Biosystems) as described previously
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. GAPDH expression was used to normalize

samples and obtain relative expression values that were used to calculate percent
changes. The sequences of the qRT-PCR primers used are as follows (5’-3’; mouse
unless

specified):

ATF4:

F,

GGCTATGGATGATGGCTTGG,

R,

AATTGGGTTCACTGTCTGAGG; ATF4 (rat): F, CTTAAGCCATGGCGCTCTTC, R,
TTGCTGGTATCGAGGAATGTG ; Chop: F, AAGTGCATCTTCATACACCACC, R,
TTGATTCTTCCTCTTCGTTTCCTG; Chop (rat): F, CTGAGGAGAGAGTGTTCCAG,
R, GTGTGGTGGTGTATGAAGATG; ASNS: F, GCCCAAGTTCAGTATCCTCTC, R,
TAAATACATGCCCACAGATGCC; mthfd2: F, AATTAAGCGAACAGGCATTCCA,
R, AGGATCGTGTGCTTCTTCAG; Trib3: F, CACTTTAGCAGCGGAAGAGG, R,
GTGTAGCTCGCATCTTGTCC;

Trib3

(rat):

TGTCTTCAGCAACTGTGAGAGGACGAA,

F,
R,

GTAGGATGGCCGGGAGCTGAGTAT; Srebp1: F, CATGCCATGGGCAAGTACAC,
R, TGTTGCCATGGAGATAGCATCT; FASN: F, GGGTGCTGACTACAACCTCTCC,
R, TGCACAGACACCTTCCCGTC; HMGCR: F, TGGTGGGACCAACCTTCTAC, R,
GCCATCACAGTGCCACATAC; Acly: F, AGGAAGTGCCACCTCCAACAGT, R,
CGCTCATCACAGATGCTGGTCA; ACC2: F, GGGCTCCCTGGATGACAAC,

R,

TCTTCCGGGAGGAGTTCT;

R,

GAPDH:

F,

TGCCCCCATGTTTGTGATG,

TGTGGTCATGAGCCCTTCC.

Xbp-1 splicing RT-PCR: xbp-1 splicing in Ctrl and Tfam-SCKO nerves as well as in
cultured SCs was determined from cDNA in a 25 l PCR reaction with a single 4 min
94ºC denaturation cycle followed by 35 cycles of 94ºC for 10 s, 63ºC for 30 s, and 72ºC
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for 30 s followed by separation of the unsplice (254 bp) and spliced (229 bp) XBP-1 RTPCR products on a 10 cm 2% agarose gel. Primers used were as follows (5’-3’) F:
GGCCTTGTGGTTGAGAACCAGGAG; R: GAATGCCCAAAAGGATATCAGACTC.
Explanted nerves maintained in 10% fetal bovine serum (FBS) supplemented with 2 mM
L-glutamine and 100 ng/ml of nerve growth factor in the presence of 10 g/ml of
tunicamycin served as a positive control for nerve samples.

Microarray and computational analysis: total RNA samples were prepared by isolating
and pooling RNA from at least 3 different 2 month old Tfam-SCKO and Ctrl mice.
Replicates were prepared entirely independently from two separate pools of at least three
animals each, 2 replicates were used. Total RNA concentration and purity was obtained
from an absorbance ratio at 260 nm and 280 nm. Total RNA quality was then determined
by Agilent 2100 bioanalyzer (Agilent Technologies) according to manufacturer’s
recommendations. RNA transcripts were amplified by T7 linear amplification
messageAmp TotalPrep amplification kit (ABI-Ambion) using 400 ng of each total RNA
sample. The amplified RNA samples (aRNA) were then cleaned with RNA columns and
quantified on a spectrophotometer, and RNA quality was determined by Agilent 2100
bioanalyzer (Agilent Technologies). 1500 ng of each aRNA were hybridized onto
Illumina Mouse WG-6 v2.0 Expression Beadchips according to manufacturer’s
recommendations. Arrays were scanned on an Illumina BeadArray Reader. Images were
quantitated by Illumina Beadscan, v3 and the resulting data was imported into Illumina
GenomeStudio software, where on-slide spot replicates were averaged and individual
spot probe was reported. This signal intensity data was background subtracted and
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quantile normalized in Illumina genome Studio. Probes having detection p-value>0.05 in
all samples were removed and a two class unpaired SAM analysis was performed.
Differentially expressed genes with at least 2.0 fold differential regulation between TfamSCKO and Ctrl nerves at a false discovery rate (FDR) of 0.5% were selected for further
analysis. Gene enrichment of metabolic pathway was examined using GeneGO (Genego
Inc).

Tissue and mitochondria Complex IV determination: nerve mitochondria were
isolated and maximum complex IV activity determined as previously described 12. Tissue
maximum Complex IV activity was determined using high resolution respirometry in an
OROBOROS Oxygraph 2k (Oroboros) as previously described 12, 48.

Nerve sample lipid extract preparation for mass spectrometric analysis: lipid
extraction of nerve samples was performed essentially as described previously 49. Briefly,
a protein assay on each nerve sample was performed by using BCA method with bovine
albumin as standard. Lipid internal standards (approximately one for each lipid class)
were added based on protein content of each nerve sample. The molecular species of
internal standards (e.g.,

13

C4-16:0 carnitine, N-Pentadecanoyl-psychosine (N15:0

Cerebroside), N-Hexadecanoyl-sulfatide (N16:0 sulfatide) were selected because they are
either stable isotope labeled species or represent <0.1% of the endogenous cellular lipid
mass as demonstrated by mass spectrometric analysis of the nerve lipid extract without
addition of internal standards. A modified Bligh and Dyer procedure was used to extract
lipids from each nerve sample as previously described
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49

. Each lipid extract was

reconstituted in 200 l /mg of protein (which was the measured protein content
aforementioned) in chloroform/methanol (1:1, v/v). A portion of each lipid extract (e.g.,
50 uL) was treated with LiOMe to hydrolyze phospholipids followed by washing with
hexane as previously described 50. The treated lipid samples were used for the analysis of
the sphingolipidome of each nerve sample. The original and treated lipid extracts were
flushed with nitrogen, capped and stored at -20°C until ESI/MS analysis, typically within
one week.

Lipidomic analysis of nerve lipid extracts by multi-dimensional mass spectrometrybased shotgun lipidomics: a triple-quadrupole mass spectrometer (Thermo Fisher TSQ
Quantum Ultra Plus) equipped with an automated nanospray apparatus (i.e., Nanomate
HD, Advion Bioscience Ltd., Ithaca, NY) and Xcalibur system software were utilized in
the study as previously described

49

. Briefly, each originally-prepared lipid extract was

diluted to < 50 pmol/uL with chloroform/methanol/isopropanol 1:2:4 (v/v/v) prior to
direct infusion through a nanospray apparatus linked to the mass spectrometer for the
analyses of phospholipids, lyso-phopholipids, acyl-carnitine, non-esterified fatty acids
and triacylglycerols with or without the presence of a small amount of LiOH

51

. Each

LiOMe-treated lipid extract was properly diluted prior to infusion to the mass
spectrometer for the analyses of sphingolipids (Jiang et al., 2007). Typically, a 2-min
period and 2-5-min of signal averaging in the profile mode were employed for acquisition
of each survey scan and each tandem MS scan, respectively. For tandem mass
spectrometry, a collision gas pressure was set at 1.0 mTorr but the collisional energy was
varied with the classes of lipids as previously described
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51

. All the MS spectra and

tandem MS spectra were automatically acquired by a customized sequence subroutine
operated under Xcalibur software. Each individual lipid species in a lipid class was
identified using multi-dimensional mass spectrometry through building block analyses 52.
The identified species were quantified using a two-step approach as previously described
52

.

Primary SC cultures and in vitro ISR induction: Primary rat SCs were cultured from
sciatic nerves of postnatal day1 to day3 rat pups as previously described 47. For SC in
vitro ISR induction assays, SCs were initially seeded onto collagen coated 24-well plates
(~75,000 cells/well) in 10% FBS-DMEM media supplemented with 2 M forskolin and
20 g/ml of bovine pituitary extract. 48 h later cells were switched to 1% FBS-DMEM
media for 2 days to stop proliferation. At this point, SCs were treated with either vehicle,
5 M FCCP, 2.5 M oligomycin, 10 M antimycin or 1 M tunicamycin. RNA or
protein were isolated 24 h later. Reported results are from duplicate wells from at least
three independent assays.

Acyl-carnitine release measurements: To measure the ability of Tfam-deficient SCs to
secrete long-chain acylcarnitines, nerves were explanted from Tfam-SCKO and Ctrl mice
and maintained in 100 l of 10% fetal bovine serum (FBS) supplemented with 2 mM Lglutamine and 100 ng/ml of nerve growth factor for 2.5 days. At this time, media was
collected and immediately frozen in liquid nitrogen. Media was then analyzed for
acylcarnitine species content (C2–C18 saturated, unsaturated, and hydroxylated) as butyl
esters by direct flow injection and precursor ion scanning on an API 3200 LC-MS/MS
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system (Applied Biosystems, Foster City, CA, USA). Quantitation was achieved using a
cocktail of internal standards. Concentrations were normalized to tissue weight.

DRG neuron culture and Fluo-4 imaging: mouse DRG neurons were isolated from E12
embryos in DMEM (Sigma), dissociated by incubation in 0.25% trypsin, and resuspended
(100 μl/embryo) in complete DRG medium: neurobasal medium (Invitrogen) containing
2% B27 supplement (Invitrogen), 50 ng/ml of nerve growth factor (Harlan Laboratories),
1 μM 5-fluoro-2′-deoxyuridine (Sigma), and 1 μM uridine (Sigma). Cells were then
seeded onto either 24-well or 96-well cell cultures plates coated with poly-d-lysine
(Sigma) and Laminin (Invitrogen) by spotting a single 0.5 l (96-well) or 2 l (24-well)
droplet of the concentrated cell suspension, incubating for 15 min at 37 °C to allow
neurons to adhere, then adding 100 μl (96-well) or 400 ul (24-well) of complete DRG
media. All experiments were carried out 5-6 days after seeding. For calcium imaging
experiments, neurons were incubated with the calcium indicator Fluo-4 AM (2 M,
Invitrogen) for 30 min at 37 °C, washed by replacing half the media twice, then incubated
for another 30 min to allow complete de-esterification of intracellular AM esters.
Baseline fluorescence and phase images were taken at this point. Neurons were then
treated either with vehicle, palmitoyl-carnitine (Sigma), or palmitate (Sigma) at the
appropriate concentrations. Phase and fluorescence images were acquired every 15
minutes for up to 6 hours using an Operetta imaging system equipped with an
environmental chamber (Perkin Elmer). To examine the effect of chronic acylcarnitine
exposure, DRG neurons were treated daily for up to nine days with vehicle or with
palmitoyl-carnitine at the appropriate concentration.
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Automated analysis and quantification of images: Axon degeneration, axonal calcium
accumulation, and calcium containing vacuole formation were quantified using ImageJ as
follows. For axon degeneration, bright field images of axons were binarized and
fragmented axons were detected using particle analyzer. The ratio of fragmented axon
area against the total axon area was expressed as degeneration index. Axonal calcium
accumulation was quantified from the fluorescent images of axons loaded with Fluo-4
calcium sensitive dye as described above. The fluorescent intensity of the pixels over the
axon area (as determined from accompanying bright field images) were summed and then
normalized by the total axon area. Palmitoyl-carnitine treated axons tend to form
vacuoles containing high concentration of Ca2+ which are recognized as spherical
structures with higher Fluo-4 intensity than surrounding axons. The total area of these
vacuoles was expressed as a Fluo-4 blebbing index. This index was determined by first
calculating the total Fluo-4 positive axon area. Then the area of calcium containing
vacuoles was quantified using binarized Fluo-4 images threshold such that only vacuoles
but not the rest of axons were recognized by a particle analyzer. The total vacuole area
detected was normalized against total Fluo-4 positive area to give Fluo-4 blebbing index.
Statistical analysis: All values are expressed as mean ± SEM. If not stated otherwise, p
values were determined by unpaired, two-tailed Student's t test. All statistical analyses
were performed using Microsoft Excel 2007.
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Figures
Figure 1: SC mitochondrial dysfunction induces a progressive degenerative
peripheral neuropathy that is not directly linked to energy depletion. a) Electron
micrographs of 1 month old Ctrl and Tfam-SCKO sciatic nerve cross sections depicting
early structural abnormalities of Remak bundles (SC surrounding multiple unmyelinated
axons) and degeneration of unmyelinated axons (asterisk). A, axons; N, SC nucleus; C,
SC cytoplasm. Scale bar 500 nm. b, c) Toluidene blue stained plastic sections of TfamSCKO and Ctrl sciatic nerve cross sections (b) and quantification of total number of
myelinated profiles per nerve (c) at different ages show prominent, progressive
degeneration of large-caliber myelinated axons and demyelination starting at 3-4 months
of age. Arrowheads (b) indicate axons surrounded by unusually thin myelin, a sign of
demyelination. Arrow (c) indicates the point in the progression of the pathology for all
mice used in later experiments; note that at this age nerves display only limited, early
pathological changes with minimal axon loss and demyelination. Error bars, SEM. n=4
mice per genotype at each age. *P<0.01 Scale bar 25 m. d) Adenylate energy charge in
Tfam-SCKO nerves shows only a slight decrease in the energy levels of Tfam-deficient
SCs compared to Ctrl nerves. Error bars, SEM. n=8 mice per genotype. *P<0.01 e, f)
Immunoblot analysis (e) and quantification of band intensity (f) reveals no increase in the
phosphorylation (activation) of the energy sensor AMPK in Tfam-SCKO nerves,
indicating that energy depletion is an unlikely driver of nerve pathology in these mice.
Error bars, SEM. n=4 mice per genotype.
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Figure 2: SC mitochondrial dysfunction activates a maladaptive integrated stress
response (ISR) independent of ER-stress. a) SC mitochondrial dysfunction upregulates
the expression of ISR target genes in Tfam-SCKO nerves compared to Ctrl as measured
by qRT-PCR. ATF4, activating transcription factor 4; Chop, DNA-damage inducible
transcript 3; ASNS, asparagine synthetase; MTHFD2, methylenetetrahydrofolate
dehydrogenase; TRIB3, tribbles homolog 3. Error bars, SEM. n=5 mice per genotype.
*P<0.05 b) Immunoblot analysis shows increased phosphorylation of eIF2in TfamSCKO vs. Ctrl nerves, confirming the activation of the ISR c) Immunoblot analysis
shows that application of the mitochondrial inhibitor FCCP to cultured SCs increases
phosphorylation of eIF2indicating that inhibition of the mitochondrial electron
transport chain activates the ISR. d) Inhibition of mitochondrial respiration in cultured
SCs with mitochondrial inhibitors upregulates the expression of ISR target genes as
measured by qRT-PCR. Error bars, SEM. n=duplicate wells from 3 independent
experiments. *P<0.05. e) Immunoblot analysis of the phosphorylation (activation) status
of the ER-stress sensor Perk in Ctrl and Tfam-SCKO nerves shows no differences,
indicating that ISR activation following SC mitochondrial deficits does not involve ERstress. f) Gel showing the absence of Xbp-1 splicing downstream of the activation of the
ER-stress sensor Ire-1 in Tfam-SCKO nerves, or SCs treated with mitochondrial
inhibitors, confirms that ISR activation induced by mitochondrial derangement is
independent of ER-Stress. Tunicamycin treatment of sciatic nerves cultured as explants
or of SCs, serves as a positive control for ER-stress.
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Figure 3: SC mitochondrial dysfunction causes a shift in lipid metabolism away
from lipid biosynthesis and toward fatty acid oxidation. a) Differentially expressed
mRNAs in Tfam-SCKO nerves as determined by microarray analysis are enriched for
genes involved in lipid metabolism pathways. The 10 pathways with most significant
enrichment among differentially expressed genes in Tfam-SCKO nerves are shown. b)
qRT-PCR analysis confirms that a number of lipid synthesis related enzymes are
downregulated in Tfam-SCKO vs. Ctrl nerves. SREBP1, sterol regulatory element
binding transcription factor 1; FASN, fatty acid synthase; HMGCR, 3-hydroxy-3methylglutaryl-Coenzyme A reductase; ACLY, ATP citrate lyase; ACC2, acetylCoenzyme A carboxylase beta (primarily localized to mitochondria). Error bars, SEM.
n=5 mice per genotype. *P<0.05. c) Diagram depicting the regulation by acetyl-coA
carboxylase (ACC) of the balance between fatty acid synthesis vs. oxidation and how it is
altered by ACC’s phosphorylation status. d, e) Immunoblot analysis (d) and
quantification of band intensity (e) show increased phospohorylation of ACC in TfamSCKO nerves compared to Ctrls. Phosphorylation inhibits this central regulator of the
balance between lipid synthesis vs. oxidation, indicating (together with gene expression
results) a shift in lipid metabolism away from new lipid synthesis and towards increased
lipid oxidation in SC following mitochondrial dysfunction. Error bars, SEM. n=4 mice
per genotype. *P<0.05.
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Figure 4: Abnormal lipid metabolism secondary to mitochondrial dysfunction
results in depletion of myelin lipid components in Tfam-SCKO nerves. a, b)
Lipidomic analysis revealed an early and significant depletion of two key myelin lipid
components, cerebrosides (a) and sulfatides (b), in Tfam-SCKO vs. Ctrl nerves, likely
accounting for the subsequent demyelination observed in these mice. Error bars, SEM.
n=5 mice per genotype. *P<0.05. c) Immunoblot analysis reveals that sulfatide and
cerebroside depletion precedes any decrease in expression of nerve myelin basic protein
(MBP) and myelin protein zero (P0), making lipid depletion a potential driver of the later
demyelination.
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Figure 5: Abnormal lipid metabolism secondary to mitochondrial dysfunction
causes severe accumulation of acylcarnitine fatty acid -oxidation intermediates in
Tfam-SCKO nerves a, b) Lipidomic analysis shows a significant accumulation of longchain acylcarnitines (total, a) that affects most long-chain molecular species (b) in TfamSCKO vs. Ctrl nerves. Error bars, SEM. n=5 mice per genotype. *P<0.05. c) Diagram
depicting fatty acid -oxidation in the mitochondria. Long-chain fatty acids are converted
to acylcarnitines to be shuttled into the mitochondrial matrix, the site of -oxidation,
where they are oxidized through repeated cycles of four enzymatic reactions. Red text
indicates the altered ratio of NAD/NADH+ in Tfam-SCKO nerves. Red stars indicate
lipid intermediates accumulating in Tfam-SCKO nerves following mitochondrial
dysfunction. Cpt1 and Cpt2: carnitine palmitoyltransferase 1 and 2; T outer: long-chain
fatty acid transporter; T inner: carnitine-acylcarnitine translocase; Co-Ash: coenzyme A.
d) Lipidomic analysis also shows the accumulation of hydroxy-acylcarnitine species
(derived from 3-hydroxy acyl CoA) in Tfam-SCKO nerves, indicative of inhibition of the
-oxidation reaction catalyzed by 3-hydroxyacyl CoA dehydrogenase. Error bars, SEM.
n=5 mice per genotype. *P<0.05. e) Reduced NAD+/NADH ratio in Tfam-SCKO nerves.
Error bars, SEM. n=6 mice per genotype. *P<0.05.
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Figure 6: Long-chain acylcarnitines are secreted from SCs and alter axonal calcium
homeostasis and stability. a) Explanted Tfam-SCKO nerves but not Ctrl nerves release
long-chain acylcarnitines into surrounding culture media as measured by mass
spectrometry. Error bars, SEM. n=6 mice per genotype. *P<0.05 b) Images depicting
increased fluorescence intensity of the Ca2+ dye Fluo-4 after acute (30 min) application of
palmitoyl-carnitine (PC), an acylcarnitine species highly increased in Tfam-SCKO
nerves, shows that this lipid intermediate can disrupt axonal calcium homeostasis. Note
that similar changes were not seen when the corresponding free fatty acid (Palmitate, P)
was applied. Scale bar, 100 m c, d) Quantification of the effect of palmitoyl-carnitine on
Fluo-4 intenstiy (c) and Ca2+ blebbing (d) shows that the effect of this lipid intermediate
on axonal calcium is dose-dependent, and specific to acylcarnitines; application of the
corresponding free fatty acid at the same concentrations exerted no comparable effect.
Error bars, SEM. n=triplicate wells from 1 out of 3 representative experiments. *P<0.05.
e) Images depicting a progressive increase in axonal degeneration following chronic
application of 25 M palmitoyl-carnitine (PC) after 9 days of treatment. Scale bar, 100
m f) quantification of the effect on axonal degeneration of chronic treatment with 25
M palmitoyl-carnitine (PC) shows a significant, progressive increase in the axon
degeneration index. Error bars, SEM. n=6 wells from 1 out of 2 representative
experiments. *P<0.05.
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Figure 7: Altered SC lipid metabolism accompanied by the toxic accumulation of
lipid

intermediates

induces

axonal

degeneration

and

demyelination

in

mitochondria-related peripheral neuropathies. Diagram describing the proposed
model for how a shift in lipid metabolism away from lipid synthesis and towards lipid
oxidation secondary to SC mitochondrial dysfunction may contribute to the pathology in
peripheral neuropathies. CB: cerebrosides; ST: sulfatides; AC: acylcarnitine
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Supplementary Figure 1: Increased mitochondrial content and glycolysis help
maintain cellular energy levels in Tfam-deficient SCs. a) Immunoblot analysis and
quantification of band intensity (OD, optical density; b) of porin, a mitochondrial
membrane protein that serves as a reliable marker of mitochondrial content, shows a 3fold increase in Tfam-SCKO vs Ctrl nerves. Error bars, SEM. n=3 mice per genotype.
*P<0.05. b) Increased ratio of maximum complex IV activity per mg of tissue vs
maximum complex IV activity per mg of mitochondria for Tfam-SCKOs confirms a
higher mitochondrial content in these mice. Error bars, SEM. n= complex IV activity
measured from 5 whole nerves and from 4 nerve mitochondria preparations. *P<0.05. c)
Lactate levels in Tfam-SCKO nerves are greater than in Ctrl nerves, suggesting increased
glycolysis. Error bars, SEM. n=8 mice per genotype. *P<0.05.
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Supplementary Figure 2: Depletion of myelin lipid components and accumulation of
acylcarnitine fatty acid -oxidation intermediates in Tfam-SCKO nerves a)
Representative spectrum of sulfatide species detected in Ctrl and Tfam-SCKO nerves
shows depletion of this lipid class in SCs following mitochondrial dysfunction. Asterisk
marks one of the more depleted sulfatide species, m/z = 888.6, d18:1, N24:1. IS, internal
standard. b) Representative spectrum of acylcarnitine species detected in Ctrl and TfamSCKO nerves depicts the dramatic accumulation of this lipid class in SCs following
mitochondrial dysfunction. Asterisks mark two of the more increased acylcarnitines
species m/z = 398.3, C16:1; m/z = 426.3, C18:1. IS, internal standard.
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CHAPTER 4:

Differential Regional and Subtype-Specific Vulnerability of Enteric Neurons to
Mitochondrial Dysfunction

Adapted from: Viader A, Wright-Jin EC, Vohra BPS, Heuckeroth RO, Milbrandt J
(2011) Differential regional and subtype-specific vulnerability of enteric neurons to
mitochondrial dysfunction. PlosOne,6(11):e27727.
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Abstract
Mitochondrial dysfunction is a central mediator of disease progression in diverse
neurodegenerative diseases that often present with prominent gastrointestinal
abnormalities. Gastrointestinal dysfunction in these disorders is related, at least in part, to
defects in the enteric nervous system (ENS). The role of mitochondrial deficits in ENS
neurodegeneration and their relative contribution to gastrointestinal dysfunction,
however, are unclear. To better understand how mitochondrial abnormalities in the ENS
influence enteric neurodegeneration and affect intestinal function, we generated mice
(Tfam-ENSKOs) with impaired mitochondrial metabolism in enteric neurons and glia
through the targeted deletion of the mitochondrial transcription factor A gene (Tfam).
Tfam-ENSKO mice were initially viable but, at an early age, they developed severe
gastrointestinal motility problems characterized by intestinal pseudo-obstruction resulting
in premature death. This gastrointestinal dysfunction was caused by extensive,
progressive neurodegeneration of the ENS involving both neurons and glia. Interestingly,
mitochondrial defects differentially affected specific subpopulations of enteric neurons
and regions of the gastrointestinal tract. Mitochondrial deficiency-related neuronal and
glial loss was most prominent in the proximal small intestine, but the first affected
neurons, nitrergic inhibitory neurons, had the greatest losses in the distal small intestine.
This regional and subtype-specific variability in susceptibility to mitochondrial defects
resulted in an imbalance of inhibitory and excitatory neurons that likely accounts for the
observed phenotype in Tfam-ENSKO mice. Mitochondrial dysfunction, therefore, is
likely to be an important driving force of neurodegeneration in the ENS and contribute to
gastrointestinal symptoms in people with neurodegenerative disorders.
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Introduction
Gastrointestinal dysfunction is a prevalent symptom in neurologic and systemic
diseases associated with neurodegeneration. Constipation, for example, is the most
widely recognized non-motor symptom in people with Parkinson’s disease (PD), the
second most common neurodegenerative disorder in industrialized countries [1,2].
Decreased frequency of bowel movements is in fact one of the earliest signs of PD,
predating the development of the classic motor symptoms, sometimes by many years [35]. In addition, impaired gastric emptying is estimated to affect the majority of patients
with PD and complicates treatment by interfering with levodopa absorption, which can
only be absorbed once it reaches the small intestine (SI) [1,6,7]. Similarly, up to 75%
people with diabetes mellitus, a systemic metabolic disease associated with progressive
neuronal damage [8], experience a variety of gastrointestinal symptoms ranging from
diarrhea to severe gastroparesis and constipation [9]. Gastrointestinal dysfunction in these
neurodegenerative disorders is related, at least in part, to abnormalities and cell loss in the
enteric nervous system (ENS) [9-11], the complex network of neurons and glia that
innervates the gut and controls intestinal function. A better understanding of the
pathophysiology of neurodegeneration within the ENS could therefore be relevant to the
treatment of patients with diseases characterized by neuron loss with prominent
gastrointestinal symptoms.
Mitochondria are now thought to be critical mediators of disease progression in
diverse disorders such as PD and diabetes. Studies primarily focusing on the central
nervous system (CNS) have established that mitochondrial dysfunction is involved in
both the initiation and propagation of disease processes that eventually result in neuron
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death [12,13]. A growing body of evidence indicates that mitochondrial defects may
similarly contribute to neurodegeneration in the ENS. Consistent with this notion, rodent
models of PD induced by mitochondrial toxins are characterized by ENS pathology and
cell loss, even at doses below those necessary to cause CNS pathology [14-17]. Indeed,
the ENS appears to be particularly susceptible to mitochondrial dysfunction compared to
other tissues. This is best exemplified by the fact that primary inherited mitochondrial
disorders, a heterogeneous group of complex multisystem diseases, commonly include
gastrointestinal symptoms. As is the case in PD, symptoms of gastrointestinal
dysfunction can precede other presentations of mitochondrial deficits and, in some cases
(e.g. mitochondrial neurogastrointestinal encephalomyopathy, or MNGIE) may be the
most prominent manifestation of the disease [18]. The role of mitochondrial
abnormalities in ENS neurodegeneration and its relative contribution to gastrointestinal
dysfunction, however, remain poorly understood.
With the goal of elucidating how mitochondrial abnormalities in the ENS
contribute to enteric neurodegeneration and affect gastrointestinal function, we generated
mice with impaired mitochondrial metabolism in neurons and glia of the ENS. These
Tfam-ENSKO mice were generated by tissue-specific deletion of the gene encoding
mitochondrial transcription factor A (Tfam), which is required for mitochondrial DNA
(mtDNA) transcription and replication [19]. We show that normal mitochondrial function
in the ENS is essential for the survival of both enteric neurons and glia as well as for
maintenance of normal gastrointestinal motility. Interestingly, we found that
mitochondrial dysfunction differentially affected specific subpopulations of enteric
neurons and, most surprisingly, specific regions of the gastrointestinal tract.
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Mitochondrial deficiency-related neuronal and glial loss was most prominent in the
proximal SI, but nitrergic, inhibitory neurons were less severely affected in this region
and, instead, were most affected in the distal SI. Interestingly, this regional and subtype
variability of enteric neurons appears to directly correlate to the phenotype observed in
Tfam-ENSKO mice, with dilation in the proximal SI and relative constriction in the distal
SI. Mitochondrial dysfunction in the ENS and the regional- and subtype-specific
vulnerabilities of enteric neurons are likely contributors to the gastrointestinal symptoms
of patients suffering from some neurodegenerative disorders.

Results
Cre-mediated deletion of Tfam results in mitochondrial abnormalities in the ENS:
To study how mitochondrial dysfunction in the ENS affects gastrointestinal
function and contributes to enteric neurodegeneration, we generated mice with disrupted
mitochondrial metabolism in both enteric neurons and glia (Tfam-ENSKOs). For this
purpose we used a previously developed mouse with loxP-flanked Tfam alleles (TfamloxP)
[19]. Tfam is a mitochondrial protein encoded by nuclear DNA that is essential for
mtDNA maintenance, copy number regulation and transcription [19,20]. Previous studies
have shown that cre-mediated deletion of Tfam in TfamloxP homozygous mice results in
severe tissue-specific mtDNA depletion and mitochondrial respiratory chain deficiency
[19,21-25]. The tissue-specific deletion of Tfam is, therefore, an effective way to induce
mitochondrial dysfunction in a selected population of cells.
We mated TfamloxP mice to mice expressing cre-recombinase under the control of
the Cnp1 promoter (CNP-Cre) [26]. Cnp1 encodes the enzyme 2′, 3′-cyclic nucleotide 3′-
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phosphodiesterase (CNP), a commonly used marker for myelin-forming glia. However,
we inadvertently discovered that the Cnp1 promoter also drives the expression of crerecombinase in the ENS and thereby induces recombination in the majority of enteric
neurons and glia. Consistent with this fortuitous observation, CNP has been reported to
be highly expressed in gut neural crest stem cells [27]. Indeed, when we crossed CNPCre mice with Cre-inducible Rosa26-YFP reporter animals, YFP fluorescence was visible
in over 90% of enteric neurons and glia throughout the gut (Fig. 1a and b).
Crossing of Tfam-ENSKO mice to Cre-inducible Rosa26-YFP reporter animals
(YFP/Tfam-ENSKOs) showed that Tfam was efficiently excised in all enteric neurons
and glia in which we observed Cnp1-mediated expression of cre-recombinase (as
visualized by YFP fluorescence). When we isolated YFP-positive enteric neurons and
glia from 7 week old YFP/Tfam-ENSKO mice, we could not detect the Tfam allele by
RT-PCR analysis (Fig. 1c). Given the extent and high efficiency of the Cnp1 promoterdriven expression of cre-recombinase, we conclude that the mating of TfamloxP to CNPCre mice resulted in animals that lacked Tfam in the majority of enteric neurons and glia.
To determine the functional effect of deleting Tfam in the ENS, we next assessed
mtDNA copy number in YFP-positive enteric neurons and glia from 7 week old
YFP/Tfam-ENSKO and YFP/control mice. Tfam has an essential role in the maintenance
and replication of mtDNA [19,20] and previous reports have described severe mtDNA
depletion following tissue-specific excision of Tfam from a cell of interest [19,21-25].
Consistent with this, we found an 80% reduction in total mtDNA content in enteric
neurons and glia isolated from different regions throughout the gut of YFP/Tfam-ENSKO
mice (Fig. 1d).
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In previous studies using TfamloxP mice, the depletion of mtDNA following Tfam
excision has been shown to induce severe respiratory chain deficiency, since the
mitochondrial genome encodes 13 subunits that are essential components of the electron
transport chain. In addition, Tfam deficiency-induced mitochondrial dysfunction is
accompanied by abnormalities in mitochondrial morphology [19,21-25,28]. Therefore, to
further confirm the enteric neuron- and glia-specific disruption of mitochondria in TfamENSKO mice we examined the enteric nervous system by electron microscopy.
Abundant abnormal and enlarged mitochondria with distorted cristae were found
specifically within enteric neurons and glia of Tfam-ENSKOs but not of control
littermates (Fig. 1e). Together, our results confirm that by deleting Tfam in enteric
neurons and glia we were able to generate mice with disrupted mitochondria in the ENS.

Tfam-ENSKOs develop progressive gastrointestinal dysfunction characterized by
intestinal pseudo-obstruction
Tfam-ENSKO mice were viable and born at the expected Mendelian ratios and,
for the first 2 weeks of life, they were indistinguishable from their control littermates.
After 2 weeks of age, however, Tfam-ENSKO mice displayed signs of poor growth and,
by 4 weeks of age, they were significantly smaller than their control littermates (Fig. 2a).
In addition, Tfam-ENSKO mice developed abdominal distention at about 6-8 weeks of
age, which, together with poor growth, suggests gastrointestinal dysfunction. After 8
weeks of age, the health of Tfam-ENSKO mice deteriorated rapidly and the majority of
the animals died by 12 weeks of age (Fig. 2b).
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Dissection of late stage (i.e. 10-12 weeks old) Tfam-ENSKO mice consistently
revealed massive dilation within the proximal small bowel along with relative contraction
of the distal small bowel (Fig. 2c). The region of transition from dilated proximal small
bowel to the narrower distal small bowel was consistently located within the mid-small
bowel, with variable accumulation of luminal contents in the proximal small bowel and
stomach. No stenosis or mechanical cause of the obstruction could be found and the mice
did not have malrotation or other anatomic explanations for the obstruction. Proximal to
the transition zone, in the region of dilation, the bowel was filled with dark-colored
luminal contents and the bowel wall appeared to be stretched thinner than in controls
(Fig. 2c). Luminal contents were absent distally and no stool pellets could be found in
the colon or rectum. The distal small intestine and colon in Tfam-ENSKOs generally
appeared to have a smaller diameter than in control mice. Therefore, we conclude that
disrupted mitochondrial metabolism in enteric neurons and glia in Tfam-ENSKO mice
results in significant gastrointestinal dysfunction and dysmotility.

Tfam-ENSKO mice develop progressive neuronal degeneration with distinct
regional vulnerabilities
To test the hypothesis that ENS defects underlie the bowel abnormalities and
early death observed in Tfam-ENSKO mice, we used whole mount immunohistochemical
methods to evaluate ENS structure. We initially examined total myenteric neuron density
using immunohistochemistry for HuC/HuD, a widely used pan-neuronal marker that
labels the cell body of all neurons within the myenteric plexus [29]. 2 week old TfamENSKO mice had a lower mean neuron density in all regions examined compared to WT
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animals, but these differences were not statistically significant (p>0.1 in all cases, Fig. 3b
and Table 1). This is consistent with the healthy appearance of Tfam-ENSKOs at this age
and suggests that the ENS develops normally in these animals.
We next examined the myenteric plexus of 7 week old Tfam-ENSKO and control
mice. At this age, Tfam-ENSKO mice begin to show subtle phenotypic abnormalities (i.e.
poor growth) but appear healthy, do not display signs of gastrointestinal obstruction, and
lack intestinal dilation (Fig. 2a and b). Despite their healthy appearance, at 7 weeks of
age Tfam-ENSKO mice had a 68% decrease in myenteric neuron density in the proximal
SI, and a 41% decrease in the distal SI (Fig. 3a and b and Table 1). Surprisingly, even
though the extent of Tfam excision appeared equal in all regions analyzed at 7 weeks of
age (Fig. 1), we found no difference in colon total neuron density between TfamENSKOs and control littermates at this age (Fig. 3a and b and Table 1). In fact, enteric
neuron density in the colon of Tfam-ENSKOs remained normal even at late pathological
stages (e.g. 10-12 weeks old), when enteric neurodegeneration in more proximal regions
was profound (data not shown). Thus, mitochondrial dysfunction in the ENS results in a
progressive neurodegeneration with marked differences in regional vulnerability to
neuronal loss.

Glial degeneration parallels that of neurons in Tfam-ENSKOs
A growing body of literature now implicates glial dysfunction in many
neurodegenerative diseases traditionally thought to be neuron autonomous. In animal
models of amyotrophic lateral sclerosis, PD, and Huntington’s disease among others,
glia-specific abnormalities alter disease onset and progression (for a review see [30]). To
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address the role of enteric glia in the mitochondria-related gastrointestinal dysfunction of
Tfam-ENSKO mice, we assessed the effect of Tfam-depletion on enteric glia using Sox10 immunohistochemistry. We first examined glial density in the myenteric plexus of 2
week old mice and observed very little difference between Tfam-ENSKOs and littermate
controls except in the distal SI (Fig. 3c and Table 1). By 7 weeks of age, however, TfamENSKO mice had significantly reduced glial cell density in both the proximal and distal
SI (Fig. 3a and 3c and Table 1). However, as is the case for HuC/HuD+ neurons, the glial
cell density in the colon of Tfam-ENSKO mice remained normal at 7 weeks of age (Fig.
3a and 3c and Table 1).
The changes in glial cell density in Tfam-ENSKO mice, therefore, seemed to
parallel that of neurons, involving the same regions and a similar proportion of cells. We
examined this in more detail by comparing the ratio of neurons to glia in control and
Tfam-ENSKO mice. As expected from the absence of either neuron or glial cell loss in 2
week old Tfam-ENSKOs, we found no difference in the neuron to glia ratio in any of the
regions examined compared to control animals (Fig. 3d and Table 1). Interestingly,
despite extensive neuron and glia loss in 7 week old Tfam-ENSKOs, the ratio of neurons
to glia in all regions examined remained comparable to that of control littermates (Fig. 3d
and Table 1). These results suggest that enteric neurons and glia are equally susceptible
to mitochondrial defects in Tfam-ENSKO mice.

Early and differential loss of nitrergic inhibitory neurons in Tfam-ENSKO mice
Intestinal motility and peristalsis depend on the balance between ENS excitatory
and inhibitory inputs which together produce the rhythmic coordination of contraction
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and relaxation necessary to propel luminal contents [31]. The apparent constriction
observed in the distal bowel of Tfam-ENSKO mice, as well as the dilation proximal to
this point (Fig. 2c), suggested the possibility of an imbalance between these inputs. To
address how enteric neuron loss in Tfam-ENSKO mice affects the balance between
inhibitory and excitatory inputs, we examined the number and proportion of nitric oxide
(NO)-producing inhibitory neurons in the myenteric plexus by NADPH diaphorase
(NADPH-d) staining [32]. The proportion of NADPH-d+ neurons in different gut regions
is normally within a narrow range that maintains the balance between ENS excitatory and
inhibitory inputs and allows for normal intestinal motility. As early as 2 weeks of age, the
NADPH-d+ neuron density in the proximal and distal SI in Tfam-ENSKO mice was
significantly lower than in controls (Fig. 4b and Table 1). These data suggest early
preferential loss of nitrergic inhibitory neurons relative to other neuronal subtypes.
As the pathologic changes in the ENS of Tfam-ENSKO mice progressed, the loss
of NADPH-d+ neurons became more pronounced and, moreover, by 7 weeks of age the
percentage of NADPH-d+ neurons varied quite dramatically between different regions of
the gut. NADPH-d+ neuron loss was greatest in the distal SI with a 60% decrease, but
significant decreases were also found in the proximal SI and colon (33% and 25%,
respectively; Fig. 4a and b and Table 1). Interestingly, the observed loss of nitrergic
neurons did not parallel the loss of total neurons in each region (Fig. 3a and b), causing
significant differences in the relative proportion of NADPH-d+ neurons to total neurons
(i.e. changes in inhibitory input) throughout the bowel (Fig. 4c and Table 1). In 7 week
old Tfam-ENSKOs, NADPH-d+ neurons accounted for 75% of total neurons in the
proximal SI compared to 36% in controls (Fig. 4c and Table 1). In contrast, in the distal
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SI, the proportion of NADPH-d+ inhibitory neurons was lower than in control animals,
(19% in Tfam-ENSKOs, 28% in controls; Fig. 4c and Table 1). In the colon, there was no
significant difference in the ratio of nitrergic to total neurons between control and TfamENSKO mice (Fig. 4c and Table 1). This concurrent increase in relative abundance of
inhibitory inputs in the proximal SI along with the decrease in the ratio of NADPH-d+ to
total neurons in the distal SI of Tfam-ENSKOs may thus account for the proximal
dilation and distal constriction observed in the late pathology of these mice (Fig. 4d).

Axonal degeneration is a key feature of enteric neuron loss in Tfam-ENSKOs and
may precede cell body loss
During our examination of NADPH-d+ neurons, we observed extensive and
prominent blebbing in neuronal projections in the myenteric plexus of Tfam-ENSKO
mice (Fig. 5a). In the CNS and PNS, axon blebbing has been recognized as a sign of
axonal degeneration, a central component of many neurodegenerative diseases, which can
precede and sometimes cause neuronal death [33]. To assess the role of axon
degeneration in the neuron loss observed in Tfam-ENSKOs we first examined the
neuronal projections, or neurites, extending into the villi in the proximal and distal SI. As
early as two weeks of age, Tfam-ENSKO mice displayed signs of neurite loss within
intestinal villi, although at this age neurite degeneration was limited to the proximal SI
(Fig. 5c and Table 2). Neurite loss worsened over time, and by 7 weeks of age the
number of neurites in the villi of Tfam-ENSKO mice was significantly reduced in both
the proximal and distal SI (Fig. 5b and c and Table 2) suggesting that loss of neuronal
projections could contribute to subsequent neuron loss.
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Because we are unable to easily identify the cell of origin for neurites in the villi,
we also quantified neuronal fiber density for NADPH-d+ fibers in the myenteric plexus of
7 week old mice. We found no difference in the density of large fiber bundles (i.e.,
primary fibers; [34]) in any region examined between Tfam-ENSKOs and controls (Table
3). In contrast, small fiber density (i.e., secondary and tertiary fibers; [34]) was
significantly lower (44%) in the proximal SI of Tfam-ENSKOs mice, but was similar to
controls in the distal SI and colon (Table 3). Note, however, that what we count as “small
fibers” or “large fiber bundles” are actually one or more tightly fasciculated neurites. In
Tfam-ENSKO mice both “small fibers” and “large fiber bundles” appear significantly
thinner than in control animals at 7 weeks of age (Fig. 4a and 5a), suggesting that our
counting method for NADPH-d+ neuronal projections significantly underestimates
neurite loss in the mutant mice. Because of these limitations, we devised an alternate
method to evaluate the effect of mitochondrial dysfunction on enteric neuron and neurite
degeneration in vitro.
E12.5 enteric neurons were cultured from control mouse gut and exposed to
different inhibitors of the mitochondrial electron transport chain (e.g. rotenone and
antimycin). Disrupting mitochondrial respiration induced significant neurite degeneration
within 24 hours, yet did not initially affect neuron viability as measured by ethidium
homodimer staining (Fig. 5d and e and Table 4). Moreover, even though extended
exposure to mitochondrial inhibitors eventually induced enteric neuron death, the
proportion of cells showing axonal degeneration remained larger at every time point
examined (Table 4). Together, these results suggest that axonal degeneration precedes
enteric neuron cell body loss induced by mitochondrial defects.
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Discussion
The current understanding of how mitochondrial deficits affect enteric neurons
and contribute to ENS neurodegeneration and gastrointestinal dysfunction has been
hindered by a lack of animal models. Here we describe a new mouse model with
disrupted mitochondrial function in enteric neurons and glia. We show that abnormal
mitochondrial metabolism in the ENS causes widespread enteric neurodegeneration and
results in severe intestinal pseudo-obstruction, the likely cause of premature death in
Tfam-ENSKO mice. Remarkably, mitochondrial dysfunction differentially affected
specific subpopulations of enteric neurons and regions of the gastrointestinal tract. This
regional and subtype-specific variability resulted in an imbalance of inhibitory and
excitatory enteric neurons that likely accounts for the observed phenotype in TfamENSKO mice. Our observations support the hypothesis that damage to the ENS resulting
from defects in mitochondrial function may underlie some of the pathophysiology
involved in gastrointestinal abnormalities in many human neurodegenerative diseases.
Mitochondria are thought to be critical mediators of neuron loss in diverse
neurodegenerative disorders such as PD or diabetes. We show that mitochondrial defects
in the ENS cause both neuron and glia cell loss as well as severe intestinal dysmotility.
Strikingly, not all regions of the gut were equally affected. The proximal SI suffered the
most extensive neuron and glial loss whereas the colon was largely spared (Fig. 3).
Furthermore, we observed differential vulnerability among distinct subtypes of enteric
neurons. Nitrergic neurons, which are predominantly inhibitory in nature, were lost
earliest in the progression of the disease in Tfam-ENSKOs (Fig. 4). These findings
cannot be explained by variations in the efficiency of Tfam excision or in the resulting
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effect on mitochondria. Cnp1-mediated expression of cre-recombinase (as visualized by
YFP fluorescence) and mtDNA depletion were comparable throughout the bowel of
Tfam-ENSKO mice (Fig. 1). The observed variability in sensitivity to mitochondrial
defects suggests, therefore, that there are regional and cell type specific differences in
metabolic needs for individual enteric neuron populations.
In the CNS, regional- and subtype-specific differences in the vulnerability of
neurons to mitochondrial dysfunction are well established; such differences are thought
to underlie the preferential loss of striatal neurons in PD or Huntington’s disease [35].
Early preferential loss of nitrergic neurons has also been reported in a streptozotocininduced rat model of diabetic autonomic neuropathy [36]. Similar differences in
vulnerability to metabolic insults among enteric neurons had been suggested by an earlier
study using a rotenone-induced rat model of PD [16]. The enteric nervous system
abnormalities observed in Tfam-ENSKO mice suggest that regional- and subtype-specific
differences in the susceptibility of neurons to mitochondrial defects are also present in the
ENS and may explain the gastrointestinal presentations of neurodegenerative diseases.
While the mitochondrial dysfunction in Tfam-ENSKO mice is caused by the loss
of Tfam, the way in which these mice recapitulate gastrointestinal pathological features
often seen in neurodegenerative disorders indicates that there may be broader
implications of this work for understanding the bowel dysfunction that accompanies both
rare and common human disease. For example, Tfam-ENSKO mice consistently
developed intestinal pseudo-obstruction with dilated proximal small bowel and
contracted distal bowel reminiscent of that seen in the human mitochondrial disease
MNGIE. Our results indicate that this pseudo-obstruction could occur because of an

143

imbalance in the ratio of inhibitory to excitatory inputs in the ENS. In Tfam-ENSKOs
such an imbalance arises from a relative preservation of nitrergic inhibitory neurons in
the proximal SI and preferential loss of these same neurons in the distal SI of these mice.
This is of particular interest, because the severe intestinal pseudo-obstruction resulting in
cachexia and death in MNGIE patients has traditionally been attributed to smooth muscle
abnormalities, even though mtDNA depletion is also found within enteric neurons in the
SI of MNGIE patients [37]. Our results demonstrating that mitochondrial dysfunction in
enteric neurons and glia alone is capable of producing very similar pathology, however,
suggest that the ENS may play a more prominent role in this mitochondrial disease than
previously thought.
While MNGIE is a rare disease, mitochondrial dysfunction is thought to be a
common underlying mechanism in both normal human aging [38] as well as in many
common diseases such as type 2 diabetes [39]. Defects in gastrointestinal motility
frequently cause serious problems in the elderly and in patients with diabetes [9,40].
These motility defects, similar to what we observed in Tfam-ENSKO mice, have been
attributed to enteric neurodegeneration [9,40]. Moreover, enteric neurodegeneration in
models of aging, PD and diabetes have been associated with imbalances in inhibitory and
excitatory neurons [40]. As such, understanding the ENS abnormalities in Tfam-ENSKO
mice could provide valuable insight into the pathophysiology responsible for
gastrointestinal motility disorders involved in numerous disease processes and affecting a
large number of people.
In summary, Tfam-ENSKO mice are the first genetic model of enteric nervous
system-specific mitochondrial dysfunction and interestingly recapitulate a number of
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pathological features often seen in human neurodegenerative diseases with prominent
gastrointestinal presentations, such as MNGIE, PD or diabetes mellitus. Enteric
mitochondrial dysfunction in these diseases is therefore likely to contribute to their
gastrointestinal pathology. Moreover, Tfam-ENSKOs revealed a remarkable region- and
subtype-specific differential vulnerability of enteric neurons to defects in mitochondrial
metabolism. Appropriate management of gastrointestinal dysfunction in patients with
neurodegenerative diseases might thus be facilitated by devising therapeutic strategies
that improve ENS mitochondrial function and address the differential vulnerability of
specific enteric neuron populations.

Materials and Methods
Ethics: All studies were reviewed and approved by the Washington University Animal
Studies Committee, protocol approval # 20110071 (J.M.) and # 20090190 (ROH).

Matings of transgenic animals: TfamloxP/loxP mice [19] and CNP-Cre mice [26] in pure
C57Bl/6 backgrounds were crossed to generate Tfam-ENSKO mice (CNP-Cre+/-,
TfamloxP/loxP) and their control littermates (CNP-Cre-/-, TfamloxP/loxP or CNP-Cre-/-,
Tfam+/loxP). For experiments involving YFP fluorescence-based FACS sorting or imaging
of enteric neurons and glia, Tfam-ENSKO mice were crossed to Rosa26-YFP reporter
mice

[41]

to

generate

YFP/Tfam-ENSKO

mice

(Rosa26-YFP+/-,

CNP-Cre+/-,

TfamloxP/loxP). Mice with transgenic Rosa26-YFP and CNP-Cre alleles, but with wild type
Tfam alleles (YFP/control: Rosa26-YFP+/-, CNP-Cre+/-, Tfam+/+), were used as controls in
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these experiments. TfamloxP/loxP, CNP-Cre and Rosa26-YFP genotyping were carried out
as previously described [19,26,41].

Quantitative ENS analysis: Mice were euthanized by carbon dioxide asphyxiation
followed by cervical dislocation. The gastrointestinal tract was removed and enteric
whole-mount samples were prepared. Intestines were flushed with ice cold PBS, then
opened by cutting along the mesenteric border, flattened and pinned mucosal side down,
and fixed using 4% paraformaldehyde for 30 minutes. After fixation, samples were
washed with ice cold PBS before isolating the myenteric plexus by peeling off the muscle
layers of the intestine. A 6 cm-long intestinal sample was isolated from the proximal SI
(measured from the pylorus), distal SI (measured from the ileocecal junction), and distal
colon (measured from the anus). In the 2-week-old mice, 3-4 cm long samples were
obtained from the same regions as described above. Samples were then cut into 1 to 2 cm
segments before storing in 50% glycerol/PBS at -20˚C until staining and analysis.
In the 7-week-old mice, sequential 1 cm-long samples of myenteric plexus were
stained with NADPH-d [42], biotinylated-HuC/HuD (1:250; Invitrogen A21272) and
Sox-10 (1:250; Santa Cruz). In the 2-week-old mice, sequential 1-1.5 cm long samples of
myenteric plexus were stained with NADPH-d or biotinylated-HuC/HuD and Sox-10,
again using the order described above.

For the biotinylated-HuC/HuD and Sox-10

double labeling, samples were first labeled by HuC/HuD immunohistochemistry (1:250;
Invitrogen A21272) and then labeled by Sox-10 immunohistochemistry (1:250; Santa
Cruz).
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Quantification of neuron or glial cell density was done by counting all cells
present within the borders of a 0.5 x 0.5 mm grid (20x objective lens). For instances in
which the cellular density was very high, counts were done using a 40x objective lens
(within the borders of a 0.25 x 0.25mm grid). An attempt was made to stretch all
segments evenly and equally for all samples. All analyses used three to six animals, and
counting was done without knowledge of the mouse genotype. Twenty (20) randomly
selected fields were counted for each region and data are presented as neurons/mm 2.
Averages for each animal were used to calculate the mean, standard deviation and
standard error for each genotype. Neuron-to-glia ratio was determined by dividing the
number of neurons by the number of glia present within a single field.

Villus neurite quantification: Villus preparations were made by cutting along single
rows of intestinal villi from full-thickness, pinned samples of proximal and distal small
intestine in 70% ethanol. These were then labeled by TuJ1 (1:10,000; Covance)
immunohistochemistry. Villus neurite quantification was determined by counting all
TuJ1+ projections that crossed a perpendicular line drawn through the middle of each
villus. Twenty (20) randomly selected villi were counted for each region and averaged
for each animal. At least 3 mice were used to calculate the mean, standard deviation and
standard error for each genotype.

FACS isolation of enteric neurons and glia: Rosa26-YFP+ cells were sorted by flow
cytometry after isolating and digesting unfixed myenteric plexus from 7-week-old
YFP/control and YFP/Tfam-ENSKO mice. A modified version of the protocol published
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by Schafer et al. [43] was used to isolate adult mouse ENS neurons and glia. Briefly,
muscle layers of the bowel containing the myenteric plexus were isolated by dissection as
described above, but were not fixed. Samples from the proximal SI, distal SI and colon
were cut into 1 mm2 pieces in ice-cold PBS, then treated with collagenase (1 mg/ml in
DMEM; 37oC, 45 min). After collagenase treatment, tissues were centrifuged at 4,500
rpm for 2 min and collagenase solution was replaced with 0.25% Trypsin in DMEM.
Samples were rotated (37oC, 20-30 min) and triturated by pipetting before centrifugation
(4,500 rpm for 2 min) to remove supernatant. Cells were diluted in 300 μL FACS buffer
(0.002% BSA, 0.001% Sodium Azide, 1 mM EDTA in PBS) and filtered through 70
micron MACS separation filters. Cells were then sorted for YFP expression on a MoFlo
Cell Sorter (Beckman Coulter Corp., Fullerton, CA), using 15 p.s.i. and a 120 μm sorting
nozzle. YFP fluorescence was captured with a 525/40 optical filter in the cytometer's FL
1 channel. Samples were taken from three mice of each genotype (YFP/Ctrl: Rosa26YFP+/-,

CNP-Cre+/-,

Tfam+/+;

YFP/Tfam-ENSKO:

Rosa26-YFP+/-,

CNP-Cre+/-,

TfamloxP/loxP) and a non-YFP+ littermate (Rosa26-YFP-/-, CNP-Cre+/-, Tfam+/+ or Rosa26YFP-/-, CNP-Cre+/-, TfamloxP/loxP) was used for standardization.

RNA and DNA preparation and quantitative real-time PCR (qRT-PCR): RNA and
DNA were isolated from FACS sorted enteric neurons and glia from YFP/Tfam-ENSKO
mice and YFP/Ctrl littermates. For RNA isolation, cells were lysed in Trizol reagent
(Invitrogen) and total RNA prepared according to the manufacturer’s protocol. For DNA
isolation, cells were digested and DNA isolated using DNeasy Blood and Tissue Kit
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(Qiagen) according to the manufacturer’s protocol. DNA and RNA concentration were
quantified using an ND-1000 spectrophotometer (Nanodrop Technologies).
For RT-PCR, cDNA was reverse transcribed from total RNA using M-MLV
reverse transcriptase (Invitrogen) and Tfam or GAPDH mRNA were amplified using the
following

primers

(5’-3’):

ATGTCTCCGGATCGTTTCAC;

Tfam:

F,

CAGGAGGCAAAGGATGATTC;

GAPDH: F,

TGCCCCCATGTTTGTGATG;

R,
R,

TGTGGTCATGAGCCCTTCC. mtDNA content was quantified by qRT-PCR using a
SYBR green-based detection system on a 7700 Sequence Detector instrument (Applied
Biosystems) as described previously [44]. Instead of cDNA, however, 15 ng of total
DNA were used per reaction. Primers that recognize a region unique to the mitochondrial
genome were used to determine mtDNA content normalized to nuclear DNA content, as
determined by a set of primers directed to the genomic locus of Smrt1. The primers used
were

as

follows:

mtDNA:

F,

AAGTCGTAACAAGGTAAGCA;

ATATTTGTGTAGGGCTAGGG.

Nuc.DNA:

GGGTATATTTTTGATACCTTCAATGAGTTA;

R,
F,
R,

TCTGAAACAGTAGGTAGAGACCAAAGC

Cell culture: Enteric neural crest cells were immunoselected from embryonic day 12.5
(E12.5) CD1 mice small bowel and colon using p75NTR antibody (Millipore). Bowel was
dissociated with collagenase (1 mg/ml) and dispase (1 mg/ml) to yield a single cell
suspension. After p75NTR antibody incubation (Millipore, 1:1000, 1 h, 4°C) in B27
(Invitrogen) supplemented Neurobasal medium, cells were incubated with goat antirabbit coupled paramagnetic beads (1:50, 1 h, 4°C; Miltenyi Biotec, Bergisch Gladbach,
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Germany) before separating neural crest-derived cells from unselected cells with a
positive selection column (MACS separation columns; Miltenyi Biotec). Immunoselected
crest-derived cells were plated at a density of 500 cells per well on poly-d-lysine/laminincoated 24-well plates in B27 supplemented Neurobasal medium plus 50 ng/ml glial cell
line-derived neurotrophic factor (GDNF). In all experiments, inhibitors were added to the
medium 24 h after plating using 2.5 μm antimycin (Complex III inhibitor) or 2.5 μm
rotenone (Complex I inhibitor). Control wells were treated with DMSO vehicle. All
experiments were performed in triplicate. All analyses were performed blinded.

Neuronal cell body death assay and Immunohistochemistry: Neurons were treated
with inhibitors or vehicle control and monitored for cell body damage by ethidium
homodimer exclusion (Biotium, Hayward, CA). Ethidium homodimer was added to the
cultures at a final concentration of 100 nM and after 30 minutes of incubation cells were
washed with PBS and fixed 4% paraformaldehyde. After fixation, cells were washed with
PBS and blocked with 5% normal donkey serum in TBST (Tris-buffered saline plus 0.1%
Triton X-100) (1 h, 37°C). Cells were incubated in rabbit polyclonal Tuj1 antibody
(1:1000 at 4°C overnight) and antibody binding was visualized with Alexa Fluor 488
conjugated anti-rabbit secondary antibodies (Jackson Immunoresearch Laboratory, 1:500,
25°C, 1 h).

Electron Microscopy: Samples for transmission electron microscopy were obtained
from 7 week old mice by intracardiac perfusion of Modified Karnovsky’s Fixative (2.5%
glutaraldehyde, 2% paraformaldehyde in 0.1 mmol/liter cacodylate buffer), followed by
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isolation of whole mount samples as described above, omitting peeling. Gut samples
were pinned in modified Karnovsky’s Fixative and postifixed in 2% OsO4 (in 0.1 mmol/L
cacodylate buffer). Samples were then dehydrated and embedded in PolyBed 812
(Polysciences Inc., Warrington, PA). 100 nm sections were cut with a Diatome diamond
knife and stained with uranyl acetate in 50% methanol and Venable's lead citrate.
Transmission EM was performed on a JEOL JEM 1200-EX microscope with AMT
Advantage HR (Advanced Microscopy Techniques Corp., Danvers MA) high-speed,
wide-angle 1.3 megapixel TEM digital camera.

Light Microscopy and quantification: Samples were counted using a 10 x 10 grid
counting eyepiece on an Olympus Optical Bx60 microscope or Zeiss Axioskop and an
Axiocam digital camera and AxioVision imaging software (Zeiss, Germany). Photoshop
7.0 was used to uniformly adjust contrast and brightness so that digital images appear as
they did when observed directly through the microscope.
Statistical analysis: All values are expressed as mean ± SEM. P values were determined
by paired Student’s t-test or Mann-Whitney rank sum test using Sigma Plot 11.0 (Systat
Software, San Jose, CA). In all applicable figures, an asterisk (*) indicates statistical
significance (p value < 0.05).
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Figures
Figure 1. CNP-Cre excises Tfam in enteric neurons and glia and disrupts ENS
mitochondria in Tfam-ENSKO mice. a) YFP fluorescence in 2-day-old Rosa26YFP/CNP-Cre mice overlaps (merge) with enteric neurons (HuC/HuD+ cells, Hu, red)
and glia (Sox-10+ cells, Sox, blue). Excision-dependent YFP fluorescence is visible in the
majority of enteric neurons and glia in all gut regions. Asterisks indicate the occasional
non-recombined, non-YFP+ cell. Scale bars: 30 μm. b) Quantification of the percent of
YFP+ neurons (% of HuC/HuD+ and YFP+ cells/total HuC/HuD+ cells) and glia (% of
Sox-10+ and YFP+ cells/total Sox-10+ cells) in different gut regions confirms high
efficiency of CNP-Cre mediated recombination in the ENS. n=3 mice per genotype. c)
RT-PCR of Tfam transcript demonstrates the complete excision of Tfam in YFP+ FACS
selected myenteric neurons and glia in YFP/Tfam-ENSKO mice at 7 weeks of age. n=3
mice per genotype. d) qRT-PCR results show depletion of mtDNA content in YFP+
FACS-selected myenteric neurons and glia in 7 week old YFP/Tfam-ENSKO mice.
mtDNA content was significantly reduced in YFP/Tfam-ENSKO mice in all regions
examined at this age (*, p<0.01). Reported values are normalized to nuclear DNA content
and ratio of mtDNA to nuclear DNA in control animals was set at 100; n=3 mice per
genotype. e) Electron micrographs of myenteric plexus mitochondria (arrowheads) in 7
week old control and Tfam-ENSKO mice. Tfam-ENSKO myenteric neurons and glia
contain abundant abnormal, enlarged mitochondria with dilated and distorted cristae.
Scale bars, 500 nm.
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Figure 2. Tfam-ENSKOs develop progressive GI dysfunction characterized by
intestinal pseudo-obstruction a) Growth curve of Tfam-ENSKO mice and control
littermates. Tfam-ENSKOs are initially indistinguishable from control mice, but begin to
exhibit poor growth at 4 weeks of age (n ≥ 10 mice per genotype at each time point). b)
Survival curve of Tfam-ENSKO mice and control littermates. Tfam-ENSKO mice die
prematurely beginning at 60 days old. By 90 days, nearly all Tfam-ENSKO mice are
dead. n=47 mice. c) Photograph of gastrointestinal tract of 11-12 week old control and
Tfam-ENSKO mice depicts their typical appearance. Arrowheads indicate regions of
dilation and accumulation of luminal contents. St: stomach, SI: small intestine, Co:
colon.
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Figure 3. Tfam-ENSKO mice display progressive degeneration of neurons and glia
with distinct regional vulnerabilities. a) Representative images of HuC/HuD (neurons,
red) and Sox-10 (glia, green) immunohistochemistry in three regions of myenteric plexus
of 7 week old control and Tfam-ENSKO mice. Loss of both HuC/HuD+ neurons and
Sox-10+ glia is apparent in Tfam-ENSKOs at this age. Scale bars, 100 μm. b)
Quantification of total myenteric neuron density in Tfam-ENSKOs expressed relative to
control littermates at 2 and 7 weeks of age. For 2 weeks old, n=6 (Ctrl) and n=4 (TfamENSKO). For 7 weeks old, n=3 for each genotype. c) Quantification of glial density in
Tfam-ENSKOs expressed relative to control littermates at 2 and 7 weeks of age. For 2
weeks old, n=6 (Ctrl) and n=4 (Tfam-ENSKO). For 7 weeks old, n=3 for each genotype.
d) Neuron-to-glia ratio in ENS of Tfam-ENSKOs and control littermates at 2 and 7 weeks
of age demonstrates that relative cell loss is equivalent for both neurons and glia. For 2
weeks old, n=6 (Ctrl) and n=4 (Tfam-ENSKO). For 7 weeks old, n=3 for each genotype.
PSI: proximal small intestine, DSI: distal small intestine, Co: colon.
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Figure 4. Early and differential loss of nitrergic inhibitory neurons in Tfam-ENSKO
mice. a) Representative images of NADPH-d stained myenteric plexus show inhibitory
neurons in the proximal SI and distal SI in 7 week old Tfam-ENSKO mice. Scale bar,
150 μm. b) Quantitative analysis of NADPH-d+ neuron density in Tfam-ENSKOs relative
to control littermates at 2 and 7 weeks of age. n=3 for each genotype at each age. c) Ratio
of nitrergic neurons to total neurons in 7 week old Tfam-ENSKO and control mice. n=3
for each genotype. PSI: proximal small intestine, DSI: distal small intestine, Co: colon.
d) Diagram depicting how the imbalance of inhibitory neurons to excitatory neurons in
each region in Tfam-ENSKOs could produce the observed proximal SI dilation and distal
SI constriction. In Tfam-ENSKO mice, greater total neuron loss (Tfam-ENSKO top
panel) relative to NADPH-d+ neuron loss (Tfam- ENSKO middle panel) would result in
increased inhibitory input and dilation of the proximal SI (Tfam-ENSKO bottom panel).
Greater NADPH-d+ neuron loss (Tfam-ENSKO middle panel) relative to total neuron
loss (Tfam-ENSKO top panel) would result in decreased inhibitory input and constriction
(and pseudoobstruction) of the distal SI of Tfam-ENSKO mice (bottom panel). Color
intensity represents neuronal density with WT density set as the most intense color in all
regions of the bowel.
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Figure 5. Axonal degeneration is present in Tfam-ENSKO mice and may precede
enteric neuron loss. a) Tfam-ENSKO mice show noticeable neurite blebbing
(arrowheads) in the proximal and distal SI at 7 weeks of age. Scale bars, 25 μm. b, c)
Representative images (b) and quantification (c) of TuJ1+ neurites extending into SI villi
of 7 week old control and Tfam-ENSKO mice. n=3 for each genotype. Scale bars, 40
μm. d, e) Representative images (d) and quantification (e) of axonal fragmentation (TuJ1,
green) and cell body loss (ethidium homodimer, staining not shown) in cultured enteric
neurons after treatment with the mitochondrial inhibitors rotenone or antimycin. Images
correspond to untreated or rotenone-treated enteric neurons. n= duplicate wells for each
condition from 3 independent assays. Scale bars, 100 μm.
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Tables
Table 1. Myenteric Plexus Cell Density
Region

Age
(weeks)

Total neuron density
(Cells/mm2)
Ctrl

PSI

2

DSI

2

Co

2

PSI

7

D SI

7

Co

7

1221
± 156
2355
± 381
2113
± 286
235
± 23
329
± 18
548
± 85

Glial cell density
(Cells/mm2)

Neuron-to-Glia Ratio
(Neurons/Glia)

NADPH-d+ Neuron
Density (Cells/mm2)

% of total neurons that
are NADPH-d+

Tfam% of p
Ctrl Tfam- % of p
Ctrl Tfam- % of p
Ctrl Tfam- % of p Ctrl Tfam- % of
p
ENSKO Ctrl value
ENSKO Ctrl value
ENSKO Ctrl value
ENSKO Ctrl value
ENSKO Ctrl value
839
± 148
1747
± 461
1879
± 317
74
±5
194
± 14
426
± 33

0.133 2316
± 126
0.339 3142
± 239
0.607 3633
± 372
31% 0.003 479
± 31
59% 0.004 744
± 55
0.258 1409
± 48

1831
± 216
2094
± 176
3117
± 268
250
± 31
515
± 38
1153
± 87

0.071 0.54
± 0.09
67% 0.012 0.77
± 0.14
0.343 0.61
± 0.11
52% 0.007 0.49
± 0.02
69% 0.027 0.45
± 0.03
0.062 0.37
± 0.06

0.49
± 0.12
0.83
± 0.18
0.60
± 0.08
0.32
± 0.06
0.38
± 0.04
0.35
± 0.06

0.706 303
± 24
0.794 574
± 28
0.961 578
± 73
0.054 82
±6
0.400 91
±9
0.782 147
±8

188
± 26
350
± 46
557
± 93
55
±4
36
±5
110
±7

62% 0.030 25

22

61% 0.014 24

20

0.860 27

30

67% 0.021 36
±5
40% 0.007 28
±2
75% 0.027 21
±4

75
± 12
19
±2
26
±1

208% 0.038
68% 0.035
0.288

Table 1. Myenteric Plexus Cell Density. Myenteric plexus neuron and glial cell density and ratios in 2 and 7-week-old Tfam-ENSKO
and control mice. n= 3 for each genotype for all analyses of 7 week old mice. For 2 week old mice, n=6 (Ctrl) or 4 (Tfam-ENSKO) for
total neuron density, glial density, and neuron to glia ratio and n=3 for NADPH-d+ neuron density. N/A, not applicable; due to small size
of tissue samples at 2 weeks of age, staining for both HuC/HuD+ (total) and NADPH-d+ (nitrergic) could not be performed on a single
animal and therefore statistical analysis of the proportion of total neurons that are NADPH-d+ was not possible. PSI: proximal small
intestine, DSI: distal small intestine, Co: colon.
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Table 2. Villus Neurite Density
Region

Age
(weeks)

PSI
DSI
PSI
DSI

2
2
7
7

Neurites/villus
Ctrl
Tfam-ENSKO % of Ctrl p value
4.25 ± 0.18
2.72 ± 0.09
64%
0.002
3.63 ± 0.25
3.18 ± 0.2
0.235
10 ± 1.3
2.6 ± 0.23
26%
0.006
12 ± 1.6
4.1 ± 0.35
34%
0.011

Table 2. Villus Neurite Density. Density of neuronal projections in intestinal villi in 2 and 7 week old Tfam-ENSKO and control mice.
n= 3 for each genotype and age. PSI: proximal small intestine, DSI: distal small intestine, Co: colon.

Table 3. Nitrergic Fiber Density
Region

Age
(weeks)

PSI
DSI
Co

7
7
7

NADPH-d+ Bundles/mm2
NADPH-d+ Fibers/mm2
NADPH-d+ Fibers/neuron
Ctrl
Tfam% of p value Ctrl
Tfam% of p value Ctrl
Tfam% of p value
ENSKO Ctrl
ENSKO
Ctrl
ENSKO
Ctrl
19 ± 0.5 14 ± 2
0.073 312 ± 18 174 ± 32
56% 0.020 3.9 ± 0.6 3.1 ± 0.5
0.208
22 ± 3 19 ± 0.5
0.700 298 ± 25 233 ± 6
0.100 3.4 ± 1.4 6.8 ± 4.8
0.098
25 ± 1 25 ± 1
0.844 583 ± 56 527 ± 5
0.378 4.0 ± 0.7 4.8 ± 0.2
0.099

Table 3. Nitrergic Fiber Density. Myenteric NADPH-d+ fiber density and number of NADPH-d+ fibers per neuron in 7 week old TfamENSKO and control mice. n= 3 for each genotype. PSI: proximal small intestine, DSI: distal small intestine, Co: colon.
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Table 4. In vitro Mitochondrial Inhibitor Assay Results
Time

Neurons with fragmented
axons (%/well)
Veh
Rot
Antim
24 hrs 7.3 ± 1.2 26.3 ± 3 15 ± 3.6
48 hrs 6.7 ± 1.2 51.7 ± 6.7 12 ± 1
72 hrs 7.7 ± 1.2 83.7 ± 4.7 32 ± 6.8

% of Control
Rot
360%
772%
1087%

p value

Antim Rot
205% 0.004
179% 0.003
416% <0.001

Et2D+ (dead) Neurons (%/well) % of Control

p value

Antim
Veh
Rot
Antim
Rot Antim Rot Antim
0.03 5.7 ± 0.3 8 ± 1.15 6.3 ± 1.5
0.124 0.5
0.01 6.7 ± 0.3 31 ± 3.6 12 ± 2.6 463% 179% 0.002 0.01
0.003 7 ± 0.6 58.7 ± 5.2 19.3 ± 3.2 839% 276% <0.001 0.003

Table 4. In vitro Mitochondrial Inhibitor Assay Results. In vitro mitochondrial inhibitor assay results from cultured E12.5
immunoselected enteric neurons. n= duplicate wells for each condition from 3 independent assays. Veh=Vehicle; Rot=Rotenone;
Antim=Antimycin
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CHAPTER 5

microRNAs modulate Schwann Cell response to nerve injury by reinforcing
transcriptional silencing of dedifferentiation-related genes

Adapted from: Viader A, Chang LW, Fahrner T, Nagarajan R, Milbrandt J. (2011)
miRNAs modulate Schwann Cell response to nerve injury by reinforcing transcriptional
silencing of dedifferentiation-related genes. Schwann cell mitochondrial metabolism
supports long-term axonal survival and peripheral nerve function. Journal of
Neuroscience. 31(48):17358-69.
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Abstract
In the peripheral nervous system, Schwann cells (SCs) surrounding damaged
axons undergo an injury response that is driven by an intricate transcriptional program
and is critical for nerve regeneration. To examine whether these injury-induced changes
in SCs are also regulated post-transcriptionally by miRNAs, we performed miRNA
expression profiling of mouse sciatic nerve distal segment after crush injury. We also
characterized the SC injury response in mice containing SCs with disrupted miRNA
processing due to loss of Dicer. We identified 87 miRNAs that were expressed in mouse
adult peripheral nerve, 48 of which were dynamically regulated after nerve injury. Most
of these injury-regulated SC miRNAs were computationally predicted to inhibit drivers
of SC dedifferentiation/proliferation and thereby re-enforce the transcriptional program
driving SC re-myelination. SCs deficient in miRNAs manifested a delay in the transition
between the distinct differentiation states required to support peripheral nerve
regeneration. Among the miRNAs expressed in adult mouse SCs, miR-34a and miR-140
were identified as functional regulators of SC dedifferentiation/proliferation and remyelination, respectively. We found that miR-34a interacted with positive regulators of
dedifferentiation and proliferation such as Notch1 and Ccnd1 to control cell cycle
dynamics in SCs. miR-140 targeted the transcription factor Egr2, a master regulator of
myelination, and modulated myelination in DRG/SC co-cultures. Together, these results
demonstrate that SC miRNAs are important modulators of the SC regenerative response
after nerve damage.
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Introduction
Neuronal regeneration in adult vertebrates is largely limited to the peripheral
nervous system (PNS). Unlike neurons in the central nervous system (CNS), PNS
neurons are capable of long-distance axonal regeneration. Central to the differential
plasticity of peripheral neurons are Schwann cells (SCs), the glial cells of the PNS. SCs
have the striking ability to dedifferentiate and revert back to an immature-like state
following axonal loss (Jessen and Mirsky, 2008). After a transient phase of proliferation,
dedifferentiated SCs help support axonal regeneration by clearing myelin debris, forming
tubular structures known as bands of Bungner, and upregulating the synthesis of a
number of neurotrophic factors. As peripheral axons regenerate, SCs re-differentiate to
form mature Remak bundles or new myelin sheaths, helping to restore, in this way,
peripheral nerve function (Geuna et al., 2009). Greater insight into this highly
orchestrated process of SC-mediated support of axonal regeneration could be harnessed
to improve the treatment of peripheral and central neurodegenerative diseases
characterized by axonopathy, including diabetic neuropathy and amyotrophic lateral
sclerosis (Coleman, 2005).
Micro-RNAs (miRNAs) are small (around 22 nucleotides) non-coding RNAs
capable of postrancriptionally regulating protein expression. miRNAs have emerged as
ubiquitous regulators of developmental timing and cellular differentiation (Flynt and Lai,
2008). The central role of miRNAs in cell fate determination suggests that they could
modulate the transcriptional program responsible for the dedifferentiation and
redifferentiation of SCs following nerve injury (Jessen and Mirsky, 2008). This idea is
supported by zebrafish studies implicating miRNAs in the regulation of tissue
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regeneration (Thatcher et al., 2008; Yin et al., 2008; Ramachandran et al., 2010).
Moreover, miRNAs are essential for the normal development of SCs, as miRNAdeficient SCs are unable to differentiate past an immature state (Bremer et al., 2010;
Pereira et al., 2010; Yun et al., 2010). The behavior, identity, and potential role of
miRNAs in the regenerative response of adult SCs after nerve injury, however, remain
unexplored.
In this study we examined the dynamics of miRNA expression in mouse sciatic
nerve following crush-induced axonal loss. We identified 87 miRNAs consistently
expressed in adult peripheral nerve. Most of these SC miRNAs were computationally
predicted to inhibit drivers of SC dedifferentiation/proliferation and their expression was
dynamically regulated after injury to potentially re-enforce the transcriptional program
driving the SC regenerative response. Accordingly, miRNA-deficient SCs had delayed
transitions between the distinct differentiation states involved in the SC injury response.
Among the miRNAs consistently expressed in SCs, miR-34a and miR-140 were
characterized as functional regulators of two distinct processes carried out by SCs
following peripheral nerve damage: proliferation and myelination. Together, our results
demonstrate that miRNAs are important modulators of the SC regenerative response after
nerve damage.

174

Results
Dynamics of SC miRNA expression after injury are consistent with a modulatory
role in the SC regenerative response
To study the potential regulatory role of miRNAs in the SC regenerative response
after peripheral nerve injury, we carried out miRNA microarray expression profiling of
mouse sciatic nerves after crush-induced axonal degeneration. In previous work
examining mRNA expression profiles during the SC injury response (Nagarajan et al.,
2002; Araki et al., 2001; Bosse et al., 2006), we and others found that expression of
regulators of SC dedifferentiation/proliferation and myelination peaks 4 (C4) and 14
(C14) days after nerve crush, respectively. In the present study we therefore profiled
miRNA expression in the distal stump of injured nerves at C4 and C14, as miRNAs that
are differentially expressed at these two time points are likely to be involved in the
regulation of the SC regenerative response.
We identified 87 miRNAs that were reproducibly detected in the adult peripheral
nerve (Fig. 1a). Given that SCs constitute greater than 80% of the cells in mouse sciatic
nerves (King RH, 2005), the detected miRNAs primarily represent the microRNAome of
these glia. Indeed, over one third of the miRNAs detected by our microarray analysis
were previously found to be expressed in cultured isolated SCs (Verrier et al., 2009).
Moreover, several of the most highly expressed miRNAs identified, including let-7f,
miR-138, miR-145, and miR-16, have been previously related to the postnatal
development of SCs (Bremer et al., 2010; Yun et al., 2010; Verrier et al., 2010).
Remarkably, the expression of over half of the detected miRNAs was up- or downregulated in the distal nerve segment following crush injury (48 of 87; C4 vs. Ctrl

175

p<0.05), suggesting that miRNAs may indeed play a role in modulating the processes of
SC dedifferentiation and remyelination after injury.
Genes involved in the dedifferentiation/proliferation and remyelination of SCs
following crush-induced axonal degeneration are dynamically regulated and have
reciprocal patterns of expression (Nagarajan et al., 2002). We reasoned that miRNAs
involved in the SC injury response would be dynamically regulated in a manner similar to
genes known to be important for the regulation of this process. We applied k-means
clustering to our previous SC mRNA expression profiling datasets (see Methods), and
identified gene clusters containing known regulators of SC dedifferentiation/proliferation
(proliferation profile) or differentiation/myelination (myelination profile) after injury
(Fig. 2a) (Nagarajan et al., 2002). Of the 48 miRNAs differentially regulated following
nerve crush injury, 31 of them were expressed in a pattern that was highly correlated with
either the myelination or proliferation profile (with a Pearson's correlation
coefficient>0.8). Interestingly, 21 of these miRNAs were regulated similarly to genes in
the myelination cluster; their expression was inhibited immediately after injury and
increased as remyelination ensued (Fig. 2a). The expression of a significant portion of SC
miRNAs, therefore, is dynamically regulated after crush injury in a manner consistent
with them playing a critical role in modulating the SC regenerative response.

Target bias analysis suggests that SC miRNAs modulate the injury response by
repressing positive regulators of SC dedifferentiation/proliferation
miRNAs often act in concert with transcriptional control to regulate target gene
expression more efficiently (Hornstein and Shomron, 2006). For this reason, biologically
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relevant miRNAs tend to be either co-expressed (positive target bias) or negatively
correlated (negative target bias) with their predicted targets to either fine-tune or inhibit
their activity, respectively (Tsang et al., 2007). We hypothesized that miRNAs could
modulate the SC injury response in a similar manner by cooperating with the
transcriptional regulatory program that controls this process. A miRNA whose expression
profile is correlated with that of myelination-associated genes (Fig. 2a) could thus
reinforce the transcriptional program driving remyelination by inhibiting positive
regulators of SC dedifferentiation/proliferation (demonstrating a negative target bias) or
by modulating myelination-associated genes (demonstrating a positive target bias).
Conversely,

a

miRNA

whose

expression

is

correlated

with

that

of

proliferation/dedifferentiation-associated genes could coordinate with the transcriptional
regulatory program by inhibiting drivers of myelination (negative target bias) or by finetuning proliferation-related genes (positive target bias). To begin to address the biological
function of SC miRNAs in modulating the injury response we therefore studied their
target bias as well as examined their correlation with the proliferation and myelination
expression profiles.
We first used the TargetScanS algorithm (Grimson et al., 2007) to identify SC
expressed genes that were predicted targets of the 87 miRNAs we detected in SCs. We
found that 59 of the 87 miRNAs detected by our microarray analysis had predicted
targets among the ~8000 transcripts detected in our previous SC mRNA expression
profiling datasets (Nagarajan et al., 2002 and unpublished data). TargetScanS is a
relatively stringent miRNA target prediction algorithm, which requires an exact match
between the miRNA seed sequence and any predicted sites. The 59 miRNAs we
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identified (subset 1) therefore represent a high-confidence set of modulators of the SC
injury response and were further examined in our functional analysis.
We then used a Mann-Whitney U-test to determine if the expression of each
miRNA in subset 1 had a higher positive or negative correlation with the expression of its
predicted targets than with that of predicted non-target genes (indicative of a target bias,
see Methods). We found that 25 miRNAs in subset 1 had a significant target bias.
Remarkably, 23 out of these 25 miRNAs had a negative target bias, meaning that when
the expression of a given miRNA was high the mRNA level of its putative targets tended
to be low and vice versa. This prevalence of a negative target bias is in agreement with
previous studies (Farh et al., 2005; Lau et al., 2008), and suggests that the majority of SC
miRNAs reinforce rather than fine-tune the concurrent transcriptional regulatory
processes (Tsang et al., 2007).
Finally, the extent of target bias for each miRNA in subset 1 (measured by a
Mann-Whitney z-score, See Methods) was plotted against the correlation of its
expression with the myelination or proliferation profile (measured by CC, the difference
in correlation coefficients with the proliferation profile and the myelination profile).
Interestingly, when plotted in this manner, the majority of SC miRNAs clustered in the
top left quadrant of the graph, indicative of a negative target bias and an expression
pattern that correlated with that of genes in the myelination cluster (Fig. 2b). Only six
miRNAs had a negative target bias and a high correlation with the expression pattern of
genes in the proliferation cluster. Similarly, very few miRNAs showed a positive target
bias (Fig 2b). Importantly, these results suggest that SC miRNAs are likely to modulate
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the injury response primarily through their inhibition of positive regulators of SC
dedifferentiation/proliferation.
To further validate this conclusion we carried out gene ontology enrichment
analysis for the putative targets of miRNAs that were: 1) differentially regulated after
injury (C4 vs. Ctrl p<0.05); 2) demonstrated a statistically significant target bias; and, 3)
had a high correlation with the myelination or proliferation clusters (CC>1.6). We
reasoned that miRNAs that met these three criteria were more likely to be direct
regulators of the SC injury response. Using these rigorous criteria, six miRNAs were
identified. Interestingly, these miRNAs all had a negative target bias and an expression
pattern that correlated with the myelination profile (Fig. 2c). Gene ontology enrichment
analysis showed that the predicted targets of these miRNAs were enriched for genes
involved in cellular processes that are normally more active in immature or proliferating
SCs. These processes included cell cycle regulation, cell migration, and regulation of
transcription or chromatin organization (Fig. 2d), and genes such as SC mitogens (e.g.
fibroblast growth factor), oncogenes (e.g. Kras) or cyclins (e.g. cyclin E2). These results
indicate that SC miRNAs regulate the injury response primarily by inhibiting positive
regulators of SC dedifferentiation/proliferation, and reinforce the transcriptional program
that keeps these dedifferentiation/proliferation genes quiescent in mature or
differentiating SCs. This reinforcement likely facilitates rapid and robust transitions
between the distinct differentiation states involved in the SC injury response (Farh et al.,
2005; Stark et al., 2005).
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SCs with disrupted miRNA processing show delays in cycling between
differentiation states after peripheral nerve injury
The results described above suggest that miRNAs work in concert with
transcriptional controls in order to ensure the correct extent and timing of the SC
dedifferentiation and subsequent remyelination following nerve injury. To more directly
examine this idea, we carried out nerve lesion studies on mice in which mature miRNA
synthesis was disrupted in SCs through the targeted deletion of Dicer1¸ a gene encoding
an essential enzyme in miRNA biosynthesis (Bartel and Chen, 2004). Mice harboring
loxP-flanked Dicer1 alleles (Cobb et al., 2005) were crossed to mice expressing a
tamoxifen-inducible form of Cre-recombinase in both myelinating and non-myelinating
SCs under the control of the proteolipid protein promoter (PLP-CreERT) (Doerflinger et
al., 2003). The resulting PLP-CreERT:Dicer fl/fl mice were aged to 1 month and then
-SCKOs) or vehicle (Ctrl) for 10
consecutive days (see Methods). Eight weeks after exposure to tamoxifen, a majority of
SC nuclei (82% +/- 5.1%, identified morphologically) in PLP-CreERT mice carrying a
copy of a Cre-inducible Rosa26-YFP reporter exhibited YFP fluorescence (Fig. 3a).
Accordingly, Dicer mRNA levels as well as the basal levels of a number of highly
expressed miRNAs were significantly reduced in the sciatic nerves of Dicer-SCKO vs.
Ctrl mice (Fig. 3b and data not shown). However, at 8 weeks and for as long as 14 weeks
after tamoxifen treatment, nerves from Dicer-SCKO mice showed no apparent pathology
and were indistinguishable from Ctrl nerves, indicating that disruption of miRNA
processing in SCs after peripheral nerve myelination was fully completed was well
tolerated (Fig. 3g and h and data not shown).
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To determine whether miRNA deficiency led to deficits in the SC injury response
and re-myelination, sciatic nerves of Dicer-SCKO and Ctrl littermates were crushed 8
weeks after tamoxifen administration. We first examined the response of SCs to axonal
degeneration by assessing changes in SC proliferation and in their ability to break down
existing myelin (Geuna et al., 2009). The rate of myelin loss, a measure of SC
dedifferentiation, was similar between Dicer-SCKO and Ctrl mice, with no differences
observed in the amount of myelin debris (Fig. 3c) or of myelin basic protein (MBP)
immunofluorescence in the nerves after injury (data not shown). Similarly,
immunostaining of the nerve distal stump 4 days after injury using an antibody against
the proliferation marker phospho-histone 3 (PH3) showed that, following axonal loss,
miRNA-deficient SCs were able to re-enter the cell cycle to the same extent as Ctrl SCs
(% of PH3 positive cells Ctrl= 12.37 +/- 0.47; Dicer-SCKO= 13.12 +/- 0.69; Fig. 3d and
e). Depletion of miRNAs, therefore, did not interfere with the ability of SCs to
dedifferentiate and proliferate after injury.
We next studied the late phase of the SC-injury response, during which these glia
exit the cell cycle and redifferentiate to restore peripheral nerve function. PH3
immunostaining was initially used to assess the proportion of proliferating SCs 14 days
after crush, a time when SCs have normally exited cell cycle and are actively
differentiating. Interestingly, PH3 immunoreactivity showed that while the number of
proliferating SCs in Ctrl nerves had returned to pre-injury levels, significantly more SCs
in Dicer-SCKO nerves were still actively proliferating at this time (% of PH3 positive
cells Ctrl= 0.93 +/- 0.08; Dicer-SCKO= 4.47 +/- 0.32; p<0.001; Fig. 3d and e).
Consistent with the reduced ability of miRNA-deficient SCs to exit cell cycle in a timely
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manner, nerves from Dicer-SCKO mice showed reduced remyelination compared to
nerves from Ctrl mice, as indicated by a decrease in the total number of myelinated axons
14 days after injury (Fig. 3g and h). Note that this difference in remyelination after injury
in Dicer-SCKO mice was not due to changes in the overall number of SCs (SC
number/50K

2

: Ctrl=183.4 +/- 33.7; Dicer-SCKO=203.5 +/- 18.9; p=0.6). An

examination of electron micrographs of injured sciatic nerves from Ctrl and Dicer-SCKO
mice revealed equivalent total numbers of regenerated axons (remyelinated and nonremyelinated

2

: Ctrl=525 +/- 46.2; Dicer-SCKO=576.9 +/- 2.5; p=0.3)

(Fig. 3f). Interestingly, 28 days after nerve injury the total number of myelinated axons in
nerves from Dicer-SCKO and Ctrl mice were similar (Fig. 3g and h), but the axons in
Dicer-SCKO nerves remained more thinly myelinated (G-ratio (axon area/fiber area)
Ctrl= 0.41 +/- 0.016; Dicer-SCKO= 0.46 +/- 0.012; p=0.05; Fig. 3h). Together these
results support that SC miRNAs modulate the injury response by cooperating with
transcriptional controls to ensure the correct extent and timing of SC dedifferentiation,
cell cycle re-entry/exit, and subsequent differentiation and re-myelination after nerve
injury.

miR-34a is a potential regulator of SC dedifferentiation and proliferation after
peripheral nerve injury
Cellular differentiation is tightly linked to exit from the cell cycle. Therefore, the
influence of miRNAs on cell fate decisions is often linked to their ability to modulate cell
cycle regulators (Ivey and Srivastava, 2010). Given that SCs need to dedifferentiate and
temporarily re-enter the cell cycle in order to support axonal regrowth after injury (Geuna
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et al., 2009), we hypothesized that the regulation of SC cell cycle entry/exit by miRNAs
could underlie their influence on the injury response. Among the miRNAs identified as
most likely play a role in the SC injury response (Fig. 2c), we identified miR-34a as a
particularly good candidate to regulate the competency of SCs to proliferate or
differentiate. miR-34a is a tumor suppressor gene whose ectopic expression can induce
cell cycle arrest (Hermeking, 2010). Moreover, Notch1 and cyclin D1 (Ccnd1), two
important mediators of SC dedifferentiation, proliferation, and cell cycle entry/exit, after
peripheral nerve injury (Woodhoo et al., 2009; Kim et al., 2001) are targets of miR-34a in
cancer cells (Pang et al., 2010; Sun et al, 2008). In addition, we identified a negative
target bias for miR-34a in SCs for genes in the proliferation cluster (Fig. 2c), suggesting
that miR-34a is a modulator of cell cycle regulators in SCs.
To verify a potential role of miR-34a in the regulation of cell cycle entry in SCs
we first examined the expression of this miRNA in more detail. Quantitative RT-PCR
confirmed that miR-34a is highly expressed in adult peripheral nerves (Ctrl) but that its
expression level drops sharply after nerve crush (C4) or transection (Trx14) when SCs
dedifferentiate and re-enter the cell cycle. miR-34a expression, however, is restored to
pre-injury levels as SCs exit the cell cycle and redifferentiation ensues (C7, C14) (Fig.
4a). The expression pattern of miR-34a before and after injury is consistent with a role in
the modulation of cell cycle regulators in SCs.
We next assessed the effect of the differential expression of miR-34a after nerve
injury

on

Notch1

and

Ccnd1,

two

putative

targets

relevant

to

SC

dedifferentiation/proliferation and the injury response (Woodhoo et al., 2009; Kim et al.,
2001; Atanasoski et al., 2001). We overexpressed miR-34a in HEK293T cells together
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with a luciferase construct containing the 3’-UTR of either Notch1 or Ccnd1 and
confirmed that, as previously reported (Pang et al., 2010; Sun et al., 2008), miR-34a
directly recognized and interacted with the transcripts of these two genes (Figure 4b).
Consistent with direct targeting of Notch1 and Ccnd1 by miR-34a, the expression pattern
of these two genes was reciprocally correlated with that of miR-34a following axonal
degeneration (i.e., miR-34a expression decreased after injury as Notch1 and Ccnd1
expression increased). The converse expression pattern was observed as SC
redifferentiation took place (Fig. 4c). Furthermore, when miR-34a was overexpressed in
isolated SCs, Ccnd1 and Notch1 were downregulated at both the transcript and protein
levels (Fig 4d and e). In SCs, therefore, miR-34a directly targets at least two positive
regulators of SC dedifferentiation and proliferation (Notch1 and Ccnd1). In addition to
Notch1 and Cnd1, other potentially relevant targets to SC dedifferentiation and
remyelination (e.g. YY1) could also mediate some of the effects of miR-34a on the injury
response (Chen et al., 2011; He et al., 2010)
Finally, to directly determine whether miR-34a regulates cell cycle entry and exit
in SCs we assessed the effect of overexpressing this miRNA on the axon-induced
proliferation of SCs in vitro. When isolated SCs are cultured in the presence of dorsal
root ganglion (DRG) neurons, contact with axons initially induces SCs to enter the cell
cycle and proliferate. We found that ectopic expression of miR-34a did not affect SC
health and viability, but severely inhibited DRG axon-induced proliferation of SCs in
vitro (Fig. 4f).

Together our results indicate that mir-34 can directly interact with

positive regulators of dedifferentiation and proliferation in SCs to control cell cycle
dynamics in these peripheral glial cells, thus providing a mechanism by which miRNAs
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could modulate proper cycling of SCs between the distinct differentiation states that
support nerve regeneration after injury.

miR-140 targets Egr2, a master regulator of myelination, to help modulate SC
redifferentiation after nerve injury
The differentiation status of SCs after injury is determined by the balance between
signaling systems that drive SC maturation/myelination vs. those that induce SC
dedifferentiation/proliferation (Jessen and Mirsky, 2008). While we initially found that
most SC miRNAs interact with targets involved in SC dedifferentiation/proliferation (see
above), we also searched for miRNAs that targeted positive regulators of myelination. To
this end, we focused on identifying miRNAs that interact with Egr2, a transcription factor
that is required for the formation and maintenance of myelin and that is often mutated in
patients with peripheral myelinopathies (Svaren and Meijer, 2008).
In silico analysis using PicTar (Krek et al., 2005), TargetScanS (Grimson et al.,
2007) and miRanda (John et al., 2004) algorithms identified a putative binding site for
miR-140 in the 3’-UTR of Egr2 (Fig. 5a). This binding site has an exact match to the 28bp seed sequence of mouse miR-140 (AGUGGUU), which is highly conserved in
human, rat, dog and horse, and thus this miRNA was selected for further testing.
Although our microarray analysis detected expression of miR-140* (which originates
from the opposite arm of the pre-miRNA for mir-140) rather than miR-140 in nerve
samples (Fig. 1), qRT-PCR confirmed that miR-140 is also expressed in adult peripheral
nerve. Moreover, we found that miR-140 expression was dynamically regulated after
peripheral nerve injury, i.e. its expression level was significantly decreased immediately
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after nerve crush (C4) and remained low until at least C7 (Fig. 5b). miR-140 expression
was restored to pre-injury levels once SC redifferentiation ensued (C14) (Fig. 5b).
Interestingly, the identified expression pattern of miR-140 after peripheral nerve injury is
positively correlated with that of its putative target Egr2 (Fig. 5c), suggesting that miR140 influences the injury response by fine-tuning the steady-state level of Egr2 in SCs
that are actively forming or maintaining myelin (Tsang et al., 2007).
The dynamic regulation of miR-140 during active myelin remodeling prompted us
to further examine this miRNA in SCs. To confirm that Egr2 is a target of miR-140, we
first co-transfected HEK293T cells with plasmids encoding either pre-mir-140 or a
control pre-miRNA together with a luciferase reporter construct carrying the 3’UTR of
Egr2. Co-expression of this reporter plasmid with miR-140 decreased luciferase activity
in these cells, indicating that miR-140 can directly recognize and interact with the Egr2
3’UTR (Fig. 5d). This interaction was dependent on the computationally predicted miR140 binding site in this region, as a 3’UTR fragment containing a mutant site was no
longer responsive to co-expression of pre-mir-140 (Fig. 5d). Consistent with results from
these luciferase reporter assays, Egr2 protein levels were reduced 2.8-fold in cultured SCs
overexpressing miR-140 (Fig. 5e). These results identify Egr2 as a new target of miR-140
and indicate that this miRNA directly interacts with Egr2 via a highly conserved site in
its 3’UTR to regulate the expression of this transcription factor in SCs.
Finally, we examined whether miR-140 affected the ability of SCs to differentiate
and myelinate in vitro. In the absence of neurons, prolonged exposure to cAMPstimulating agents can promote SC growth arrest and differentiation and induce
expression of genes typically associated with myelinating SCs (e.g. Mpz and Pmp22)
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(Jessen et al., 1991; Monje et al., 2009). Using this system, we evaluated the effect of
miR-140 overexpression on SC differentiation. Consistent with the down-regulation of
Egr2 protein by mir-140 in SCs (Fig. 5e), cAMP-induced, Egr2-mediated upregulation of
myelin markers in cultured SCs was inhibited in the presence of this miRNA (cAMPinduced gene expression fold induction, MPZ: Ctrl miR= 4.7 +/- 0.51; miR-140= 2.09 +/0.35; p<0.05; PMP22: Ctrl miR= 1.5 +/- 0.06; miR-140= 0.9 +/- 0.06; p<0.05)
When SCs are cultured together with dorsal root ganglion neurons (DRGs) in the
presence of ascorbic acid, DRG axons will support the differentiation of SCs and the
formation of myelin (Wood et al., 1990). Myelination can be monitored in this system by
using myelin basic protein (MBP) immunostaining as a marker. We found that
overexpression of miR-140 in SCs co-cultured with DRGs inhibited the expression of
Egr2 as well as a number of myelination markers (Fig. 5f). Most importantly, miR-140
overexpression inhibited myelination in this in vitro assay as evidenced by the decreased
number of myelin segments detected by MBP immunostaining (Fig. 5g). Together, our
results indicate that miR-140 can directly interact with Egr2 and modulate the level of
this transcription factor to regulate myelination. This suggests another mechanism by
which miRNAs may modulate the injury-induced regenerative process of SCs in
peripheral nerves.

Discussion
Following axonal loss, SCs mount a regenerative response involving coordinated
dedifferentiation, proliferation and redifferentiation that helps restore peripheral nerve
function. Extensive work has established that this SC injury response is driven by an
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intricate transcriptional program controlling the balance between positive and negative
regulators of SC differentiation (Jessen and Mirsky, 2008). The present study describes a
new regulatory layer of the SC injury response involving post-transcriptional regulation
by miRNAs. We show that SC miRNAs modulate the injury response by targeting
primarily positive regulators of SC dedifferentiation/proliferation, cooperating with
transcriptional controls to ensure rapid and robust transitions between the distinct
differentiation states that support nerve regeneration. Moreover, we also identify miR-34a
and miR-140 as important functional regulators of SC proliferation and myelination, two
central processes of the SC regenerative response after injury. miRNAs therefore appear
to be important modulators of the SC regenerative response after peripheral nerve injury.
miRNAs are thought to have evolved to canalize the genetic network and confer
robustness to gene expression programs (Hornstein and Shomron, 2006). miRNAs
achieve this by integrating into the pre-existing genetic network in two ways. On the one
hand, miRNAs can wire into coherent feed-forward loops (FFLs) such that high
expression of a given miRNA is induced at a time or location when the transcription of its
predicted targets is repressed (negative target bias) (Hornstein and Shomron, 2006; Tsang
et al., 2007). This type of network motif functions as a post-transcriptional failsafe and
results in mutually exclusive expression domains for the miRNA and its putative targets
(Stark et al., 2005; Mansfield et al., 2004). On the other hand, miRNAs can wire into
incoherent FFLs, which would promote high expression of a given miRNA at a time or
location where its predicted targets are also abundant (positive target bias) (Hornstein and
Shomron, 2006; Tsang et al., 2007). Biological examples of incoherent FFLs (Karres et
al., 2007) have shown that in this type of network motif miRNAs have a fine-tuning
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action and keep protein levels in the correct functional range. Our work demonstrates that
SC miRNAs show a prevalence of negative target biases during the SC injury response.
This indicates that SC miRNAs primarily participate in coherent FFLs. Moreover, the
expression of most SC miRNAs after injury was negatively correlated with that of
positive regulator of SC dedifferentiation/proliferation. Interestingly, we also found that
predicted targets of SC miRNAs are enriched for genes active in immature or
proliferating SCs that are quiescent in adult, differentiated SCs. Together these
observations indicate that SC miRNAs regulate the injury response primarily by
inhibiting positive regulators of SC dedifferentiation/proliferation and thereby reinforcing
a

preexisting

transcriptional

silencing

mechanism

that

keeps

dedifferentiation/proliferation-related genes quiescent in differentiated SCs yet allows
their induction following axonal degeneration.
The above results imply that the majority of miRNAs expressed in mature SCs are
involved in maintaining the differentiated state. In accordance, we found that
immediately after injury most SC miRNAs are down-regulated, which allows for the
transcriptionally driven dedifferentiation of SCs. We also observed that, similar to what
has been reported for SC postnatal development (Bremer et al., 2010; Pereira et al., 2010;
Yun et al., 2010), the expression of most SC miRNAs is up-regulated once again shortly
after axonal regrowth. Because most SC miRNAs target positive regulators of SC
dedifferentiation/proliferation that must be repressed for proper SC differentiation to
occur (Le et al., 2005), this serves to facilitate redifferentiation and stabilization of the
mature SC phenotype. This observation is consistent with studies showing that miRNAs
are generally expressed at lower levels in immature or dedifferentiated tissues than in
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differentiated ones (Wienholds et al., 2005; Lu et al., 2005), and with the idea that
miRNAs are largely involved in promoting, inducing, and stabilizing differentiated
phenotypes (Wienholds and Plasterk, 2005). It is possible that manipulation of SC
miRNAs could be used therapeutically to facilitate SC differentiation after injury or
reverse the effects of neuropathy.
The therapeutic modulation of SC miRNAs, however, requires the identification
of specific miRNAs playing critical roles in the establishment and maintenance of SC
differentiation as well as in the modulation of the SC injury response. We identify miR34a as one such candidate. We found that miR-34 was able to critically regulate SC cell
cycle exit by directly interacting with Ccnd1 transcripts and impinging on Notch
signaling, a central modulator of SC dedifferentiation after injury (Woodhoo et al., 2009).
Other miRNAs are likely to play similar roles; for example, let-7 family members
enhance differentiation and inhibit stem-cell self-renewance (Melton et al., 2010).
Moreover, this family of miRNAs participates in regenerative processes in zebrafish
(Ramachandran et al., 2010). Intriguingly, our microarray analysis found that several
members of the let-7 family were differentially regulated in SCs after peripheral nerve
injury.
While our work shows that most SC miRNAs interact with targets involved in SC
dedifferentiation/proliferation, we also identified miR-140 as a potential regulator of Egr2. Egr2 is an essential transcription factor for myelinogenesis and is often mutated in
patients with peripheral myelinopathy (Svaren and Meijer, 2008). Accordingly, we found
that overexpression of miR-140 in SCs impaired their ability to form myelin in vitro.
Interestingly, the expression pattern of miR-140 and Egr2 indicates the presence of an
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incoherent FFL (Hornstein and Shomron, 2006; Tsang et al., 2007) in which both
transcript and miRNA are co-expressed at the same time in SCs. This suggests that miR140 may act to maintain Egr2 expression within precise functional levels. This is
particularly interesting because myelin formation and maintenance is very sensitive to
gene dosage effects. In fact, both abnormally low or high levels of specific myelin
proteins can cause peripheral neuropathy in humans (Meyer zu Horste et al., 2006).
Regulation of expression thresholds could therefore be a second mechanism, together
with reinforcement of transcriptional silencing, by which SC miRNAs modulate the
injury response of these glia and promote regeneration of peripheral nerves.
In summary, through miRNA expression profiling after nerve damage and
examination of the effects of impaired miRNA processing on the SC injury response, the
present study establishes a critical role for miRNAs in the modulation of the SC
regenerative response in peripheral nerves. We demonstrate that SC miRNAs ensure
rapid and robust transitions between the distinct differentiation states necessary to
support

nerve

regeneration

by

reinforcing

the

transcriptional

silencing

of

dedifferentiation and proliferation-related genes. Modulation of SC miRNAs could offer
therefore a new therapeutic avenue to enhance nerve regeneration and improve the
treatment of neurodegenerative diseases characterized by axonopathy

Materials and Methods
Animals and matings: All animal experiments were carried out in compliance with
institutional animal protocols. For all nerve lesion studies, except those involving mice
lacking Dicer specifically in SCs (Dicer-SCKOs), C57Bl6 mice of either gender were
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used. Dicer-SCKO mice were generated by crossing Dicer

loxP/loxP

mice (Cobb et al.,

2005) to PLP-CreERT+/- mice (Doerflinger et al., 2003). Compound heterozytoges (PLPCreERT+/-, Dicer+/loxP) were then backcrossed to homozygous Dicer

loxP/loxP

to generate

PLP-CreERT+/-, DicerloxP/loxP mice. One-month-old PLP-CreERT+/-, DicerloxP/loxP mice of
either gender were injected daily with 100 g/g of tamoxifen (10 mg/ml stock dissolved
in a 10:1 peanut oil/ethanol mixture) for a total of 10 days (with a 2 day break after day
5) to generate Dicer-SCKOs. Ctrl mice were injected in the same way with vehicle alone
(10:1 peanut oil/ethanol mixture). PLP-CreERT+/- were also crossed to Rosa26-YFP+/mice to generate PLP-CreERT+/-, Rosa26-YFP+/- mice, which were treated with tamoxifen
in an analogous manner.

Surgical procedures: For lesion studies, adult mice (2-3 months of age) were
anaesthetized by intraperitoneal injection of avertin. The sciatic nerve was exposed at the
hip and either crushed using #5 jeweler’s forceps for 30 sec or transected using small
scissors. In the case of transection, the distal stump was deflected onto an adjacent
muscle to prevent regeneration. When necessary, the site of injury was marked with a
single 10-0 nylon epineural suture. Nerve lesions were produced on the right side and the
intact contralateral nerve served as the uninjured control. At the appropriate time points
nerves were harvested and processed for histology or immediately frozen in liquid
nitrogen for subsequent extraction of RNA.
RNA preparation, and quantitative real-time PCR: Total RNA was isolated after
homogenization (for sciatic nerves) or lysis (for cultured SCs) in Qiazol lysis reagent
(Qiagen) using a miRNeasy Minikit (Qiagen) according to the manufacturer’s protocol.

192

RNA concentration was quantified using an ND-1000 spectrophotometer (Nanodrop
Technologies). mRNA was reverse transcribed from 100 ng of total RNA using qScript
cDNA SuperMix (Quanta Biosciences) while miRNA was reverse transcribed from 100
ng of total RNA using NCode Vilo miRNA cDNA Synthesis kit (Invitrogen). mRNA
qRT-PCR was performed using a SYBR green-based detection system on a 7900 HT
Sequence Detector instrument (Applied Biosystems) as described previously (Nagarajan
et al., 2001). GAPDH expression was used to normalize samples and obtain relative
expression values that were used to calculate percent changes. miRNA qRT-PCR was
carried out in an analogous manner but cycling conditions were adapted as per NCode
Vilo miRNA qRT-PCR kit (Invitrogen) recommendations. U6 snRNA was used for
normalization. The sequences of the qRT-PCR primers used are as follows (5’-3’): Dicer:
F, AATTGGCTTCCTCCTGGTTAT; R, GTCAGGTCCTCCTCCTCCTC. mir-34a: F,
GGCAGTGTCTTAGCTGG

TTGT.

GATTTCAAGTAATCCAGGATAGGCT.
TATGGTAG.

All

miRs

R,

CATGGGCAAATTCTCCATTGA;

mir-26a:
mir-140:

NCode
R,

Vilo

Universal

F,

CAGTGGTTTTACCC
Primer.

Egr-2:

F,

TTGCAAGATGCCCGCAC.

MPZ:

F,

CCCTGGCCATTGTGGTTTAC; R, CCATTCACTGGACCAGAAGGAG. MBP: F,
CCAGTAGTCCATTTCTTCAAGAACATT; R, AGCTAAATCTGCTGAGGGACAGG.
Ccnd1: F, GCGTACCCTGACACCAATCT; R, GAACCGGTCCAGGTAGTT CA;
Notch1:

F,

TGACCTGCTCACTCTCACAGA

CGACAGATGTATGAAGACT CAAAGG.
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GTAC;

R,

Microarray and computational analysis: SC microarray gene expression profiling
experiments were performed in previous studies using Affymetrix MU74v2 chips
(Nagarajan et al., 2002). Expression data were processed and normalized using
Affymetrix MAS5 algorithm. A SC expressed gene was defined as one that was called
present in at least one time point during SC regeneration. k-means clustering was used to
cluster genes based on their expression profiles, and gene clusters that had an expression
pattern similar to the previously identified myelination or proliferation profile (Nagarajan
et al., 2002) based on the Pearson correlation coefficient were identified and merged. The
average expression profile, i.e. the centroid, was calculated as the final myelination or
proliferation profile.
For miRNA expression profiling, total RNA samples were prepared by isolating
and pooling RNA from at least 3 different mice at the appropriate times after nerve crush.
Replicates were prepared entirely independently from two separate pools of at least three
animals each. 2 replicates were used for hybridization onto HTG Molecular qNPA
miRNA microarrays (HTG Molecular) according to the manufacturer’s protocol, and
microarray images were obtained and background substracted as per HTG Molecular
recommendations. Scanned miRNA microarray expression data were first processed
using the software provided by the manufacturer of the array. This microarray platform
includes duplicate probesets for 1046 miRNAs. miRNA expression data were further
filtered using the following criteria: 1) the average of the expression of control miRNA
probesets on the array was used as a cutoff to remove miRNAs that have low or no
expression, and 2) miRNAs for which the expression of one duplicate probeset at all time
points are significantly higher than that of the other duplicate probeset were also removed
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for further analysis, based on a Mann-Whitney U test. Expression data were then Z-score
normalized for each miRNA, and at each time point the average expression of the two
duplicate probesets was calculated. These miRNA expression profiles were compared to
the previously identified myelination or proliferation profiles in the following target bias
analysis.
TargetScanS, PicTar, and miRanda algorithms were used to predict potential
miRNA regulatory targets. miRNA targets predicted by these programs were downloaded
from the program websites. miRNA target bias analysis was performed as follows: for
each miRNA, SC expressed genes that have a miRNA seed sequence match in the 3’UTR
were identified using TargetScanS. The Pearson’s correlation coefficient of gene and
miRNA expression profiles was calculated for each target and non-target. The MannWhitney test P-value was calculated to test if miRNA target genes tend to have higher
expression correlations with miRNA than non-target genes, i.e. a positive target bias.

Immunohistochemistry: The following primary and secondary antibodies were used:
chicken anti-GFP (1:1000, Aves), rabbit anti-βIII tubulin (1:1000, Covance), rabbit antiphospho histone 3 (1:200, Millipore), rat anti-MBP (1:100, Millipore), anti-rabbit Cy3
(1:500, Jackson ImmunoResearch Laboratories), anti-rat Cy3 (1:500, Jackson
ImmunoResearch Laboratories),

and anti-chicken Alexa 488 (1:500, Jackson

ImmunoResearch Laboratories).
For immunohistochemical analysis of sciatic nerves, nerves were dissected,
immersion fixed in 4% paraformaldehyde for 2 h, rinsed with PBS, and cryoprotected in
30% sucrose. Sciatic nerves were then embedded in Tissue-Tek OCT Compound (Sakura
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Finetek) and sectioned at 6 m. All frozen sections were immunostained by post-fixing in
ice-cold acetone at -20°C for 10 min and blocking in 5% fish skin gelatin in PBS-0.2%
Triton for 1 h at room temperature. Sections were then incubated with primary antibody
diluted in blocking buffer overnight at 4°C. Secondary antibody incubation was
performed at room temperature for 1 h also in blocking buffer. After all stainings,
sections were mounted with Vectashield Mounting Medium with DAPI (Vector
Laboratories) for microscopic visualization. Images were captured using an upright
microscope equipped for epifluorescence microscopy (Nikon 80i; CoolSnapES camera)
and were processed using MetaMorph, Image-J and Gimp software using global
adjustments in brightness and contrast. All cell number quantifications were carried out
by counting the cells of interest in 4 randomly selected regions in longitudinal nerve
sections from each animal assessed (at least 3 mice per genotype at each time point) at a
20x magnification. The area covered by MBP immunostaining was determined using
Image-J after automated background adjustment and binarization (Sasaki et al., 2009),
from 4 randomly selected fields at a 20x magnification in longitudinal nerve sections.
MBP area was normalized to total nerve area and results represent the average of at least
3 mice per genotype.

Nerve light and electron microscopy and morphometry: Sciatic nerve segments from
Dicer-SCKO or Ctrl mice were dissected at the appropriate times after injury and placed
in 3% glutaraldehyde overnight. The isolated nerve segments were approximately 15 mm
in length and, in the case of crush-injured nerves, included the distal regenerated stump.
After washing with phosphate buffer, nerves were postfixed in 1% osmium tetraoxide in
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phosphate buffer overnight at 4°C. Specimens were then dehydrated in graded alcohols
and embedded in 100% epoxy (Araldite 502). One-micrometer-thick plastic embedded
sections were prepared and stained with toluidene blue for light microscopy. For electron
microscopy, thin sections were prepared, stained with uranyl acetate and lead citrate, and
photographed with a JEOL (Akishima) 1200 electron microscope. All nerves underwent
qualitative assessment of neural architecture followed by detailed histomorphometric
analysis carried out in a blinded fashion as previously described (Hunter et al., 2007),
using at least three mice per genotype at each time point. For injured nerves,
histomorphometric analysis was carried out 5 mm distal to the crush site. Total
regenerated axon counts were determined by counting both remyelinated and nonremyelinated axons in Ctrl and Dicer-SCKO nerves 14 days after injury from electron
micrographs taken at 5000x magnification.

Plasmids: miRNAs were obtained by PCR amplifying individual miRNA precursors
from genomic DNA. The resulting fragments were cloned between the BamHI and Nhe I
sites in the miRNASelect pEP-MIR Cloning and Expression Vector (Cell Biolabs) using
the InFusion HD cloning system (Clonetech) according to the manufacurer’s
recommendations. Pre-miRNAs included the miRNA stem loop and ~100 nt of flanking
sequence on either side and were amplified using the following primers: pre-mir-34a: F,
TAGTTCTCGAGGATCCCCAGCTGAATCCCGACTA

GT;

R,

AAAAGCTCGAGCTAGCTCTCTTAGCCAGAAGTGCTC. pre-mir-140: F, TAGTTC
TCGAGGATCCGCCTCTGACCCTGCTTGCTGGTGGTGTA;
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R,

AAAAGCTCGAGCTAGC

CCAACACCCACCCAATAGACGCCT.

pEP-mir

Null

Vector (Cell Biolabs) was used as Ctrl.
A lentiviral miRNA expression vector was made by PCR amplifying the pEPMIR expression cassette (promoter, miR processing portion, and mCherry reporter; F,
AGATCCAGTTTGGTTAATTAAGTGAGG CTCCGGTGCCCGTCA; R, TAGAG
TCGCGGCCGCTTTACTTGTACAGCTCGTCCATGCCGCCGGTGGA)

and

subcloning it between the PacI and BsrgI sites of an FCIV lentiviral vector (Araki et al.,
2004) using the InFusion HD cloning system (Clonetech) according to the manufacurer’s
recommendations. For luciferase assays, the 3’UTR regions of Egr2, Notch1 and Ccnd1
were PCR amplified from genomic DNA using the following primers: Ccnd1 3’UTR: F,
AAAGCTGCGCACTAGTGGG

CCACCGGGCAGGCGGGAGCCA;

ATCCTTTATTAAGCTTTGAGATTTTACCAATTT TATTT;

Notch1 3’UTR:

AAAGCTGCGCACTAGTACAGAGATGTGGGATGCAGGACC;
ATCCTTTATTAAGCTTGTTTAGCAAAATGTGGACAACCA;
AAAGCT

R,
F,
R,

Egr2

3’UTR:

GCGCACTAGTGATGAAGCTCTGGCTGACACACCA;

F,
R,

ATCCTTTATTAAGCTTACCA TAGTCAATAAGCCATCCAT. DNA fragments were
cloned downstream of the luciferase gene between the HindIII and SpeI sites in the
pMIR-REPORT miRNA Expression Reporter Vector (Ambion). The 3’UTR of Egr2
lacking the miR-140 landing pad was cloned in an analogous manner using the following
sets

of

overlapping

primers:

AAAGCTGCGCACTAGTGATGAAGCTCTGGCTGACACACCA

F1,
R1,

ACAGCCATACTTA
AACCCAAGTCTCGAGCTCGCGGCGCCTCTAGAAAGGCATCCTGTACACATGC
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A

F2,

TGCATGTGTACAGGATGCCTTTCTAGAGGCGCCGCGAGCTCGAGACTTGGGT
TTAAGTATGGCTGT

R2

AAAGATCCTTTATTAAGCTTACCATAGTCAATAAGCCATCCATTAT
CTGAACTCCAGTTTCAAAGCTTGGCGCGCCAGAATAGATTGTTTCTCTCT.
pRL-CMV Renilla Luciferase Reporter vector (promega) was used as a transfection
control.

Lentivirus production: Lentiviruses expressing miR-34a, miR-140 or a Ctrl miRNA
were produced in HEK293T cells as previously described (Sasaki et al., 2006).

Luciferase assays: HEK293T cells were seeded at a density of 50,000 cells/well in 24
well plates in DMEM media (Invitrogen) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine. Cell were transfected 24 h later, with either a pEP-MIR vector
expressing a pre-miRNA or with the pEP-mir Null control and with the pMIR-REPORT
luciferase reporter vector containing the appropriate 3’UTR linked to luciferase. pRLCMV Renilla Luciferase Reporter vector (Promega) was used as a transfection control. A
total of 200 ng of plasmid DNA/well were transfected at a ratio of 50:1:0.5 (miRNA :
luciferase reporter : transfection Ctrl). Cells were harvested 48 h post-transfection and
assayed using a Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer’s protocol.
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Primary SC cultures and lentiviral infection: Primary rat SCs were cultured from
postnatal day1 to day3 rat pups sciatic nerves as previously described (Nagarajan et al.,
2001). Established SC cultures were then transduced at an early passage (<passage 3)
with a lentiviral vector expressing miR-34a, miR-140 or a Ctrl miRNA. Efficiency of
infection was confirmed by visualization of expression of mCherry fluorescent reporter in
the pEP-MIR cassette in almost 100% cells.

SC in vitro proliferation, differentiation, or myelination assays: For SC in vitro
differentiation assays, Ctrl or miR-140 overexpressing SCs were initially seeded onto
collagen coated 24-well plates (~75,000 cells/well) in 10% FBS-DMEM media and 24
hours later cells were switched to 1% FBS-DMEM media for 2 days. SCs were then
induced to differentiate by adding 1% FBS-DMEM media containing 250 M 8-(4Chlorophenylthio) adenosine-3',5' cyclic monophosphate (cpt-cAMP, Biolog). RNA was
isolated 72 h later. Reported results are from duplicated wells from two independent
assays. For SC proliferation and in vitro myelination assays, dorsal root ganglion neurons
were dissected from E14 rat embryos, dissociated, and seeded onto Matrigel-coated (BD
Biosciences) 4-well plates in Neurobasal media (Invitrogen) containing 2% B27
(Invitrogen) and 50 ng/ml NGF. Glia were eliminated by addition of 20 μM 5-fluoro-2deoxyuridine (Sigma) and 20 μM uridine (Sigma) to the media for 4 days. Seven days
after seeding DRGs were switched to F-12/DMEM media supplemented with 15% FBS,
2mM L-glutamine and 50 ng/ml NGF, and Ctrl or miR overexpressing SCs were added to
each well. To examine SC proliferation, 25,000 Ctrl or miR-34a overexpressing SCs/well
were plated onto DRG neurons and growth curves were generated by monitoring changes
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in cell number over 5 days. mCherry positive cells expressing miR-34a were visualized at
a 20x magnification and quantified from 5 randomly selected fields. Results are averages
from triplicate wells from 2 independent assays. For in vitro myelination assays, 50,000
Ctrl of miR-140 overexpressing SCs/well were plated onto DRG neurons and allowed to
proliferate and ensheath axons for 7 days. At this point, myelination was induced by
adding 50 μg/ml of ascorbic acid. Myelination was allowed to proceed for 14 days and
myelinated segments were visualized through MBP immunostaining at a 20x
magnification as previously described (Ryu et al., 2008). The number of myelinated
segments was quantified by averaging five different fields from triplicate wells in 3
independent assays.

Western Blotting: Ctrl and miRNA overexpressing SCs were lysed in 200 l of buffer
containing 150 mM sodium chloride, 50 mM Hepes, 1% NP-40, 1 mM EDTA, 1 mM
sodium fluoride, 1 mM sodium orthovanodate, and complete protease inhibitor cocktail
(Roche Applied Science). Lysates were clarified by centrifugation at 14,000 rpm for 10
min and quantified using the MicroBCAProtein Assay kit (Pierce). For Western blotting,
the proteins were separated by SDS-PAGE and transferred to a PVDF membrane
(Millipore). Membranes were blocked in 5% milk in 0.1% TBS-Tween and incubated
overnight with the appropriate primary antibody. Following incubation with secondary
antibodies conjugated to HRP (GE Healthcare), membranes were developed with
SuperSignal West Dura substrate (Pierce). The primary antibodies used were mouse antiCcnd1 (1:1000, Cell Signaling), anti-Notch1 (1:1000, Cell Signaling) and rabbit anti-
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Egr2 (1:1000, Covance). The secondary antibodies used were anti-mouse and anti-rabbit
HRP (1:5000; Jackson ImmunoResearch Laboratories).

Statistical analysis: All values are expressed as mean ± SEM. If not stated otherwise, p
values were determined by unpaired, two-tailed Student's t test. All statistical analyses
were performed using Microsoft Excel 2007.
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Figures
Figure 1: Expression profiles of 87 miRNAs expressed in SC. a) Z-score normalized
miRNA expression levels 4 days (C4) and 14 days (C14) after nerve crush injury as well
as in uninjured nerves (Ctrl) are shown in a heatmap. Red indicates higher expression
than the average across all samples while green indicates lower expression. mmu refers to
the standard abbreviation used to designate miRNAs of mouse origin.
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Figure 2: Target bias analysis suggests that SC miRNAs modulate the injury
response by repressing positive regulators of SC dedifferentiation/proliferation. a)
mRNA expression profiles of gene clusters containing known regulators of SC
dedifferentiation/proliferation (the proliferation profile) or differentiation/myelination
(the myelination profile) after injury. b) Graph plotting the target bias for each miRNA in
subset 1 (measured by a Mann-Whitney z-score) against the correlation of its expression
with the myelination or proliferation profile (measured by CC, the difference in
correlation coefficients with the proliferation profile and the myelination profile).
Biological functions of miRNAs in regulating the SC injury response may be inferred
from their correlation with the proliferation or myelination gene clusters and by their
positive or negative target bias. The majority of SC miRNAs cluster in the top left
quadrant of the graph (negative target bias, correlation with the myelination profile),
suggesting that SC miRNAs are likely to modulate the injury response primarily through
their inhibition of positive regulators of SC dedifferentiation/proliferation. Dotted and
dashed lines represent statistical significance cutoffs. miRNAs differentially regulated
after injury (C4 vs. Ctrl p<0.05), with a statistically significant target bias and a high
correlation with the myelination or proliferation clusters (CC>1.6) are represented by
triangles. Empty dots represent miRNAs that met statistical significance cutoffs for
target bias and high correlation with the myelination or proliferation clusters, but were
not differentially regulated after injury. c) miRNAs likely to be direct regulators of the
SC injury response (represented as triangles in b) based on their differential regulation
after injury, significant target bias and a high correlation with the myelination or
proliferation clusters. d) Predicted targets for miRNAs in (c) are enriched for genes
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involved in cellular processes that are normally inhibited in adult or differentiating SCs
but are active in immature or proliferating SCs.
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Figure 3: SCs with disrupted miRNA processing have delayed cycling between
differentiation states after peripheral nerve injury. a) YFP fluorescence in SCs
(arrowheads) of longitudinal sciatic nerve sections of Rosa26-YFP/ PLP-CreERT mice 8
weeks after injection with tamoxifen. PLP-CreERT induces specific and efficient
recombination in most SCs and excision-dependent YFP fluorescence is localized to
regions of SC cytoplasm but not to axons (Tuj1; note non-overlapping Tuj1 and YFP
staining). Scale Bars: 50 m. b) qRT-PCR results show efficient depletion of Dicer1
mRNA and of mature miRNAs in Dicer-SCKO sciatic nerves 8 weeks after tamoxifeninduced recombination. Dicer mRNA levels and the levels of miR-34a and miR26a in the
sciatic nerve of Dicer-SCKO mice at this time were decreased by over 60% (p<0.001 in
all three cases, two-tailed Student’s t-test) compared to Ctrl littermates. Reported values
are normalized to GAPDH for mRNA and U6 for miRNAs; error bars, SEM; n=5 mice
per genotype. c) Quantification of the amount of myelin debris present in Ctrl and DicerSCKO nerves 14 days after crush injury shows no impairment in the ability of Tfamdeficient SCs to break down existing myelin. Error bars, SEM; n=3 mice per genotype. d
and e) Pictures (d) and quantification (e) of phospho-histone 3 (PH3) immunostaining
between sciatic nerves of Ctrl and Dicer-SCKO mice collected 4 (C4) or 14 (C14) days
after crush injury. No difference in the number of proliferating SCs between Ctrl and
Dicer-SCKO sciatic nerves was observed 4 days after crush injury. At C14, however,
there were significantly more PH3 positive SCs in the sciatic nerves of Dicer-SCKO vs.
Ctrl mice (p<0.05, two-tailed Student’s t-test), indicating exit from cell-cycle was
delayed in SCs with disrupted miRNA processing. Scale Bar: 25 m. Error bars, SEM;
n=3 mice per genotype. f) At C14, electron micrographs of sciatic nerves from Ctrl and
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Dicer-SCKO mice show equivalent numbers of regenerated axons (remyelinated, arrows;
non-remyelinated, arrow heads). Note the increased number of non-remyelinated axons
(arrowheads) in Dicer-SCKO nerves. Scale Bar: 2 m. g and h) Pictures (h) and
quantification (g) of myelinated profiles in nerves from Ctrl and Dicer-SCKO mice
before crush injury, or at C14 or C28. There is no difference in total number of
myelinated axons in nerves from Dicer-SCKO vs. Ctrl mice before crush injury.
However, examination of toluidene-blue stained plastic sections revealed a significant
decrease (p<0.05, two-tailed Student’s t-test) in the number of myelinated profiles at C14
in nerves from Dicer-SCKO mice. By C28 there is no longer a difference in total number
of myelinated profiles between Dicer-SCKO and Ctrl nerves, however nerves in DicerSCKO mice are more thinly myelinated. Scale Bar: 25 m. Error bars, SEM; n=3 or 4
mice per genotype at each time point.
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Figure 4: miR-34a targets Notch-1 and Ccnd1 to regulate SC proliferation in vitro.
a) The dynamic regulation of miR-34a expression in sciatic nerves after crush injury
suggests a potential role in the modulation of cell cycle regulators. miR-34a levels are
significantly decreased 4 days after crush injury (p<0.01, two-tailed Student’s t-test) but
recover as re-differentiation ensues (C14). After nerve transection (Trx), an injury
paradigm in which remyelination does not occur, mir-34a levels remain low compared to
uninjured nerves even 14 days after injury (p<0.05, two-tailed Student’s t-test). Reported
values are normalized to U6; error bars, SEM; n=3-6 mice at each time point. b) miR-34a
directly interacts with the 3’UTRs of Ccnd1 (top) and Notch1 (bottom). Overexpression
of miR-34a but not of a Ctrl miRNA in HEK293T cells expressing a luciferase reporter
construct carrying the 3’UTR of either Notch1 or Ccnd1 results in significantly decreased
luciferase activity (p<0.01 in both cases, two-tailed Student’s t-test). Error bars, SEM;
n=3 independent assays c) qRT-PCR measurements show that the expression pattern of
Ccnd1 (top) and Notch1 (bottom) after injury is inversely correlated with that of miR34a, suggesting a direct targeting of these transcripts by miR-34a. Reported values are
normalized to GAPDH for mRNA and U6 for miRNAs; error bars, SEM; n=3-6 mice at
each time point. d, e) Lentivirus-mediated mir-34a overexpression (≈ 3-fold) in cultured
SCs significantly reduces Notch1 and Ccnd1 mRNA (d; p<0.05, in both cases, two-tailed
Student’s t-test) and protein levels (e, ≈ 2.5-fold decrease; Notch FL, Full-length; Notch
NTM, cleaved transmembrane/intracellular region). qRT-PCR reported values are
normalized to GAPDH; error bars, SEM; n=duplicate wells from three independent
assays. f) Lentivirus-mediated mir-34a overexpression (≈ 3-fold) impairs the ability of
SCs to proliferate in the presence of DRG axons. miR-34a expressing SCs have a
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significantly decreased axon-induced proliferation in vitro compared to control SCs (no
significant difference at day 1; p<0.01 at days 3 and 5; two-tailed Student’s t-test). Error
bars, SEM; n=triplicate wells from two independent assays.
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Figure 5: miR-140 directly interacts with Egr2 to regulate SC myelination in vitro.
a) PicTar, TargetScanS, and miRanda algorithms all identify a putative binding site for
miR-140 in the 3’-UTR of Egr2. b) qRT-PCR results show that miR-140 is expressed in
mouse sciatic nerves and that its expression is dynamically regulated after injury. miR140 expression is significantly decreased after injury (C4 and C7 p<0.05; two-tailed
Student’s t-test) but recovers as re-differentiation ensues (C14 no significant difference).
Reported values are normalized to U6; error bars, SEM; n=3-6 mice at each time point. c)
qRT-PCR measurements show that the expression pattern of Egr2 is correlated with that
of miR-140. Reported values are normalized to GAPDH for mRNA and U6 for miRNAs;
error bars, SEM; n=3-6 mice at each time point. d) Luciferase assays confirm a direct
interaction between miR-140 and the 3’-UTR of Egr2. Overexpression of miR-140 but
not of a Ctrl miRNA in HEK293T cells expressing a luciferase reporter construct
carrying the 3’-UTR of Egr2 results in significantly decreased luciferase activity (p<0.05,
two-tailed Student’s t-test). Mutating the predicted landing pad for miR-140 in the 3’UTR of Egr2 disrupts the interaction between miR-140 and the Egr2 3’-UTR luciferase
construct and restores luciferase activity.

e) Western blot analysis shows that

overexpression of miR-140 in cultured SCs reduces the levels of Egr-2 protein ≈ 2.8 fold.
f) Overexpression of miR-140 in SCs significantly decreases the levels of Egr2 as well as
of a number of myelin markers when these cells are co-cultured with DRGs and induced
to myelinate ( in all cases p<0.05, two-tailed Student’s t-test). Reported values are
normalized to GAPDH; error bars, SEM; n=duplicate wells from two independent assays.
g) Similarly, miR-140 overexpression significantly inhibits the ability of SCs to form
myelin in vitro in co-cultures with DRG neurons as visualized by MBP immunostaining

222

(p<0.05, two-tailed Student’s t-test). Error bars, SEM; n=triplicate wells from three
independent assays.
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CHAPTER 6

An integrated approach to infer transcription factor and microRNA regulatory
networks

Adapted from: Chang LW, Viader A, Payton JE, Varghese N, Milbrandt J, Nagarajan R.
2011. An integrated approach to infer transcription factor and microRNAs regulatory
networks. Nucleic Acid Research. Submitted.
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Abstract
Regulation of cell fate and developmental timing as well as maintenance of
cellular and tissue homeostasis requires precise spatiotemporal control of gene
expression, which is modulated by key transcription factors (TF) and microRNAs
(miRNA) via a complex gene regulatory network. Elucidation of TF and miRNA
regulatory networks is crucial to understand how normal gene regulatory mechanisms are
disrupted in human disease. Computational methods have been developed to infer TF or
miRNA mediated gene regulation, but few methods integrate these results to construct
integrated TF and miRNA gene regulatory networks. In this study we present a
systematic approach, IntegraNet, which combines mRNA and miRNA expression data,
chromatin immunoprecipitation with sequencing (ChIP-Seq) data and computation TF
and miRNA target prediction to build integrated TF and miRNA gene regulatory
networks. We applied IntegraNet to expand a previously published miRNA-mRNA
regulatory network as well as to infer the TF and miRNA regulatory network involved in
Schwann cell (SC) response to nerve injury. Further analysis of regulatory network
motifs in this SC injury response network provided insight on cooperative regulation of
this process by TFs and miRNAs. This work demonstrates a systematic method for gene
regulatory network inference that may be used to gain new insights on local and global
features of gene regulation by TFs and miRNAs.
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Introduction
Regulation of cell fate and developmental timing as well as maintenance of
cellular and tissue homeostasis requires precise spatiotemporal control of gene
expression. It is now apparent that such intricate control mechanisms are regulated by
transcription factors (TFs) and microRNAs (miRNAs), which organize into exquisitely
coordinated gene regulatory networks (Tsang et al. 2007; Martinez and Walhout 2009;
Shalgi et al. 2009). Alteration or disruption of these regulatory networks often results in
disease, including cancer and developmental disorders (Tenen 2003; Villard 2004; Zeng
et al. 2010). Comprehensive delineations of how TFs and miRNAs cooperate in specific
genetic programs are thus critical to understanding physiological and pathological
processes.
Systematically inferring TF and miRNA regulatory networks is difficult to
achieve by experimental methods and has motivated development of computational
approaches. Thus, computational tools have been created to construct TF and miRNA
regulatory networks using information such as gene expression profiling, miRNA
expression profiling, and predicted TF and miRNA binding sites (Joung et al. 2007;
Bandyopadhyay and Bhattacharyya 2009; Lionetti et al. 2009; Peng et al. 2009; Wang et
al. 2009). Few studies, however, have combined all of these data to infer an integrated
network of TFs and miRNAs. Particularly, transcriptional regulation of miRNAs is often
excluded in these analyses due to the challenge in reliable prediction of miRNA
promoters (Shalgi et al. 2007; Guo et al. 2010). In addition, chromatin
immunoprecipitation with sequencing (ChIP-Seq) data for TFs, which experimentally
characterizes TF regulatory targets and provides critical information for understanding
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gene regulation, is seldom incorporated. These limitations highlight the need for new
tools for gene regulatory network construction.
In this study we developed a novel approach (IntegraNet) to inferring human or
mouse gene regulatory networks, which include TF-mRNA, TF-miRNA and miRNAmRNA interactions. This method integrates mRNA and miRNA expression data, ChIPSeq data, and computational TF and miRNA target predictions. Starting with a set of
genes or miRNAs obtained from expression profiling analysis, our approach initially
constructs a network by using TF targets identified from ChIP-Seq experiments. This
network is then expanded to include additional regulatory targets of TFs and miRNAs by
using genome-wide target prediction. To demonstrate the utility of our approach, we first
applied IntegraNet to expand a published miRNA regulatory network involved in
Hepatitis C Virus (HCV) infection (Peng et al. 2009). In addition, we used IntegraNet to
construct the regulatory network involved in Schwann cell (SC) response to injury, a
process driven by TFs and modulated by miRNAs. Using this network, we study
cooperative TF/miRNA regulation in this regenerative process. This work demonstrates a
systematic approach to infer TF and miRNA regulatory networks, which may be used to
better understand coordinated gene regulation by TFs and miRNAs in complex biological
systems.

Results
Overview of TF and miRNA regulatory network inference
We developed a systematic approach for TF and miRNA regulatory network
inference. This approach, termed IntegraNet, integrates mRNA and miRNA expression
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profiling data, chromatin immuneprecipitation with sequencing (ChIP-Seq) data, and
computational TF and miRNA target predictions (Fig. 1). Two major applications of gene
expression profiling analysis (including microarrays or RNA-Seq experiments) in order
to understand gene regulation involve identification of differentially expressed genes
between two conditions (e.g., disease vs. normal and mutant vs. wild type) or
characterization of gene clusters that share a specific expression profile (over a time
course or across multiple samples). Therefore, our approach for regulatory network
inference starts with sets of coherently expressed or differentially expressed genes
(termed core gene clusters, CGCs) and/or miRNAs (termed core miRNA clusters, CMCs)
(Step 0). TF genes in CGCs and miRNAs in CMCs constitute the initial set of potential
regulators in the gene regulatory network. In the first step, ChIP-Seq data is used to
identify regulatory interactions between TFs and CGC mRNAs and between TFs and
CMC miRNAs (Step 1). Additional mRNAs and miRNAs regulated by these TFs, as well
as other TFs without ChIP-Seq data, are identified by genome-wide analysis of TFBS
enrichment (Step 2). Next, genes in CGCs that may be regulated by miRNAs in CMCs
are identified using computational miRNA target prediction (Step 3). The resulting
regulatory network is further expanded to include TFs that, although not included in
CGCs in the initial expression data analysis, are master regulators of genes in CGCs or
miRNAs in CMCs (Step 4). Similarly, miRNAs that are not included in CMCs in the
expression analysis but whose predicted targets are enriched in CGCs are identified (Step
5). Finally, upstream or downstream regulatory interactions of additional TFs and
miRNAs added in Steps 4 and 5 are identified using ChIP-Seq data (as described in Step
1) and computational predictions (as described in Step 2) (Step 6). This final step
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completes the regulatory network inference. In these steps, we have compiled and
precalculated datasets of experimentally characterized and computationally predicted TFmRNA, TF-miRNA, and miRNA-mRNA interactions, which are available as
supplementary files and may be queried by an API to our in-house database upon request.
Each step of IntegraNet is described in detail as follows.

Step 1: Identification of TF targets using ChIP-Seq data
To find TF-mRNA interactions among CGCs genes, IntegraNet first used
experimentally validated TF targets characterized by ChIP-Seq results. We compiled a
compendium of publicly available TF ChIP-Seq data, which included 47 independent
datasets on 78 TFs (24 human TFs and 54 mouse TFs) (Supplementary Table 1). To use
this dataset to identify TF targets conserved between human and mouse, we mapped the
identified ChIP-Seq peak locations across the human and mouse genomes (see Methods).
To assemble a high-confidence and high-quality TF target dataset and to reduce falsepositive targets introduced by this mapping, we only used ChIP-Seq peaks that contained
at least one match to one the TF's position weight matrix binding models. Additionally,
we only included peaks that were located between -10kb and +5kb from the transcription
start sites (TSSs) of annotated genes. After this filtering, 19.9% of the original ChIP-Seq
peaks were retained in the list of high confidence TF target list, which consists of a total
of 71,346 mouse and 64,367 human TF-mRNA interactions (Supplementary Files 1 and
2).
In addition to TF-mRNA interactions, the genome-wide mapped reads of ChIPSeq data may be used to identify TF-miRNA interactions. Performance of such analysis
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depends on accurate characterization of pri-miRNA promoters. Several studies have
developed computational methods to predict pri-miRNA TSSs using several promoter
features (Marson et al. 2008; Ozsolak et al. 2008; Saini et al. 2008; Corcoran et al. 2009).
However, given that many of these methods rely on limited experimental datasets, they
tend to only predict TSSs for a subset of miRNAs. To address this limitation we
developed a new voting algorithm (TSSvote) for predicting human and mouse miRNA
TSSs, which uses a comprehensive set of transcription-related sequence features (Fig.
2A, see Methods). These included mapping of known transcripts/ESTs, CpG islands,
CAGE tags, H3K4me3 marks, and evolutionary conservation. Using TSSvote's predicted
pri-miRNA TSSs, we defined the promoter sequences of miRNAs as the genomic region
between -5kb and +1kb from the predicted TSS. We then identified ChiP-Seq peaks of
TFs located within these predicted miRNA promoters. Only peaks that contained at least
one sequence match to the TF's binding model were retained, so as to obtain high
confidence TF target predictions. This analysis generated a high quality list of 1,183
mouse and 1,511 human TF-miRNA interactions (Supplementary Files 3 and 4).
Note, that the performance of TSSvote was tested by a compiled benchmark set of
21 experimentally determined human and mouse miRNA TSSs (Supplementary Table 2).
TSSvote predicted 52% of these test TSSs within 500bp and 81% of them within 2500bp,
outperforming all other currently available methods tested (as measured by the number of
miRNA TSSs predicted within a given error range; Fig. 2B). The predictions of TSSvote
were further supported by the fact that a large proportion of miRNAs (63% of intergenic
and 45% of intragenic miRNAs in mouse) were located within 10kb from the pre-miRNA
sequence (Fig. 2C, Supplementary Table 3). Furthermore, the miRNA promoter
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sequences (as defined above) were more conserved than randomly selected intergenic
sequences of the same length (Chi-square P-value=1.45E-51) (Fig. 2D) and contained
significantly more TF binding sites than random sequences (Chi-square P-value=1.28E34) (Fig. 2E).

Step 2: TF target prediction using genome-wide TFBS enrichment analysis
Although ChIP-Seq data of TFs allowed the extraction of experimentally
characterized TF-target interactions, this information was only available for a subset of
TFs. Moreover, because ChIP-Seq experiments might have been performed under
different conditions, some transcriptional regulatory interactions critical to the CGCs
under study might not be identified. To address this shortcoming our IntegraNet
algorithm included computationally predicted genome-wide TF regulatory interactions
based on an improved version of a previously developed statistical model for TF binding
site (TFBS) enrichment (Chang et al. 2008). This approach calculated a binding
probability score for a TF-gene pair using conserved TF binding sites in proximal
promoters and evaluated a P-value using TFBS permutation (See Methods,
Supplementary Fig. 1). In this study, the model was improved by using a phylogenetic
tree-based scoring function to incorporate evolutionary conservation information from
more species. Using this model, we predicted 108,204 mouse and 132,516 human TFmRNA interactions (Supplementary Files 5 and 6). By applying this model to the miRNA
promoters predicted by TSSvote (Supplementary Fig. 1) we also predicted a total of
2,658 mouse and 5,395 human TF-miRNA interactions (Supplementary Files 7 and 8).
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We validated this computational model using the compendium of ChIP-Seq
datasets for 78 TFs described earlier. In this validation, we tested if the target genes
identified by ChIP-Seq tended to have significantly higher scores for binding among all
the genes in the genome, based on a Mann-Whitney U-test (Fig. 3A). We found that
ChIP-Seq identified mouse and human mRNA targets had significantly higher scores in
94% and 93% of the ChIP-Seq datasets, and ChIP-Seq identified mouse and human
miRNA targets had significantly higher scores in 55% and 64% of the datasets (Fig. 3B).
This analysis showed that our computational TF-target prediction was consistent with
experimental results, for both TF-mRNA and TF-miRNA regulation.

Step 3: Identification of miRNA targets using computational prediction
The previous ChIP-Seq data analysis and genome-wide TF target prediction
identified TF-mRNA and TF-miRNA interactions. To identify miRNA-mRNA
interactions we performed computational miRNA target prediction. A recent study
showed that better performance of miRNA target prediction may be achieved by
combining multiple currently available algorithms in order to reach reasonable specificity
while minimizing loss of sensitivity (Sethupathy et al. 2006). Therefore we chose to
combine TargetscanS (Lewis et al. 2005) and pictar (Krek et al. 2005), which provides
higher specificity, with miRanda (John et al. 2004), which provide higher sensitivity, to
identify targets of miRNAs. Only targets of miRNAs predicted by at least two of these
three methods were included in the network construction. Using this approach, we
identified 57,980 mouse and 75,570 human miRNA-mRNA interactions (Supplementary
Files 9 and 10). The average number of targets is 250 genes per miRNA, respectively,
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which is close to the speculated number of targets per miRNA (Martinez and Walhout
2009).

Step 4: Expanding networks by adding master TF regulators of CGC and CMC
genes
Up to this step, TFs included in the regulatory network were identified either by
their correlation with expression profiles of interest or by their differential expression.
However, master regulators of genes in the CGCs may share a coherent expression
profile but with a lag time (hence not being identified by cluster analysis of expression
data). Alternatively, they may be modulated by mechanisms other than transcriptional
control and have similarly expression under two experimental conditions (hence not
being identified by differential expression). These TFs could be identified by
computational tools such as PAP (Chang et al. 2006), oPOSSUM (Ho Sui et al. 2007),
and ToppGene (Chen et al. 2009), which predict common regulators of gene sets based
on enriched TBFS in proximal promoters. To ensure that the final regulatory networks
contain all important TFs, the IntegraNet algorithm incorporated the PAP algorithm.

Step 5: Expanding networks by adding master miRNA regulators of CGC genes
Similar to TFs, common miRNA regulators of genes in the CGCs may not have
expression profiles that are tightly correlated/anti-correlated with their mRNA targets or
may not have significant differential expression. Therefore, to ensure that the regulatory
networks inferred by IntegraNet contain all critical miRNAs, we identified miRNAs
whose predicted targets were enriched among CGC genes using a hypergeometric
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distribution (see Methods). This target enrichment analysis may also identify miRNA
regulators whose expression is not accurately measured on microarray.

Step 6: Identifying regulatory interactions for master TF and miRNA regulators
After additional TF and miRNA regulators found in Steps 4 and 5 were added to
the network, additional TF-mRNA, TF-miRNA, and miRNA-mRNA interactions were
characterized using ChIP-Seq data of TFs (Step 1) and computational predictions (Steps 2
and 3). This final step completed the regulatory network construction.

Application of IntegraNet to expand a previously identified miRNA regulatory
network
To demonstrate the utility of IntegraNet, we first applied our approach to analyze
a published dataset of mRNA and miRNA expression profiling data from Hepatitis C
Virus (HCV) negative or positive human liver biopsy samples (Peng et al. 2009). The
goal of this study was to identify miRNA regulatory networks that were associated with
HCV infection. The authors found that 54 miRNAs were differentially expressed between
HCV positive and negative samples. The study then constructed a miRNA-target
regulatory network using computationally predicted miRNA-mRNA interactions. We
expanded this network by applying IntegraNet to add TF-mRNA and TF-miRNA
interactions.
Using the 54 differentially expressed miRNAs as the CMC, we found 773 genes
whose expression was correlated or anti-correlated with CMC miRNAs (based on a
cutoff of CC=0.65). These genes were defined as the CGC. These 773 genes contain 5
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TFs with available ChIP-Seq data and 18 TFs with available binding profiles. Using
enrichment of TFBS, we identified 14 additional TFs as master regulators of the CGC or
CMC. Using enrichment of miRNA targets in the CGC, we added 5 miRNAs to the
network (using a hypergeometric P-value cutoff of 0.01). Overall, we identified 32 TFs
and 5 additional miRNAs as important regulators of the previously characterized miRNA
regulatory network. We identified and predicted a total of 55 TF-TF and 45 TF-miRNA
regulatory interactions (Supplementary Fig. 2, Supplementary Table 4). This analysis
demonstrated that IntegraNet can be adopted to extract additional biological information
using previously collected genomic profiling datasets.

Application of IntegraNet to identify TF and miRNA regulation networks involved
in Schwann cell response to peripheral nerve injury
In the peripheral nervous system (PNS), Schwann cells (SCs) surrounding
damaged axons undergo an injury response that is critical for nerve regeneration. This
regenerative process relies on the unique ability of SCs to dedifferentiate/proliferate to
support axonal re-growth and to subsequently re-differentiate to restore peripheral nerve
function (Geuna et al. 2009). The cycling between the different SC differentiation states
after injury are controlled by an intricate regulatory program that involves TFs and
miRNAs (Jessen and Mirsky 2008; Bremer et al. 2010; Pereira et al. 2010; Yun et al.
2010), but the interactions between them are unknown. Therefore, we applied IntegraNet
to study the TF and miRNA regulatory networks governing the SC injury response.
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Identification of important TFs and miRNAs in the SC injury response network
To identify important regulators involved in SC response to injury, we first
reanalyzed a published gene expression profiling dataset on a mouse nerve injury model
(Nagarajan et al. 2002). Using unsupervised k-means clustering, we identified coexpressed gene clusters that were differentially expressed after nerve injury and that
contained known myelination genes (see Methods). Four coexpressed core gene clusters
for injury response (CGCIR) were identified (Supplementary Table 5). Two of the
clusters included genes that were downregulated immediately after crush and returned to
pre-injury levels as the nerve regenertated (CGCIRs 1 and 2), while the other two
displayed the reciprocal expression pattern (CGCIRs 3 and 4) (Supplementary Fig. 3A).
Gene Ontology analysis showed that CGCIRs 1 and 2 contain genes related to
myelination and CGCIRs 3 and 4 were enriched for proliferation related genes
(Supplementary Fig. 3B). In total, these CGCIRs contained 35 TFs.
Next, we identified core miRNA clusters for SC injury response (CMCIRs) by
profiling nerve miRNA expression before and after crush injury (A Viader, L Chang, T
Fahrner, R Nagarajan, J Milbrandt, in press). We focused on miRNAs whose expression
was correlated or anti-correlated with one of the four CGCIRs. Overall, this analysis
identified 30 miRNAs that were expressed similar to genes in CGCIRs 1 and 2 and
identified 6 miRNAs that were expressed similar to genes in CGCIRs 3 and 4
(Supplementary Table 6, Supplementary Fig. 3C).
Applying IntegraNet, we first identified 37 TF-TF and 15 TF-miRNA regulatory
interactions for 8 TFs from the compiled ChIP-Seq datasets (Step 1). We then used
computational TF target predictions and expanded the network to include 79 TF-TF and
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70 TF-miRNA interactions (Step 2). Using miRNA target prediction we next added 43
miRNA-TF interactions (Step 3). Furthermore, using the Promoter Analysis Pipeline
(PAP) (Chang et al. 2006), we identified 12 and 1 TFBS significantly enriched in
CGCIRs and CMCIRs, respectively (Step 4). We also identified 7 miRNAs with
significantly enriched targets in CGCIRs (Step 5). Overall, the final TF and miRNA
network for SC injury response included 146 TF-TF, 117 TF-miRNA, and 71 miRNA-TF
interactions, connecting 48 TFs and 32 miRNAs (Fig. 4, Supplementary Table 7).

Regulatory network for SC injury response inferred by IntegraNet is consistent
with current knowledge
The regulatory network constructed above provided a global view of TF and
miRNA mediated gene regulation in SC injury response. When we organized the SC
injury response regulatory network to show its cluster structures (using the "organic
layout" in Cytoscape (Shannon et al. 2003)), one of the nodes in the center of the network
was Egr2, the early growth response 2 (Egr2/Krox-20) transcription factor. Egr2 is
required for peripheral nerve myelin formation and maintenance and it is often mutated in
patients with peripheral myelinopathies (Svaren and Meijer 2008). Five TFs were
predicted to regulate the expression of Egr2 (Fig. 5A), two of which (Nfkb1 and Fos)
have been previously associated with SC myelination (Nickols et al. 2003) and
dedifferentiation (Stevens and Fields 2000; Parkinson et al. 2008). In addition to TFs, two
miRNAs, miR-140 and miR-124, were found to target Egr2. Additional experimental
studies confirmed these interactions and showed that these two miRNAs contribute to the
modulation of the expression of Egr2 (Supplementary Fig. 4, A Viader, L Chang, T
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Fahrner, R Nagarajan, J Milbrandt, in press). Egr2 was in turn predicted to directly
regulate the expression of the TF Hic1 and 3 miRNAs (let-7f, let-7a, and miR-22) (Fig.
5A). The tumor suppressor miR-22 has been shown to target the 3’UTR of Pten and
modulate Akt signaling, which critically determines the extent of SC myelination (Ogata
et al. 2004; Cotter et al. 2010). These results showed that our method to delineate the
genetic networks driving the SC injury response elucidated Egr2 regulatory pathways that
were consistent with current knowledge on the regulation of SC differentiation.

TF and miRNA feedforward loops in the SC injury response network
The importance of transcriptional and post-transcriptional control in the SC injury
response as well as the reciprocal nature of the genetic programs driving this process
make SC recovery after injury an ideal system for studying the cooperation of TF and
miRNA mediated gene regulation. TFs and miRNAs form cooperative regulatory
network motifs to reinforce (via coherent loops) or modulate (via incoherent loops) the
expression of target genes (Tsang et al. 2007; Martinez and Walhout 2009; Shalgi et al.
2009). In the regulation of SC injury response, an incoherent or coherent feedforward
loop

may

target

genes

that

are

correlated

with

the

expression

of

differentiation/myelination genes (i.e., genes in CGCIRs 1 and 2) or with the expression
of proliferation genes (i.e., genes in CGCIRs 3 and 4), with the participating miRNA
acting as a reinforcer or modulator (Fig. 5B). Thus, to understand the coordinated
regulation of TFs and miRNAs we examined the regulatory network inferred by
IntegraNet for the presence of coherent and incoherent loops (Supplementary Table 8).
When we categorized all the regulatory loops based on the target gene's expression and
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the type of the feedforward loop, we found a significantly higher frequency of
myelination genes in the incoherent loops than in the coherent loops (Fig. 5B, I1 as
opposed to C1). In contrast, there was a significantly higher frequency of proliferation
genes in the coherent loops than in the incoherent loops (Fig. 5B, C2 as opposed to I2).
These results suggest that in SC injury response, regulation of myelination gene
expression tends to be modulated or carefully controlled by miRNAs in incoherent
feedforward loops, whereas regulation of proliferation gene expression tends to be
reinforced by miRNAs in coherent feedforward loops. This analysis demonstrated that
the gene regulatory networks inferred by IntegraNet may provide new insights on the
cooperative gene regulation by TF and miRNA in complex biological systems.

Discussion
In this study, we developed the IntegraNet algorithm for TF and miRNA
regulatory network inference that integrates expression profiling data of mRNAs and
miRNAs, TF regulatory targets derived from ChIP-Seq data, and computational TF and
miRNA target prediction. IntegraNet takes a step-wise, bottom-up approach that starts
with clusters of dynamically regulated or differentially expressed genes or miRNAs as
the basic network node set and sequentially adds TFs and miRNAs and their regulatory
interactions to the network. We applied IntegraNet to reanalyze a published dataset of
mRNA and miRNA expression profiling and expanded a previously identified miRNA
regulatory network to include TF regulation. By applying IntegraNet to comprehensively
delineate the gene regulatory network underlying the Schwann cell response to nerve
injury, we showed that IntegraNet allows integrated inference of gene regulation by TFs
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and miRNAs in complex biological settings. Our method was able to provide valuable
new insights into fundamental aspects of the SC regenerative response, indicating its
potential to help elucidate the complexities of biological processes governed by intricate
networks of TFs and miRNAs.
Importantly, the design of IntegraNet took into account the confidence level of
multiple types of gene regulation information. For example, experimentally identified
transcriptional regulatory interactions derived from ChIP-Seq datasets were added before
the regulatory interactions for correlated or anti-correlated regulators, which are followed
by interactions for regulators with enriched binding sequences but without observed
coordinated expression (Fig. 1). To further ensure the quality of the network construction,
the computational predictions used in our method were tested and verified in several
ways. The computational model for TF target prediction was previously validated using
ChIP-chip data (Chang et al. 2006). This model was further validated in this study using a
much larger set of ChIP-Seq experiment data for 70 TFs. When we applied IntegraNet to
study the gene regulatory network involved in SC response to nerve injury, we compared
the inferred subnetwork around Egr2, a well-known transcription regulator of
myelination, to current knowledge of gene regulation in SC and found high consistency.
Finally, the post-transcriptional regulation of Egr2 by two miRNAs, miR-124 and miR140, identified in our network were validated experimentally using luciferase assays
(Supplementary Fig. 4, A Viader, L Chang, T Fahrner, R Nagarajan, J Milbrandt, in
press). These results suggest that our method produced an informative and reliable
regulatory network for SC injury response.
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An important step in our approach was to use available Chip-Seq data to derive
mRNA and miRNA targets of TFs. While a significant number of transcription factor
ChIP-Seq data has been accumulated, only few studies have combined these datasets and
used this resource to study transcriptional regulation of mRNAs (Hannah et al. 2011), and
no studies have co-analyzed these datasets to infer transcriptional regulation of miRNAs.
This is partly due to the lack of reliable prediction of miRNA promoters. By developing a
new miRNA TSS prediction algorithm, TSSvote, we were able to circumvent this
problem. Our prediction algorithm incorporates several sequence features that imply TSS
and our method does not rely on experimental data that probe promoter usage, which may
be dependent on the experimental conditions. Testing our algorithm using experimentally
validated miRNA TSS sites showed that the accuracy of our prediction was within
2500bp in 81% of the cases and the performance was better than current methods (Fig.
2B). These predicted miRNA TSS allowed for the identification of ChIP-Seq peaks that
were located within miRNA promoters. The identified miRNA promoters also allowed
for the computational prediction of TFs that regulate miRNAs (Supplementary Fig. 1).
Our computational predictions are expected to be more accurate than previously reported
methods (Shalgi et al. 2007; Guo et al. 2010) due to the more accurate miRNA promoter
annotation and a more robust TF binding site analysis model.
A notable strength of our methods is that while it integrates multiple types of
experimental and computational data, it is also modular in its design. Thus, individual
components of the network inference pipeline may be improved or replaced separately,
and additional information about TF or miRNA regulation may be added to the prediction
model. For example, the computational prediction of TF targets may be further improved
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by incorporating epigenetic information (Ramsey et al. 2010). Also, additional regulatory
mechanisms, such as regulation by non-coding RNAs and by RNA binding proteins
(Viswanathan et al. 2008), may be added into the network once experimental data or
computational prediction become available for these interactions.
miRNAs and TFs tend to cooperate in coherent or incoherent feed-forward loops,
in which miRNAs may function as either a reinforcer or a modulator, to control the
expression of a target gene (Tsang et al. 2007; Martinez and Walhout 2009; Shalgi et al.
2009). In our analysis of network motifs in the SC injury response network, we found
that genes involved in proliferation tend to be regulated by coherent loops, where their
repression during SC injury response is reinforced by miRNAs. Genes involved in
myelination, on the other hand, tend to be regulated by incoherent loops, where their
activation during SC injury response is “fine-tuned” by miRNAs (Fig. 5B). This suggests
that fast and precise timing of the activation/inactivation of genes associated with the
immature state of SCs is most critical for the dedifferentiation of these glia after nerve
injury. In contrast, proper remyelination seems not to require as carefully controlled
timing of gene expression, but instead depend mostly on achieving precise functional
levels of myelin-related proteins. This is particularly interesting because myelin
formation and maintenance is very sensitive to gene dosage effects. In fact, both
abnormally low or high levels of specific myelin proteins can cause peripheral
neuropathy in humans (Meyer zu Horste et al. 2006).
To conclude, we present in this work a new algorithm, IntegraNet, for TF and
miRNA regulatory network inference. Our approach systematically integrates multiple
types of experimental data and computational prediction on gene regulation and thus
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produces more reliable gene regulatory networks. Applying our approach to the SC injury
response dataset demonstrates that our method may be used to gain new insight on the
local and global features of gene regulation by TFs and miRNAs.

Methods
Analysis of ChIP-Seq datasets: Publicly available ChIP-Seq datasets for human and
mouse transcription factors were compiled and collected from literature search. Peak
locations identified in the original studies were used if they are available. When peak
locations were not available, Partek Genomic Suite with default parameters was used to
identify peaks using raw alignment data. All peak locations were converted to genomic
coordinates of human genome build hg18 or mouse genome build mm9. Peak locations of
human datasets were then mapped to the mouse genome using UCSC’s liftover tool and
vice versa. ChIP-Seq peaks that contained binding sites of a TF were identified using the
position weight matrix models of TFs available in the TRANSFAC, JASPAR and
UniPROBE databases (Newburger and Bulyk 2009). Peaks that were located near
mRNAs or miRNAs were identified using NCBI’s gene annotation for mRNAs and
computationally predicted miRNA TSS (see below).

Computational prediction of miRNA TSS: To predict miRNA TSS, all human and
mouse miRNAs were categorized as intergenic or intragenic miRNAs. Intragenic
miRNAs were defined as miRNAs located between the start and end of a protein coding
gene that is on the same strand (termed the host gene). miRNAs that are not intragenic
were defined as intergenic. For intergenic miRNAs, the TSS search range was defined as
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the genomic sequence between the end of the upstream gene and the start of the premiRNA. For intragenic miRNAs, the TSS search range was defined as the genomic
sequence between the start of the host gene and the start of the pre-miRNA. To predict
miRNA TSS, a new algorithm, TSSvote, was developed to score each 100bp window
within the TSS search range based on transcription related sequence features. Mapping
locations of known transcripts or ESTs and CpG islands were downloaded from the
UCSC genome browser. CAGE tags were downloaded from the FANTOM project
(Severin et al. 2009). H3K4me3 histon modification marks were collected from a
compiled set of H3K4me3 ChIP-Seq studies (Barski et al. 2007; Mikkelsen et al. 2007;
Pan et al. 2007; Zhao et al. 2007; Robertson et al. 2008; Araki et al. 2009; Wei et al.
2009; Cheung et al. 2010; Guenther et al. 2010). Conservation score was calculated as the
number of aligned species in the 100bp sequence window divided by the number of
species in which the pre-miRNA was conserved. Using these sequence features, TSSvote
calculated the score of each sequence window by
where
located within the sequence window. Otherwise,

equals one if a given feature is
equals zero. For each miRNA,

the sequence window within the TSS search range that had the highest score was
predicted as the miRNA TSS. When multiple sequence windows had the same score, the
sequence window closest to the miRNA was assigned as the predicted TSS.

Computational prediction of TF regulatory targets: To predict TF regulatory targets,
we applied a previously developed computational model of transcription factor binding
site (TFBS) enrichment to the mouse genome (Chang et al. 2008). This approach
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calculated a binding probability score for a TF-gene pair using all the TF binding sites in
the proximal promoters of protein coding genes. In this study, we improved this model by
including 10 mammalian species, whose genomes were completely sequenced with a
good coverage (>6x). Using NCBI’s mouse genome annotation (build 37.1), for each
mouse gene the multiple alignments of genomic sequence (downloaded from the UCSC
genome browser site) from -100kb of the TSS to the end of the gene itself were extracted.
Within this range, the sequence between -10kb and +5kb of the TSS and the sequence
regions that have a regulatory potential (RP) score (Kolbe et al. 2004) larger than 0.1
were identified and collected as the TFBS search space. To search for TFBS, a total of
867 vertebrate position weight matrix models (PWMs) of TFs were compiled from the
TRANSFAC, JASPAR, and UniProbe (Newburger and Bulyk 2009) databases. Using
these PWMs, putative TFBS were identified in the TFBS search space, and the
evolutionary conservation of each site was determined using multiple sequence
alignments.
The original PAP model only considered TFBS conserved in human, mouse and
rat. Therefore, transcriptional regulation based on non-conserved sites was not accurately
modeled, and the regulation of non-conserved genes was neglected. To overcome these
limitations of the original model, we developed a phylogenetic tree-based scoring
function to weight the contribution of each TFBS by the total tree branch length of all the
species in which the TFBS is conserved. Thus, TFBS that are conserved in a distantly
related species will gain a higher weight than those conserved in a closely related species.
Using this scoring model, for each TF-gene pair, the probability score for binding
and the P-value were calculated based on all the identified TFBSs. Regulatory targets of
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TFs were identified using a P-value cutoff of 0.005, which was determined by comparing
the number of computationally predicted targets to the number of ChIP-Seq identified
targets for available TFs. The same analysis was applied to identify TFs that regulate
miRNAs using miRNA promoters, which were defined as the sequence between -5kb and
+1kb of the miRNA TSS predicted by TSSvote.

Identification of master TF regulators CGC mRNAs or CMC miRNAs: Common TF
regulators of coexpressed mRNAs were identified by the previously developed Promoter
Analysis Pipeline tool (Chang et al. 2006), which searches for the enriched TF binding
sites in the promoter sequences of coexpressed mRNAs or miRNAs. Briefly, an R-score
was calculated for each gene in the mouse genome based on the ranking of the
probability score for binding. Genes that are more likely to be regulated by a TF will
have a higher R-score for that TF. For a set of coexpressed genes, the average of the Rscores of the member genes were calculated for each TF. The P-value for a given R-score
was then calculated by using randomly selected gene clusters of the same size. A
Bonferroni corrected P-value cutoff of 0.05 was used to identify TFs that had
significantly higher average R-scores as common regulators. The same analysis was
applied to identify common TF regulators of coexpressed miRNAs based on miRNA Rscores, which were calculated using the probability score for binding for miRNAs.

Identification of master miRNA regulators of CGC mRNAs: Common miRNA
regulators of coexpressed mRNA genes were identified by the enrichment of miRNA
targets in the coexpresed genes. The hypergeometric P-value for enrichment was
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calculated for a miRNA using the total number of nerve expressed genes that were
predicted as targets of any miRNA (population size), the number of coexpressed mRNA
genes (sample size), the number of nerve expressed genes that were predicted as targets
of the miRNA (number of successes in population), and the number of coexpressed genes
that were predicted as targets of the miRNA (number of successes in sample). Common
miRNA regulators were identified using a hypergeometric P-value cutoff of 0.05.

Analysis of the mRNA and miRNA expression profiling data in HCV infection: Raw
data of mRNA and miRNA expression profiling data were downloaded from GEO
(GSE15387). For miRNA microarray data, the total gene signal was used. The expression
data was normalized across arrays using median centered approach and log2-transformed,
as described in the original study (Peng et al. 2009). For mRNA microarray data, logtransformed signal ratios from replicates of the same sample were averaged and used as
the expression level of the sample. Processed expression data were used to calculate the
correlation coefficients between the expression profiles of mRNAs and miRNAs.

Identification of core gene clusters for SC injury response (CGCIRs): SC mRNA
expression profiling before and after crush and transection injury were performed using
Affymetrix MU74Av2 chips in a previous study (Nagarajan et al., 2002). Gene
expression levels were measured for uninjured nerves, on days 4, 7 and 10 after crush
injury, and on days 1, 4, 7, and 10 after transection injury. Mouse gene expression
profiling data during SC development were collected from an independent study
(Verheijen et al. 2003). This dataset profiled mRNA expression on days 0, 2, 4, and 10
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after birth. Expression data were processed and normalized using Affymetrix MAS5
algorithm. k-means clustering was used to cluster genes based on the combined
expression profiles of injury response and development. Gene clusters that contained
known myelin genes and that were differentially expressed before and after crush injury
based on a t-test were identified. Clusters with similar expression profiles based on the
Pearson correlation coefficient were identified and merged. The average expression
profile, i.e. the centroid, was calculated for each cluster. Nerve-expressed genes that were
correlated with the centroids based on a Pearson correlation coefficient cutoff of 0.8 were
identified as the final CGCIRs.

Identification of core miRNA clusters for SC injury response (CMCIRs): SC miRNA
expression profiling before and after crush injury were performed using HTG Molecular
qNPA miRNA microarrays in a previous study (A Viader, L Chang, T Fahrner, R
Nagarajan, J Milbrandt, unpublished). Expression of 1046 miRNAs was profiled using
this microarray platform on days 0, 4 and 14 after crush injury. miRNA expression data
were filtered using the following criteria: miRNAs that had an expression level lower
than the average expression of the control miRNA probesets were removed from further
analysis. miRNAs for which the expression of one duplicate probeset at all time points
were significantly higher than that of the other duplicate probeset based on a MannWhitney U test were also removed from further analysis. After this filtering procedure,
the average expression of the two duplicate probesets at each time point was used as the
expression at that time point. miRNAs that were correlated or anti-correlated with the
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expression of one of the four CGCIRs were identified as CMCIRs using crush injury
mRNA expression data on days 0, 4, and 10.

Experimental validation: Plasmids: pre-mir-124 was obtained through PCR
amplification from genomic DNA. The resulting fragment was cloned between the
BamHI and Nhe I sites in the miRNASelect pEP-MIR Cloning and Expression Vector
(Cell Biolabs) using the InFusion HD cloning system (Clonetech) according to the
manufacurer’s recommendations. Pre-mir-124 included the miRNA stem loop and ~100
nt of flanking sequence on either side. For luciferase assays, the 3’UTR region of Egr2
was PCR amplified from genomic DNA using the following primers: Egr2 3’UTR: F,
AAAGCT

GCGCACTAGTGATGAAGCTCTGGCTGACACACCA;

R,

ATCCTTTATTAAGCTTACCA TAGTCAATAAGCCATCCAT. DNA fragments were
cloned downstream of the luciferase gene between the HindIII and SpeI sites in the
pMIR-REPORT miRNA Expression Reporter Vector (Ambion). The 3’UTR of Egr2
lacking the miR-124 pad was cloned in an analogous manner. pRL-CMV Renilla
Luciferase Reporter vector (promega) was used as a transfection control.
Luciferase assays: HEK293T cells were seeded at a density of 50,000 cells/well in
24 well plates in DMEM media (Invitrogen) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine. Cell were transfected 24 h later, with either a pEP-MIR vector
expressing a pre-miRNA or with the pEP-mir Null control and with the pMIR-REPORT
luciferase reporter vector containing the appropriate 3’UTR linked to luciferase. pRLCMV Renilla Luciferase Reporter vector (Promega) was used as a transfection control. A
total of 200 ng of plasmid DNA/well were transfected at a ratio of 50:1:0.5 (miRNA :
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luciferase reporter : transfection Ctrl). Cells were harvested 48 h post-transfection and
assayed using a Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer’s protocol.
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Figures
Figure 1. The IntegraNet algorithm for gene regulatory network construction.
Starting with TFs and miRNAs that are correlated with particular expression profiles or
differentially expressed between two conditions, IntegraNet takes sequential steps in this
workflow to integrate multiple types of experimental and computational information. In
each step, nodes and interactions identified from earlier steps are placed in the
background. Circles: TFs. Hexagons: miRNAs. Blue or red nodes: TFs or miRNAs that
are identified by expression analysis. Grey nodes: master TF or miRNA regulators
identified by enrichment of binding sites or targets.
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Figure 2. A new computational method, TSSvote, predicts the TSS of miRNAs
reliably. (A) Illustration of the TSSvote algorithm. For intergenic miRNAs (top sequence
bar), the TSS search range is defined as the genomic sequence between the end of the
upstream gene and the start of the pre-miRNA. For intragenic miRNAs (bottom sequence
bar), the TSS search range is between the TSS of the host gene and the start of the premiRNA. TSSvote calculates a score for each 100bp sequence window within the TSS
search range based on five supporting sequence features of TSS. The sequence window
that is “voted” by the most features is predicted as the miRNA TSS. (B) Benchmarking
computational methods for miRNA TSS prediction using a set of 21 experimentally
validated miRNA TSS. For each method, the percentage of test cases where the distance
between the predicted TSS and the true TSS is with a given distance is plotted. (C) The
distribution of the distance between the predicted miRNA TSS and the pre-miRNA. (D)
The distribution of the percentage of sequence conservation in predicted miRNA
promoters versus random sequences. (E) The distribution of the number of TF binding
sites found in predicted miRNA promoters versus random sequences. In (C), (D), and
(E), mouse data were used, while using human data produced similar results.
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Figure 3. Validating computational TF target prediction using the compendium of
TF ChIP-Seq datasets. (A) ChIP-Seq identified TF binding locations (peaks) near
annotated mRNA transcription start sites (TSS) or predicted miRNA TSS were identified.
Peaks that also contained TF binding sites (TFBS) based on known TF binding profiles
were used to identify regulatory targets of TFs. Mann-Whitney U test was used to test if
identified targets have higher binding scores calculated by the computational model. (B)
Percent of ChIP-Seq datasets that were consistent with computational TF target
prediction when tested using mouse or human mRNAs or miRNAs.
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Figure 4. The SC injury response regulatory network inferred by integrating
experimental data and computational prediction. Circles: TFs. Hexagons: miRNAs.
Blue nodes: TFs or miRNAs correlated with myelination gene clusters. Red nodes: TFs
or miRNAs correlated with proliferation gene clusters. Grey nodes: master TF or miRNA
regulators of coexpressed genes. Black edges: regulatory interactions derived from TF
ChIP-Seq data. Grey edges: regulatory interactions inferred by computational prediction.
Arrowed edges: activation by TFs. T-shaped edges: repression by TFs or miRNAs.
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Figure 5. Local and global analysis of the SC injury response regulatory network.
(A) Upstream regulators and downstream targets of Egr2 and regulatory interactions
among them. (B) Biased usage of incoherent and coherent feedforward loops in the SC
injury response network. Feedforward loops are divided into four categories according to
the expression pattern of its target gene: I1: an incoherent loop regulating myelination
genes, I2: an incoherent loop regulating proliferation genes, C1: a coherent loop
regulating myelination genes, and C2: a coherent loop regulating proliferation genes. For
each category, the number of network motifs in the SC injury response network and the
number of TFs, miRNAs, and targets that participate in those motifs are shown, with
more prevalent network motifs highlighted in grey. Circles: TFs. Hexagons: miRNAs.
Rectangles: target mRNAs. Blue nodes: TFs or miRNAs correlated with myelination
gene clusters. Red nodes: TFs or miRNAs correlated with proliferation gene clusters.
Grey nodes: master TF or miRNA regulators. White boxes: downstream target genes not
included in the network. Arrowed edges: activation by TFs. T-shaped edges: repression
by TFs or miRNAs.
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Supplementary Figure 1. Workflow of the computational method for predicting TFs
that regulate mRNAs, using NCBI’s TSS annotation, or miRNAs, using
computational TSS prediction.

270

Supplementary Figure 2. The hepatitis C virus (HCV) associated gene regulatory
network. Circles: TFs. Hexagons: miRNAs. Blue nodes: TFs or miRNAs over-expressed
in HCV-positive samples. Red nodes: TFs or miRNAs over-expressed in HCV-negative
samples. Grey nodes: master TF or miRNA regulators of differentially expressed genes.
Black edges: regulatory interactions derived from TF ChIP-Seq data. Grey edges:
regulatory interactions inferred by computational prediction. Arrowed edges: activation
by TFs. T-shaped edges: repression by TFs or miRNAs.
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Supplementary Figure 3. CGCIRs and CMCIRs dynamically regulated in SC injury
response. (A) Expression profiles of the four CGCIRs. (B) Gene Ontology terms enriched
in each of the four CGCIRs. Color coding of bars matches that of the expression profiles
shown in (A). (C) Expression profiles of miRNAs that are correlated with CGCIRs 1 or 2
(blue) and miRNAs that are correlated with CGCIRs 3 or 4 (red).
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Supplementary Figure 4. Luciferase assays confirm a direct interaction between
miR-124 and the 3’-UTR of Egr2. Overexpression of miR-124 but not of a Ctrl miRNA
in HEK293T cells expressing a luciferase reporter construct carrying the 3’-UTR of Egr2
results in significantly decreased luciferase activity (p<0.05, two-tailed Student’s t-test).
Mutating the predicted landing pad for miR-124 in the 3’-UTR of Egr2 disrupts the
interaction between miR-124 and the Egr2 3’-UTR luciferase construct and restores
luciferase activity.
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CHAPTER 7

Conclusions and Future Directions
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Conclusions and Future Directions
Mitochondria are critical mediators of disease progression in peripheral
neuropathies. Mitochondrial dysfunction, for example, is thought to be largely
responsible for peripheral nerve diseases associated with systemic metabolic disorders
such as diabetes (Fernyhough et al., 2010). Similarly, abnormalities in mitochondrial
metabolism ultimately account for the presentation of some forms of CMT in which
mitochondrial proteins are mutated (Niemann et al., 2006). With the hope of developing
new therapies much effort is being devoted to understanding how mitochondrial
deficiencies influence nerve function. To date, most work has focused on clarifying the
role played by neuronal/axonal mitochondria (Baloh, 2008). The contribution of SCspecific mitochondrial deficits to the pathophysiology of peripheral neuropathy, however,
has remained largely unexplored. Given that SCs intimately associate with and critically
support all peripheral nerve axons (Chen et al., 2003; Meyer zu Horste et al., 2007;
Reddy et al., 2003), greater insight into the biology and pathology of SC mitochondrial
metabolism could be relevant to the treatment of peripheral neuropathies. In the present
thesis we addressed the contribution of mitochondrial deficits specifically in SCs to
disease progression in peripheral nerve disease. We also explored some of the
mechanisms by which mitochondrial metabolism abnormalities in SCs may contribute to
axonal degeneration and damage peripheral nerves. Finally, we examined the gene
regulatory network that is important for peripheral nerve regeneration after injury and in
disease states.
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Mitochondrial derangements in SCs are underappreciated contributors to the
pathology of peripheral neuropathies
With the goal of understanding whether SC mitochondrial abnormalities affect
axonal survival and peripheral nerve function, we generated and characterized the first
mouse model useful in directly interrogating the contribution of SC mitochondrial
dysfunction to peripheral neuropathy (Chapter 2) (Viader et al., 2011). These mice
(Tfam-SCKOs), were produced through the tissue-specific deletion of the mitochondrial
transcription factor A gene (Tfam), which is required for mtDNA transcription and
replication and when excised induces progressive defects in the mitochondrial electron
transport chain (Larsson et al., 1998) Interestingly, we found that the induction of
mitochondrial dysfunction specifically in SCs did not affect their survival; instead it
resulted in a severe, progressive peripheral neuropathy characterized by extensive axonal
degeneration. These results showed that disrupted mitochondrial function specifically in
SCs can itself cause axonal degeneration and peripheral nerve disease. Moreover, these
results highlighted that much of the pathology present in peripheral neuropathies may
primarily reflect metabolic abnormalities in SCs. This is in agreement with previous work
examining the role of the polyol pathway in diabetic neuropathy (Tomlinson and
Gardiner, 2008), and emphasizes the potential of targeting metabolic abnormalities that
affect SCs as a way to treat peripheral neuropathies.
Importantly, Tfam-SCKO mice generated in our study recapitulated a number of
critical pathological features of human peripheral neuropathies. Disrupting mitochondrial
metabolism specifically in SCs was sufficient to induce both axonal degeneration as well
as demyelination. Tfam-SCKOs also displayed distal weakness and sensory deficits, two
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common problems in human patients. Finally, Tfam-SCKOs suffered preferential early
loss of unmyelinated C fibers followed by the degeneration of large-caliber myelinated
axons. This was of particular interest because preferential loss of small-caliber
unmyelinated fibers is characteristic of peripheral and optic neuropathies associated with
systemic diseases such as diabetes or with exposure to environmental toxins (Kennedy et
al., 1996; McArthur et al., 2005; Sadun, 2002). Together, our results indicated that key
pathological features commonly encountered in human peripheral nerve disease can
potentially be explained by SC-specific mitochondrial dysfunction. Moreover, our
observations suggested that Tfam-SCKO mice may be particularly useful in
understanding some of the pathophysiology of diabetic and other mitochondria-related
neuropathies, as these mice are one of few metabolic mutants (Sullivan et al., 2007) that
strongly recapitulate some of the pathology of human peripheral nerve diseases.

Role of SC mitochondrial metabolism in the biology of these glia and the metabolic
support of axons
Unexpectedly, severe respiratory chain abnormalities in the SCs of Tfam-SCKO
mice did not affect their survival. This observation suggested that SCs have an adaptable
energy metabolism. In fact, we observed that following Tfam-depletion and inhibition of
mitochondrial respiration SCs induced mitochondrial biogenesis and increased
glycolysis. These two metabolic adaptations that often follow mitochondrial deficits
(Chabi et al., 2005; Piao et al., 2010), likely account for the relative preservation of
energy levels in Tfam-SCKO nerves as well as the limited or largely delayed death of
SCs. Our current knowledge of the basic energy metabolism and requirements of SCs,
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however, is still very rudimentary. SCs, for example, have been hypothesized to be
largely glycolytic and rely on the non-oxidative catabolism of glucose to meet their
energy needs (Pellerin and Magistretti, 2003). This idea is supported by the observation
that in explant systems SCs take up a disproportionately large amount of glucose (Vega et
al., 2003). The fact that disruption of mitochondrial energy metabolism in Tfam-SCKO
mice did not affect SC survival and resulted in increased glycolysis provided indirect
support for this hypothesis. At the same time, increased mitochondrial biogenesis in
Tfam-deficient SCs suggested that these glia still depend on mitochondria to meet some
of their metabolic needs.

Future work aimed at understanding the basic metabolic

requirements of SCs and the adaptations that follow disturbances of specific energy
metabolism pathways (e.g. OXPHOS, glycolysis, fatty acid oxidation…) should provide
valuable insight into both the biology and pathology of SCs.
One of the more intriguing aspects of the pathology in Tfam-SCKO nerves is that
it may reflect a disruption of SC-mediated metabolic support of axons. SCs have a
primary role in supporting axonal function and survival (Chen et al., 2003; Meyer zu
Horste et al., 2007; Reddy et al., 2003), and metabolic support of axons by ensheathing
glia is hypothesized to be critical to this function of SCs (Nave and Trapp, 2008). Similar
to what happens in the CNS between neurons and astrocytes, SCs may support axons
through the transfer of metabolites or by helping axons eliminate certain toxic species
(Benarroch, 2005). Tfam-SCKO mice provide an in vivo system in which begin to
address some of the details of the mechanisms behind the putative metabolic support of
axons by SCs. Tfam-SCKO mice may be a particularly valuable model when combined
with other systems designed to more directly examine the transfer of specific energy

279

metabolites likely to shuttle between SCs and neurons (e.g. lactate, glutamine, 2oxoglutarate, malate) (Miller et al., 2002). In this context, the generation of new
transgenic mice lacking certain metabolite transporters specifically in SCs or axons could
prove especially informative (Voutsinos-Porche et al., 2003). Mechanistic inside derived
from such studies will complement our basic observation of that SC mitochondria are
essential for the SC-mediated support of axonal function and survival; it should also be
important in identifying new potential therapeutic targets for peripheral neuropathy.

The integrated stress response as a common maladaptive mechanism in peripheral
neuropathies
Having established the relevance of the characterization Tfam-SCKO mice to
understanding and potentially treating peripheral neuropathies, chapter three in this thesis
described our efforts aimed at discovering the mechanisms underlying the nerve
pathology in these mice. Our examination of Tfam-SCKO mice uncovered the activation
of the ISR in Tfam-deficient SCs secondary to mitochondrial dysfunction. The ISR is an
evolutionarily conserved, “stress”-activated, gene expression program centered on
phosphorylation of eIF2. Activation of this program is meant to promote a cellular
stress-resistant state by global attenuation of protein synthesis, which reduces the ER load
and diverts amino acids from energetically costly protein synthesis to other metabolic
pathways (Ron and Walter, 2007). Activation of this program in SCs, however, is
particularly maladaptive and is thought to cause some of the pathology present in
neuropathies associated with mutations to structural myelin proteins (Pennuto et al.,
2008). In this context, induction of the ISR in SCs is associated with the accumulation of
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mutant myelin proteins in the ER and an unfoled protein response (Lin and Popko, 2009).
Activation of the ISR in Tfam-SCKO, mice, however, was not associated with ER stress
or an unfolded protein response. The maladaptive induction of the ISR in SCs could
therefore be a common pathological mechanism in different forms of peripheral
neuropathy, including those associated with mutations to structural myelin as well as
metabolic abnormalities.
While the idea that ISR activation may be a common pathological mechanism in
peripheral neuropathies of diverse etiology is attractive, this hypothesis would be greatly
strengthened by evidence that confirms the role of this pathway in the pathology of TfamSCKO mice. This evidence could come from the examination of nerve disease
progression in Tfam-SCKOs that also lack the key downstream mediator of the ISR
Chop, as previously done by Pennuto and colleages in another neuropathy model
(Pennuto et al., 2008). Intriguingly, neuropathy-causing chemotherapy drugs have also
been shown to activate the ISR in cell lines in vitro (Gately et al., 1996). Experiments
that explore whether chemotherapy drugs activate the ISR in SCs would also provide
further credit to our hypothesis.

A shift in SC lipid metabolism as a key driver of the pathology of Tfam-SCKO
nerves
Lipids play a crucial role in the normal biology of SCs; they are required for
myelin assembly and maintenance, regulate the differentiation status of these glia, and
may also be important for SC-mediated metabolic support of axons (Chrast et al., 2010).
Our work identified a shift in lipid metabolism early in the disease progression of Tfam-
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SCKO nerves. This alteration in SC lipid metabolism was characterized by a decreased
flux of fatty acids towards new lipid synthesis and a concomitant increase in lipid
oxidation. Importantly, this shift in SC lipid metabolism secondary to mitochondrial
dysfunction in Tfam-deficient SCs preceded much of the nerve pathology in TfamSCKOs and could thus ultimately account for the disease phenotype in these mice.
Abnormalities in nerve lipid composition are present in a number of peripheral
neuropathies in which mitochondrial dysfunction is known to occur (Chrast et al., 2010;
Navarro et al., 2010; Niemann et al., 2006). Our results suggested therefore that
alterations in SC lipid metabolism may be at the center of the pathology of
mitochondrial-related neuropathies modeled in Tfam-SCKO nerves.
The shift in the lipid metabolism in Tfam-deficient SCs resulted in depletion of
sulfatides and cerebrosides, key myelin lipid components that together represent almost
30% of all myelin lipid content (Garbay et al., 2000). The early reduction of these lipids
likely accounted for the prominent demyelinating phenotype apparent in late stages of
disease in Tfam-SCKO mice (Viader et al., 2011). Interestingly, sulfatides and
cerebrosides also have an important role in maintaining axon-glial contact (Dupree et al.,
1998; Hoshi et al., 2007). Depletion of these galactolipids could thus also drive some of
the later axon loss in Tfam-SCKO nerves by disrupting the ability of SCs to properly
associate with and support axons. As our understanding of SC-mediated metabolic
support of axons expands it will be interesting to examine how this support is affected by
depletion of sulfatides and cerebrosides and disruption normal axon-glial interactions.
We also observed a significant accumulation of acylcarnitines in Tfam-SKCO
nerves. Our work provided initial evidence that such accumulation of fatty acid -
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oxidation intermediates in SCs following mitochondrial deficits could also be
contributing to axonal degeneration in peripheral neuropathies. We found that long-chain
acylcarnitines could be released from SCs, disrupt the membrane properties of axons, and
induce their degeneration. These results are in agreement with the fact that neuropathy is
among the long-term complications of genetic disorders leading to buildup of
acylcarnitines (Schaefer et al Turnbull, 1996; Tyni & Pihko, 1999). To unequivocally
link acylcarnitine accumulation to axonal degeneration in Tfam-SCKO nerves, however,
one will need to assess the benefits of preventing the increase of these lipid intermediates
in Tfam-SCKOs. Etomoxir treatment, an inhibitor of the acylcarnitine synthesizing
enzyme Cpt1, could be useful in pursuing this line of investigation, particularly as
etomoxir has shown therapeutic potential in the treatment of other neurodegenerative
conditions (Shriver et al., 2011). Crossing Tfam-SCKOs to mice lacking malonyl-coA
decarboxylase, an enzyme that degrades the natural CPT1 inhibitor malonyl-CoA, could
provide an alternative genetic model to further asses the role of acylcarnitine
accumulation in peripheral neuropathy. Intriguinly, malonyl-coA decarboxyalse deficient
mice are protected against diet induced glucose-intolerance (Koves et al., 2008)

miRNAs modulate the ability of SCs to support peripheral nerve regeneration
To complement the work describe in the first part of this thesis, which aimed at
understanding the basic pathological mechanism that drive peripheral nerve disease, we
also examined the transcriptional and post-transcriptional gene regulatory networks that
are responsible for the regenerative response of Schwann cells (chapters 5 and 6). Greater
insight into this highly orchestrated process could be harnessed to help restore function in
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peripheral and central neurodegenerative diseases characterized by axonopathy, including
diabetic neuropathy and amyotrophic lateral sclerosis (Coleman, 2005). We explored
whether injury-induced changes in SCs were orchestrated post-transcriptionally by
microRNAs (miRNAs). Interestingly, we found that SC miRNAs modulated the injury
response largely by targeting positive regulators of SC dedifferentiation/proliferation. SC
miRNAs cooperated with transcriptional controls to promote rapid and robust transitions
between the distinct differentiation states necessary to support nerve regeneration. Our
results suggested, therefore, that that manipulation of SC miRNAs could be used
therapeutically to facilitate SC differentiation after injury or reverse the effects of
neuropathy.
The therapeutic modulation of SC miRNAs, however, requires the identification
of specific miRNAs playing critical roles in the establishment and maintenance of SC
differentiation as well as in the modulation of the SC injury response. We identified miR34a and miR-140 as two such candidates that critically regulate SC proliferation and
myelination, respectively. mir-34a and mir-140 deficient mice have been generated (Choi
et al., 2011; Miyaki et al., 2010) and examination of the SC injury response in these mice
could be especially useful in determining the therapeutic value of these two miRNAs.
Future experiments that examine some of the other miRNAs identified in this thesis to be
potentially important for the SC regenerative response (e.g. let-7 familiy members, mir22, mir-26a…) could also be interesting.

In conclusion, the results described in the present thesis expand our understanding
of how mitochondrial abnormalities specifically in SCs contribute to the clinical
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impairment in patients afflicted with peripheral neuropathy. Our findings emphasize that
future therapies for peripheral neuropathy will need to address metabolic abnormalities in
SCs and not just in axons if they hope to effectively prevent disease progression. More
importantly, our work identifies new potentially important therapeutic targets that may
eventually enhance the quality of life of patients with peripheral nerve diseases.
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